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MAF Minor allele frequency 
Mb Megabases 
MD Macular dystrophy 
mERG Multifocal electroretinogram 
MIM Mendelian inheritance in man 
MKS Meckel-Grüber syndrome 
MRI Magnetic resonance imaging 
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STGD Stargardt disease 
VA Visual acuity 
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XL X-linked 
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bp Base pair 
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CD Cone dysfunction 
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cGMP Cyclic guanosine monophosphate 
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CNG-channel Cyclic nucleotide gated channel 
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GCL Ganglion cell layer 
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1.1
General introduction
Seeing is believing. Vision is an intriguing phenomenon in life, enabled by highly organized pro-
cesses in the eye. Visual perception is one of our primary recourses of retrieving information 
from the outside world. Visual perception has been investigated since the dawn of mankind, 
however, the actual processes required for perceiving a colorful image remain brain-teasing.
the eye and the general ProCess of vision
The visual process is a sophisticated system that is able to identify and discriminate among 
stimuli varying from chromatic or achromatic, motion or motionless and designed or unpat-
terned. The human eye is composed of three main structures. The outer layer maintains the 
shape of the eye, and serves as a protector of the inner layers. It is formed by connective tissue 
structures, the sclera and the cornea. The middle layer is formed by the choroid, ciliary body 
and iris. The choroid is important for blood supply and nutrition of the eye. The iris enables 
further accommodation of the incoming light. The inner layer, the retina, provides the final 
step in translating light to a sharp image and serves as the sensory part of the visual system 
(Figure 1).
Figure 1 Anatomy of the human eye
(Figure adapted from: http://www.drpion.be/bouw-van-het-oog.htm)
A beam of light reflected by an image enters the eye though the cornea, and for further visual 
processing needs to be focused on the retina. The light passes through the anterior chamber 
and pupil, a round opening central of the colored iris. A protective mechanism of the eye against 
overexposure of light is the adjustment of pupil size. High intensities of light constrict the pupil 
diameter, whereas in limited light intensities the pupil expands enabling more light to enter 
the eye. The subsequent structure is the transparent crystalline lens, which together with the 
cornea refracts the beam of light entering the eye to grant a sharp focus onto the retina.
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Besides the RPE, the retina is composed of the neural (or sensory) retina, which is connected 
to the central nervous system (Figure 2).5 and the references therein The incoming light first hits the 
photoreceptors, which transfer the energy of an absorbed photon into an electric signal which 
is transmitted via the synaptic terminal to the second layer of bipolar horizontal and amacrine 
cells. These second order neurons are responsible for the first stage of processing the image 
by connecting the input from multiple photoreceptors. These signals are then transported 
towards the third layer, composed of ganglion cells, which communicate the neuronal signal 
through the optic nerve to the lateral geniculate body, where the signal crosses a synaps and 
travels via the optic radiation to the striate cortex and extrastriate associated cortices for final 
visual processing.
the maCula lutea
The posterior retina contains the macula, which is recognizable as a yellowish region on the 
temporal side slightly below the optic disc and covers a diameter of 5.5 mm (Figure 3). The 
color of the macular region is generated by two xanthophyll pigments, lutein and zeaxanthin, 
which serve as antioxidants and protection against sunlight for the eye.6-9
The central region of the macula, called the fovea, is characterized by a ~1.5 mm-wide depres-
sion in the inner retina surface. This region of the macula provides acute high-resolution vision 
in the human eye. The fovea is not composed of layers like the other regions of the retina, does 
not contain rods, is capillary free, and is exclusively composed of cone photoreceptor cells. 
The importance of the fovea is striking, as approximately 50% of the nerve fibers in the optic 
nerve acquire their information from the fovea. 
Figure 3 Position of the fovea in the posterior pole of the human eye
(Figure adapted and published with permission from http://www.positscience.com/media-gallery/
detail/160/62)
The retina, the light-sensitive layer lining the inner-eye, contains the rod and cone photorecep-
tors and exerts three functions. Firstly, the retina serves as a converter of the optical image 
to an electrical signal which is facilitated by these photoreceptors. The outer region of the 
retina provides peripheral vision and is mainly populated by rod photoreceptors, whereas the 
central region (called the macula) contains mostly cone photoreceptor cells and is necessary 
for detailed color vision. The most centered region (one square millimeter) of the macula is 
called the fovea. The 0.35 mm diameter centre of fovea, the foveola, exclusively contains cone 
photoreceptor cells. The second function of the retina is to send the electrical signal generated 
by the photoreceptor cells via the optic nerve to the brain where it is translated to an image 
which we know as vision. A third function of the retina is to create signals through specialized 
ganglion cells. Information on the 24-hour light/dark cycle is processed via the optic nerve to 
the suprachiasmatic nucleus. This brain structure contains ~20,000 neurons and regulates the 
body’s biological ‘clock’, which influences changes in mental and physical characteristics during 
the day, i.e. the circadian rhythms.
anatomy of the retina-rPe
The retina is a complex tissue composed of two major layers; the neural retina and the retinal 
pigment epithelium (RPE, figure 2). The RPE is a highly pigmented monolayer which acts as 
a blood-retina barrier, allowing exchange of nutrients, growth factors and waste products 
between the subretinal space and the choriocapillaris. The pigmentation of the RPE provides 
absorption of excess light focused on the retina after entering the eye. The RPE also functions 
in retinal metabolism by regulating photoreceptor excitability, the visual cycle and phagocyto-
sis of shed photoreceptor outer segments,1-3 and maintains structural integrity. The RPE also 
regulates the secretion of immunosuppressive agents or factors and thereby co-ordinates the 
immune response potential.
Figure 2 Cellular organisation of the retina
Schematic representation of the various cell types within the two retinal layers (Figure derived 
by and published with permission of J.L Wilkinson-Berka4).
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Figure 5 Schematic representation of the rod and cone photoreceptor cell 
The synaptic terminus acts as a medium by forming synapses to transmit the generated electri-
cal membrane potential to the bipolar cells. The inner and outer segments are linked via the 
connecting cilium. The outer segments contain the light absorbing proteins and processes, 
whereas the inner segments host various organelles such as the mitochondria, ribosomes and 
rough endoplasmic reticulum. The body of the photoreceptor cell contains the cell nucleus. 
The outer segments of rods consist of tightly packed discs surrounded by a plasma membrane, 
which create the surface area for the photosensitive pigment rhodopsin. Cones are not built up 
of separate discs, but the conical shaped outer segments have invaginations of their cell mem-
branes, which form a stack of continuous membranes. The photopigments for cones, opsins, 
are embedded and synthesized and regenerated by the replacement of the all-trans-retinal by 
11-cis-retinal by the RPE.
Photoreceptor cells do not divide anymore, their membranous discs decay, and in the case of 
rods they are detached at the end of the outer segment, taken up by RPE cells, absorbed by 
phagosomes and recycled. Approximately 10%, equal to ~100 rod discs, are recycled in this 
way every night in humans. Cone outer segments are not detached for recycling, but apical 
processes of the RPE phagocytize parts of cone outer segments. Different than rods, this 
occurs in the light.
PhotoreCePtors
The human retina contains two types of photoreceptor cells, the rods and cones. Scotopic 
vision, at lower light intensities, involves perceiving contrast and brightness of light, as well 
as peripheral vision and detection of motion is provided by the highly sensitive rods. The less 
sensitive cones enable photopic vision at higher intensities of light, are responsible for color 
vision and seeing details at high spatial acuity. A healthy human retina contains close to 3 million 
cones, which presents ~5% of all photoreceptors, while the remaining ~95% is composed of 
approximately 60 million rods. Rods are absent in the fovea, are highly concentrated near the 
macula, and are the dominating photoreceptor cell in the mid-peripheral and peripheral retina. 
Cone photoreceptor cells are highly concentrated in the fovea (~160,000/mm2), but these 
numbers decrease rapidly towards the periphery.
Rods can detect a single photon and provide sight in dimmed light, which makes humans capa-
ble of seeing objects by focusing slightly besides the object. The object could be missed by the 
cones, as they need approximately 100 photons to produce the same response due to their 
low sensitivity in dimmed light. 
Figure 4 Cone and rod cell distribution in the retina
(Figure derived from http://www.olympusmicro.com/primer/lightandcolor/images/humanvisionfigure4.jpg)
Whilst cones have the necessity of relatively bright light, they provide us the sharpest images 
and give humans the ability to see colors. Color vision is created by three types of cones: 1) 
long wavelength, L-cones, are sensitive for the yellow spectrum (but are called red cones) from 
565-580 nm; 2) medium wavelength, M-cones, absorb green light from 534-545 nm and 3) 
short wavelength, S-cones, respond to blue (violet) wavelengths with a peak absorption at 440 
nm. These different absorption signals from different cones are converted by the brain into a 
color image with all possible colors.
Cones are shorter with a wider base and have cone-shaped outer segments, whereas rods are 
longer and are cylindrical-shaped. The photoreceptor cells are both composed of a synaptic 
terminus, an inner segment and an outer segment (Figure 5). 
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Color vision
Organisms can perceive colors or have color vision by the ability to distinguish the different 
wavelengths of light. Color vision remains an intriguing phenomenon and is created by billions 
of interacting neurons in the brain. How the brain handles these properties of light and trans-
lates them into color vision remains largely a mystery. An important concept in color vision is 
that a cone only responds to the energy it absorbs (Maxwell 1872). If the energy absorbed by 
the cone is the same for different wavelengths, they would produce identical responses. This 
univariant response may give problems when an object reflects a similar amount of energy as 
the background. Hence, the contrast in wavelength allows one to distinguish objects, even 
when energy contrast is minimal or absent. Thus, color vision combines the energy and wave-
lengths of light to detect objects. 
Figure 6 Absorption spectra of cones and major colors produced by trichromatic 
color vision in humans
(Figure derived from http://www1.appstate.edu/~kms/classes/psy3203/Color/absorption_spectrum.jpg)
To differentiate between objects based on spectral reflectance, two or more cones are needed. 
Human color vision is trichromatic, meaning that three classes of cones contain pigments that 
absorb different light wavelength sensitivities (Figure 6). The visual spectrum of human vision 
is dependent on the ability of light penetration in the eye and absorbance by the photorecep-
tors. The anterior segment of the eye absorbs ultra-violet light and therefore seldom reaches 
the photoreceptors, whereas infra-red light is able to penetrate the eye, but the energy may 
be too small to activate opsins. This trichromatic cone system contributes to the large variety 
of major colors humans can appreciate. Vision of colors varies among species. Other than 
trichromatic humans or most related primates, most mammals have dichromacy showing a 
red-shift in the absorption spectrum, which likely enables these usually nocturnal animals to 
distinguish colors in dim light.
Marine mammals are monochromats with a single cone type as they are adapted for low-light 
vision. Invertebrates like (honey- and bumble) bees, wasps and sawflies are also trichromatic 
and cannot visualize the color red, but instead they are sensitive to ultraviolet. Tetrachromatic 
vision by four cone types, or pentrachromatic vision by five types of cone is present in birds and 
reptiles, respectively. Butterflies are also thought to be pentachromatic, but the most complex 
color vision is found in the mantin shrimp which has 12 different spectral cone receptors. 
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Genomics technologies and disease identification strategies
The studies in this thesis have been facilitated by the ongoing developments of technologies 
in genomics. To discover gene defects in CD knowledge on the genetic variation in the popu-
lation is crucial. In this paragraph genetic variation and the most widely used technologies 
in this thesis are explained. These techniques have paved the way to identify a spectrum of 
genetic defects underlying CDs that are comprehensively described in chapter 1.3.
genetiC variation
Although the deoxyribonucleic acid (DNA) of two individuals is more than 99.9% identical, 
there remain differences both in composition and structure of the DNA between individu-
als.10 A nucleotide that varies in more than 1% in the normal population is called a polymor-
phism. If this variation affects only one nucleotide it is referred to as a single nucleotide 
polymorphism (SNP), while highly variable repeated sequences of 1-6 basepairs (bp) are 
called microsatellites.11 SNPs are the most common genetic variations among persons and 
cover approximately 0.1% of the genome, with an estimated occurrence of one SNP in every 
100-300 bp. The frequency of a specific SNP or allele in a population is called the allele 
frequency. Current estimates are that there are approximately 15 million SNPs with a minor 
allele frequency (MAF) of >1%.10 A diploid genome has 6 million differences with any other 
individual, of which at least 20,000 occur in the coding parts (the exons) of genes.10 When a 
variant is only on one copy of the chromosomes it is called heterozygous, and when the same 
variant occurs in both chromosomes it is referred to as homozygous. Variants that cause 
disease, and/or affect the function of a gene, are called mutations.
homozygosity maPPing 
In autosomal recessive disease, an individual needs to carry mutations on both chromosomes 
in order to be affected. When identical mutations are observed these are called homozygous 
mutations, whereas two different mutations in the same gene are called compound hetero-
zygous. The latter are mostly found in patients of outbred populations, whereas homozygous 
mutations are often found in patients originating from isolated populations due to geographic 
restrictions, religion, cultural or language reasons. Homozygosity mapping is a method used 
to detect homozygous mutations and is based on the following principle. In reproductive 
cells, during meiosis, a process called recombination occurs, which implies the exchange of 
two chromosomes at random positions. not only a mutation is passed on to the next genera-
tion, but also the surrounding region of the chromosome. A combination of polymorphisms 
on a merged chromosome is called a haplotype, and its length and position is determined by 
recombinations between the original parental haplotypes. A haplotype containing a muta-
tion will decrease in size through generations, and can occur in offspring as an identical-by-
descent (i.e. homozygous) region. In isolated populations or in families in which the parents 
are consanguineous, the homozygous regions containing the mutation generally span 20-40 
cM of the genomic DNA (Figure 1A).12 When the ancestor who carried the mutation lived 
several generations ago, the homozygous region containing the mutation in a patient will be 
much smaller (1 - 7 cM) due to the higher number of recombinations (Figure 1B). Genome-
wide genotyping arrays can be used to detect these homozygous regions by assessing hun-
dreds of thousands of SNPs in a person’s DNA. When identical SNPs on both chromosomes 
are found, the SNP is called homozygous. A stretch of homozygous SNPs, composing a 
homozygous region, potentially originates from a common ancestor. 
Homozygous regions can also occur by chance as there may be limited haplotype diver-
sity, little historic recombinations (i.e. haplotype blocks) or regions near the centromere of 
chromosomes which present a lower number of recombinations.13 Despite this drawback, 
homozygosity mapping has been proven to be an effective tool for the identification of the 
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Ancestor
Patient
Homozygous region 1-7 cM
Homozygous region 20-40 cM
Year
1650
1750
1800
1900
2014
A
B
Figure 1 Schematic representation of the inheritance of ancestral chromosome 
that harbors a mutation 
The chromosomal region carrying the culprit mutation and originating from the original ances-
tral chromosome in the great grandparent reduces in size due to recombination between 
homologues chromosomes with every generation. A) In consanguineous families, a recent com-
mon ancestor likely spreads the mutation. Because the limited number of generations between 
the ancestor and the affected individual, a large fraction of the ancestral haplotype is present in 
both copies of the affected individual, which results in a relatively large homozygous region.12 
B) When the common ancestor with a heterozygous mutation lived many generations ago, only 
a small fraction of this haplotype will be present on both chromosomes of a patient. Therefore 
the homozygous region of this affected individual is relatively small. (Figure derived by and pub-
lished with permission of K.L. Littink.)
disease region, and in combination with a positional candidate gene approach has been widely 
used to elucidate the genetic defect in individuals who suffer from an autosomal recessive 
disease.14-18
next generation sequenCing
DNA sequencing technology has evolved tremendously in the last 4 decades. In 1977, the 
enzymatic dideoxy Sanger sequencing technique and the Gilbert chemical degradation meth-
od were described.19; 20 Since the early 1990s, semi-automated Sanger biochemistry has been 
implemented to perform DNA sequence analysis.19-21 Although this technique covers the 
optimal resolution for genetic variant detection, its downside is that the scale generally 
allows only 96 to 384 reactions in parallel, which makes this a time-intensive and expensive 
approach at a cost of roughly $500 per Mega base (Mb) of DNA. Giant leaps were made in 
technology in the last years by the development of next generation sequencing (NGS), which 
is capable of sequencing millions of DNA fragments in a highly parallel fashion. Whole exome 
sequencing (WES) targets ~50 Mb of human coding regions, together called the exome, 
and covers approximately 1% of the entire genome. After the first successful application 
of exome sequencing in Miller syndrome 22 and Kabuki syndrome23 only a few years ago, 
its power has grown by the identification of large numbers of novel genes associated with 
rare as well as common disorders,22 and the costs of performing exome sequencing are still 
decreasing. Currently, NGS technology has expanded to cover the entire genome sequence, 
referred to as whole genome sequencing (WGS), in which not only the coding variant but 
also all intronic variants of a genome can be determined. Great interpretational challenges 
are faced to pinpoint gene defects to intronic variants as they may cause regulatory or 
translational defects, but do not have a clear effect on the protein itself. Functional studies 
on these intronic variants are needed to provide the knowledge to make great use of this 
technology.
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1. introduCtion
Cone disorders (CDs) are a group of inherited diseases of the cone, or cone and rod pho-
toreceptors, or retinal pigment epithelium (RPE), that are associated with various forms of 
stationary or progressive visual impairment. Linkage analysis, homozygosity mapping, and more 
recently whole exome sequencing (WES), facilitated the identification of genes mutated in 
patients with CDs such as achromatopsia (ACHM), cone dystrophy (COD), cone-rod dystrophy 
(CRD), and other cone-related disorders. CDs can follow all modes of Mendelian inheritance, 
i.e. autosomal recessive (AR), autosomal dominant (AD) and X-linked (XL), and can present 
as non-syndromic and syndromic forms. Thus far, reviews were focused on stationary cone 
disorders24 as well as the genetic spectrum of cone disorders.25 Here, we provide an overview 
of the expanded genetic repertoire of inherited cone disorders and novel genotype-phenotype 
correlations. Despite the high clinical and genetic heterogeneity of CDs the genetic defects 
underlying 21-93% of the cases have been identified. The proteins encoded by CD-associated 
genes are involved in a variety of processes, including the cone phototransduction cascade, 
visual cycles, photoreceptor development, ciliary transport, disk membrane morphogenesis 
and synaptic transport. Studies in mammalian models show that gene replacement therapies, 
due to the accessibility and immune-privileged nature of the eye, provide an opportunity to 
correct the visual impairment. In this review we present a comprehensive overview of the 
genes and associated disease mechanisms of non-syndromic CDs, touch upon the genetic 
causes of syndromic CDs, and evaluate therapeutic strategies aiming to prevent vision loss in 
CD in the future.
2. PhenotyPiC and genetiC CharaCteristiCs of Cone disorders
Hereditary CDs constitute a large clinically heterogeneous group of diseases in which the cone 
photoreceptors or RPE are primarily affected. Cone photoreceptor cells account for only 5% 
of the total number of photoreceptors, the other 95% consisting of rods. In humans, the retina 
contains 3-6 million cone photoreceptors concentrated in the fovea enabling detailed vision, 
spatial resolution, reading, facial recognition and color vision. These important cone func-
tions explain why CDs have such a disabling impact on the daily living tasks of those affected, 
further compounded by the early onset of disease and severe visual outcome of many of these 
disorders.
We analyzed all publicly available literature on CDs and, to estimate the contribution of spe-
cific genes, only included studies with clearly defined patient cohorts (Supplementary Tables 
1-5). Using this approach, we estimated that AR/isolated (I) CDs are found in 76.7% of cases, 
AD inheritance in 21.6% of cases and X-linked inheritance in the remaining 1.4% (Figure 1). 
In this chapter we provide an overview of the clinical and genetic characteristics of different 
forms of non-syndromic and syndromic CDs.
Figure 1 Frequency of clinical subtypes and inheritance 
patterns of genetically heterogeneous cone disorders
Estimate of the frequencies of clinical subtypes and modes of 
inheritance of the genetically heterogeneous forms of CD, 
i.e. achromatopsia (ACHM), which invariably is inherited in an 
AR manner, cone dystrophy (COD), and cone-rod dystrophy 
(CRD). The majority of the AR COD and AR CRD cases are 
isolated (I) cases in which a recessive mode of inheritance is 
most likely. In most studies in which AD forms of COD and 
CRD were analyzed, no clear distinction was made between 
these disease entities, and therefore they are grouped together.
abstraCt
Hereditary cone disorders (CDs) are characterized by defects of the cone photoreceptors or 
retinal pigment epithelium, and include achromatopsia (ACHM), cone dystrophy (COD), cone-
rod dystrophy (CRD), color vision impairment, Stargardt disease (STGD) and other maculopa-
thies. Forty-two genes have been implicated in non-syndromic inherited CDs. Mutations in the 
5 genes implicated in ACHM explain ~93% of the cases. On the contrary, only 21% of CRDs 
(17 genes) and 25% of CODs (8 genes) have been elucidated. The fact that the large major-
ity of COD and CRD-associated genes are yet to be discovered hints towards the existence 
of unknown cone-specific or cone-sensitive processes. The ACHM-associated genes encode 
proteins that fulfill crucial roles in the cone phototransduction cascade, which is the most 
frequently compromised (10 genes) process in CDs. Another 7 CD-associated proteins are 
required for transport processes towards or through the connecting cilium. The remaining 
CD-associated proteins are involved in cell membrane morphogenesis and maintenance, syn-
aptic transduction, and the retinoid cycle. Further novel genes are likely to be identified in the 
near future by combining large-scale DNA sequencing and transcriptomics technologies. For 
31 of 42 CD-associated genes, mammalian models are available, 14 of which have successfully 
been used for gene augmentation studies. However, gene augmentation for CDs should ideally 
be developed in large mammalian models with cone-rich areas, which are currently available for 
only 11 CD genes. Future research will aim to elucidate the remaining causative genes, identify 
the molecular mechanisms of CD, and develop novel therapies aimed at preventing vision loss 
in individuals with CD in the future.
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Table 1 Clinincal characteristics to differentiate the major inherited cone disorders
ACHM OT BCM COD CRD STGD
Vision 0.05-0.20 0.05-0.40 ~0.10 0.05-0.40 0.05-0.40 0.1-0.5
Nystagmus + +/- + - - -
Color vision Disturbed in 
protan/deutan/ 
tritan color 
axes
Not disturbed Disturbed in 
protan and 
deutan color 
axes
Disturbed in 
protan/deutan/ 
tritan color 
axes
Disturbed in 
protan/deutan/ 
tritan color 
axes
Disturbed in 
protan/deutan 
color axes
Photophobia + +/- + +/- +/- +/-
Hemeralopia - - - +/- +/- -
Nyctalopia - - - - +/- -
Hyperme-
tropia  
>+2D
+; ~30% ? - - - -
Myopia  
<-2D
+; ~25% ? + +; ~20% even 
more than 
>-6D
+; ~20% even 
more than 
>-6D
-
Retinal ap-
pearance
Normal to 
bull’s eye/  
atrophic  
macular lesions
Normal to 
bull’s eye/  
atrophic  
macular lesions
Normal to 
macular  
atrophy and 
RPE atrophy
Normal to 
bull’s eye/ 
atrophic 
macular lesions, 
temporal pallor 
of optic disc
Normal to bull’s 
eye/ atrophic  
lesions, 
peripheral RPE 
atrophy, vascular 
attenuation
Bull’s eye, 
mostly  
surrounded by 
flecks. In rare 
cases flecks 
spread up to 
the arcades
SD-OCT Normal-  
absence of  
central cone 
PRL
Thinner central 
retina, no  
absence of 
cone PRL
Absence of 
central cone 
PRL
Normal- 
absence of  
central cone 
PRL
Normal- 
absence of  
central cone 
PRL, central 
retinal thinning
Thinning or  
absence of  
central cone 
PRL
FAF Normal to 
absent FAF in 
the macula
ND Normal to 
absent FAF in 
the macula
Normal to 
absent FAF in 
the macula
Normal to 
absent FAF in 
the macula
70% dark 
choroid
Goldmann 
perimetry
Reduced central 
sensitivity to 
(relative)  
central scotoma
Reduced central 
sensitivity
Reduced central 
sensitivity to 
(relative)  
central scotoma
Reduced central 
sensitivity to 
(relative)  
central scotoma
Reduced central 
sensitivity to 
(relative)  
central scotoma, 
with variable 
peripheral 
involvement
Reduced central 
sensitivity
mfERG Reduced/non 
detectable  
macular 
responses
Reduced/non 
detectable  
macular 
responses
Reduced/non 
detectable  
macular 
responses
Reduced/non 
detectable  
macular 
responses
Reduced/non 
detectable  
macular 
responses
Reduced
ffERG Reduced/absent 
cone responses. 
Normal rod 
responses
Normal to 
slightly reduced 
cone responses. 
Normal rod 
responses
Reduced/absent 
cone responses 
with a preser-
vation of the 
blue cones
Reduced/absent 
cone responses. 
Initial normal 
rod responses
Cone 
responses 
are absent or 
more severely 
reduced than 
rod responses
Reduced cone 
responses
+, present; -, absent; ACHM, achromatopsia; AD, autosomal dominant; AR, autosomal reces-
sive; BCM, blue cone monochromatism; COD, cone dystrophy; CRD, cone-rod dystrophy; D, 
Diopters; FAF, fundus autofluorescense; ffERG, full-field electroretinogram; mfERG, multifocal 
electroretinogram; NA, not analyzed; ND, not described; OT, oligocone trichromacy; 
PRL,photoreceptor layer; SD-OCT, spectral domain-optical coherence tomography; STGD, 
Stargardt disease; XL, X-linked. 
2.1. CliniCal methods
Ophthalmic examination and diagnostic testing is essential to differentiate cone-rod from rod-
cone (i.e. RP) disorders. Although a number of tests are helpful in the diagnostic process, color 
vision testing of all three color axes such as Hardy Rand and Rittler tests, full-field ERG, and 
Goldmann perimetry, have been proven to be the most useful (Thiadens et al., 2013). With 
SD-OCT the morphology of the cone photoreceptor cells can be visualized. A single-section 
scan to obtain a longitudinal section across the center of the macula, and a volume scan should 
be performed to ensure capturing the center of the fovea. Retinal thickness measurements in 
the fovea including the outer nuclear layer, inner and outer segments of the cone cells, and RPE. 
For future gene therapy purposes, SD-OCT can be considered as a useful diagnostic tool for 
visualizing the severity of cone photoreceptor loss.
In Table 1, we summarized the ophthalmic symptoms and characteristics for ACHM, oligo-
cone trichromacy (OT), blue cone monochromatism (BCM), COD, CRD and Stargardt disease 
(STGD). Further details of these and other CDs can be found below.
2.2. CliniCal CharaCteristiCs of non-syndromiC Cone disorders
2.2.1. aChromatoPsia
Patients with achromatopsia (ACHM, figures 2A and 2B, table 1) present shortly after birth 
with significantly reduced visual acuity, severe photophobia, a congenital pendular nystagmus, 
and color vision defects in the protan, deutan and tritan color axes. High refractive errors are 
common in these patients. The macula can have a variable appearance ranging from no abnor-
malities to atrophic lesions. Full-field electroretinography (ERG) demonstrates absent or resid-
ual cone responses with normal rod responses.26,27 The first signs of pathology on SD-OCT 
are loss of inner- and outer cone segments with disruption of the ciliary layer, which may be 
followed by the appearance of an optical empty cavity with cell loss in the cone photoreceptor 
layer, at least in some studies. The end stage is generally characterized by a complete loss of 
photoreceptor and atrophy of the RPE in the fovea. This cascade of events takes place in the 
second decade and progresses with age.28,29 For future gene therapy purposes, SD-OCT can be 
considered as a useful diagnostic tool for visualizing the severity of cone photoreceptor loss. 
The estimated prevalence of ACHM is 1:40,000 individuals and it is exclusively inherited in an 
AR manner. The genetic etiology of ACHM has been almost completely unraveled. Mutations 
in the five genes associated with ACHM (Figure 3A) explain 92,8% of cases in the Caucasian 
population. All causal genes encode essential proteins in the cone phototransduction cascade 
(see paragraph 3).26,27 Importantly, the limited number of genes involved in ACHM renders this 
disease a suitable candidate for future gene-based therapies. Nevertheless these therapies can 
only succeed if viable cone photoreceptor cells are still present in the retina.30-33 
2.2.2. Cone dystroPhy
Patients with cone dystrophy (COD, figures 2C and 2D, table 1) have normal cone function 
initially, but present with visual loss and color vision disturbances in the first or second decades 
of life. Complaints of photophobia or hemeralopia may also exist. In X-linked (XL) COD cases 
with a mutation in the ORF15 region of RPGR, hemeralopia has been reported as a first symp-
tom preceding visual loss in more than a quarter of the patients.34 These RPGR-associated 
COD patients typically have high myopic refractive errors of more than 6 diopters.34 Because 
the cone function is initially normal in COD nystagmus is usually not observed. Macular abnor-
malities may be present ranging from no abnormalities to a bull’s eye maculopathy or RPE 
atrophy. The optic nerve may have variable degrees of temporal pallor. Goldmann perimetry 
shows a reduced central sensitivity or (relative) scotoma with intact peripheral visual fields.35 
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the center, surrounded by a discrete lesion of higher FAF intensity (FAF image). G/H) Stargardt 
disease. G) The posterior pole shows multiple yellow fish-tailed flecks, some pigment clumping, 
and bull’s eye maculopathy with RPE atrophy (color photograph). H) The central macula shows 
decreased FAF, whereas the flecks exhibit increased FAF on a background of irregular FAF 
(FAF image); I/J) Best vitelliform macula dystrophy. I) The macula has an egg-yolk appearance 
corresponding to the vitelliform stage of Best (color photograph). J) The FAF of the lesion is 
intensely increased (FAF image); K/L) Central areolar choroidal dystrophy. K) In the macula a 
sharply demarcated lesion with RPE atrophy is visible, surrounded by a few small round white 
lesions (color photograph). L) The atrophic area causes a decreased FAF bordered by a small 
band of increased FAF (FAF image). M/N) Butterfly-shaped macular dystrophy. M) The macula 
shows an irregular yellow pigmented lesion with some RPE degeneration (color photograph). 
N) The central area has decreased FAF while the yellow pigment show increased FAF resem-
bling a ‘pattern’ (FAF image). O/P) Adult-onset foveomacular vitelliform dystrophy. O) The 
macula reveals an oval yellow subfoveal lesion with central pigment (color photograph). P) The 
lesion shows an intensely increased FAF; the border of the lesion shows a band of decreased 
FAF (FAF image). Q/R) Cystoid macular dystrophy. Q) The macula shows focal thickening of the 
retina in the center (color photograph). R) The pooling of fluid in the macula gives a classical 
flower-petal pattern of FAF (FAF image).
Color vision is generally affected in all three axes. Reduced cone responses with preserved 
rod responses on ERG are an important clinical hallmark for the diagnosis of COD, although 
the vast majority of patients with COD develop rod involvement over time complicating the 
diagnosis. The mean onset of disease is at adolescence but the course of the disease may vary. 
Visual acuity generally worsens to legal blindness before 50 years of age.34 
COD has an estimated prevalence of 1:30,000-40,000.24 Although all Mendelian inheritance 
patterns have been reported the AR form is by far the most common. The genetic causes of 
the autosomal dominant (AD) and XL forms have been solved to a large extent, but 75% of AR 
forms remain to be elucidated (see Figure 3B). This is remarkable and hints towards the exis-
tence of completely unknown and uncharacterized cone-specific or cone-sensitive processes. 
Some of the genes associated with AR forms have a characteristic phenotypic appearance, like 
COD patients with mutations in the KCNV2 gene. Mutations in this gene show supra-normal 
rod responses on ERG. Besides these remarkable ERG findings, most young patients also have 
a relatively late onset in loss of visual acuity.36 The rod responses on ERG do not appear to 
coincide with a gain of rod visual acuity, on the contrary, studies showed loss of acuity for rod 
as well as cone cells in patients carrying KCNV2 mutations.36-38 The clinical course of ABCA4-
associated COD has also been studied in detail. This gene encodes a transmembrane protein 
located in rod and cone outer segments. AR-COD patients with mutations in this gene show 
an earlier onset, a rapid decline of visual acuity, and a significantly worse visual outcome than 
patients without ABCA4 mutations.34
2.2.3. Cone-rod dystroPhy
Cone-rod dystrophy (CRD, figures 2E and 2F, table 1) can be distinguished from COD by early 
rod involvement or concomitant loss of both cones and rods on ERG. Symptoms resemble 
those of COD, with complaints of visual acuity and central vision, sometimes photophobia, and 
color vision disturbances. However, patients may also experience nyctalopia due to rod degen-
eration. With an onset in childhood and a rapid decline of the visual function to legal blind-
ness before the age of 40, the course of CRD seems more severe than COD.34 The macular 
appearance resembles that of COD, but patients may also develop retinal vascular attenuation 
and peripheral pigment deposits. Visual fields show a (relative) central scotoma with variable 
Figure 2 Fundus and autofluorescence images of cone disoders
Fundus and autofluorescence images of patients with a cone disorder (CD), in order of descrip-
tion in the article from left to right and up and down (A-R). A/B) Achromatopsia. A) The 
central macula shows mottling of the RPE, which corresponds with B) the small region of 
absent fundus autofluorescence (FAF) in the center due to the RPE alterations. C/D) Cone 
dystrophy. C) The optic disc shows temporal pallor of the optic disc; the macula presents with 
a bull’s eye maculopathy with mottling of the RPE (color photograph). D) The fovea shows a 
small central region with absent FAF caused by RPE atrophy, surrounded by discrete hyperfluo-
rescent lesions (FAF image). E/F) Cone-rod dystrophy. E) The central macula shows an area of 
diffuse RPE degeneration (color photograph). F) The lesion corresponds to absence of FAF in 
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genic ABCA4 variants, the observed visual prognosis is significantly worse than in patients with 
mutations in other genes, with a mean age of legal blindness more than 20 years earlier.34
One study suggested that CNGB3 (3/47) and PDE6C (2/47) are involved in CRD (Huang et al 
2013), while previous studies only identified CNGB3 and PDE6C mutations in COD. Reasons for 
this discrepancy could include different genetic backgrounds, or insufficient phenotyping. 
2.2.4. Color vision imPairment
Normal human color vision is mediated by three types of cone photoreceptors that are maxi-
mally sensitive to light at 565 nm (the red cones, long [L] wavelength sensitive), at 535 nm (the 
green cones, middle [M] wavelength sensitive), and at 440 nm (the blue cones, short [S] wave-
length sensitive). The rods are maximally sensitive to light at 500 nm, mediate vision in dim light, 
and contribute little to color sense. Humans thereby generally have trichromatic color percep-
tion. The most frequent form of color vision impairment is dichromacy, which is observed in 
~6% of males and 0.4% of females. Dichromats have lost one class of pigment, either the L, M or 
S pigments, and are named protanopes, deuteranopes, and tritanopes, respectively, the latter 
of which are very rare. The more frequent protanopes and deuteranopes carry deletions of 
the red (OPN1LW) or green (OPN1MW) pigment genes, nonsense mutations in these genes, or 
missense mutations that influence their spectral tuning.43,44
Persons with X-linked blue cone monochromatism (XL-BCM) have the same clinical presenta-
tion as those with ACHM with photophobia, nystagmus, severe color vision disturbances, and 
a low visual acuity of ~0.10 in early childhood (table 1).45 To distinguish BCM from ACHM it is 
necessary to use color vision tests that specifically select for the blue color axis such as Berson 
plates.46 Color ERGs may also distinguish between responses from different cone types and 
may detect signals from intact blue cones on a background of absent signals from red and green 
cones.47 
XL-BCM is very rare with a prevalence of 1:100,000 individuals.24 The red and green cone 
opsins are absent which in almost 40% of BCM can be explained by deletions in the locus con-
trol region, the region regulating transcription of the red and green opsin genes.45,48
Other BCM patients carry a p.Cys203Arg variant in a single green or red-green hybrid gene that 
remained after non-homologous recombination.48 Together with a cystein at amino acid posi-
tion 126, this cystein forms a conserved disulfide bond that is important for protein stability.
Bornholm eye disease is an XL disease that has been reported in a large Danish family originat-
ing from the Danish island of Bornholm, characterized by a low visual acuity, a reduced photopic 
ERG, moderate to high myopia, and deuteranopia. Linkage analysis mapped the defect to a 
chromosomal region encompassing the red and green opsin gene array, suggesting overlap with 
congenital color blindness (deuteranopia). Recently, families with Bornholm eye disease, that 
display dichromacy and myopia, were shown to carry sequence variants in the first OPN1LW 
gene copy, which presumably lowers the amount of functional protein.49-51
Oligocone trichromacy (OT) is a rare condition first described in 1973 by van Lith.52 It is 
characterized by reduced visual acuity, mild photophobia, nearly normal color vision, a normal 
fundus appearance, and reduced cone responses with normal rod responses on multifocal ERG 
(table 1). It has been proposed that these patients have a reduced number of central cones or 
a reduced number in total (oligocone). The disease has an AR inheritance, and genetically there 
is considerable overlap with ACHM, as mutations in CNGA3, CNGB3 and GNAT2 have been 
associated with this form of CD.53,54
2.2.5. stargardt disease
Autosomal recessive Stargardt disease (STGD1), figures 2G and 2H, table 1) is the most preva-
lent inherited AR juvenile retinal dystrophy, with an estimated frequency of ~1:10,000.55 Fundus 
flavimaculatus is a largely overlapping phenotype with a later onset, slower progression, and 
degrees of peripheral involvement. CRD is usually non-syndromic but it can manifest as part 
of a syndrome (see 2.3).
As in COD the prevalence of CRD is 1:30,000-40,000 and can be inherited in an AR, AD or 
XL manner.39 Currently, 17 genes and some additional loci are known to be involved in AR 
CRD explaining approximately 22% of the cases (Figure 3C). As COD and CRD cases are often 
difficult to distinguish clinically, we have combined genetic data from the autosomal dominant 
forms of COD and CRD. In AD COD/CRD 21% of the cases were solved (Figure 3D) and in 
XL COD/CRD 74% (Figure 3E). 
Figure 3 Frequency and genetic causes of cone disorders
Estimates of the current frequency and genetic causes in cone disorders (CD). We only 
assessed studies in which cohort sizes were clearly indicated. A) ACHM. Mutations in five 
genes explain 93% of the cases, with the largest contribution by CNGB3, followed by CNGA3. 
For the included studies see supplemental table 1. B) Autosomal recessive and isolated COD. 
Eight genes each are mutated in a small proportion of the cases and together form the basis of 
disease in 25% of the cases. For the included studies see supplemental table 2; DNA samples 
in the study of Littink et al. (2010) have been scanned using homozygosity mapping (no Sanger 
sequencing) and therefore have been excluded from numerical analysis, C) Autosomal reces-
sive and isolated CRD. Seventeen genes are implicated in AR/I CRD, together responsible for 
23% of the cases, of which only ABCA4 is mutated in a significant proportion. For the included 
studies see supplemental table 3. D) Autosomal dominant COD and CRD. Ten genes are 
mutated in these conditions, mutations in which explain not more than 20% of the cases. For 
the included studies see supplemental table 4, and E) X-linked COD and CRD. For the included 
studies see supplemental table 5.
Mutations in the ABCA4 gene are not only implicated in Stargardt disease, but also the most 
prevalent cause of AR CRD. However its involvement varies widely between studies. In the 
Caucasian population this percentage varies between 26-65%;34,40 in a recent Chinese study 
only 1/47 cases carried ABCA4 variants. This also suggests a much lower prevalence of Stargardt 
disease (STGD1) in this population as previously suggested.41,42 In CRD patients with two patho-
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ated with a high phenotypic heterogeneity and limited genotype-phenotype correlation.70,82
Genes with a minor contribution to AD macular dystrophies are C1QTNF5, EFEMP1, FSCN2, 
GUCA1B, HMCN1, IMPG1, RP1L1 and TIMP3. Three of these present a rare but particular pheno-
type; EFEMP1 mutations are a cause of AD Doyne honeycomb retinal degeneration (Malattia 
Leventinese)83 which presents with drusen deposits at the level of Bruch’s membrane in the 
macula around the edge of the optic nerve head.84 Occult macular degeneration is caused by 
heterozygous mutations in RP1L1 and is characterized by central cone dysfunction and vision 
loss with a normal appearing retina.85 Sorby’s fundus dystrophy develops due to mutations in 
TIMP3 and is recognized by loss of central vision from subretinal neovascularization, as well as 
atrophy of the choriocapillaris, RPE and retina.86
For seven other AD macular conditions, the underlying genetic causes are not yet known. 
Autosomal dominant macular dystrophy with cystoid macular edema (dominant cystoid mcular 
dystrophy, DCMD; a.k.a. cystoids macular dystrophy, CYMD, figure 2Q and 2R) causes visual 
acuity loss in the second decade of life with or without strabismus.87 As the disease progresses, 
the macula will develop a central zone of ‘beaten bronze’ atrophy. The DCMD locus was posi-
tioned to an approximately 20-cM region between markers D7S493 and D7S526 on chromo-
some 7p15-p21,88 but the gene has remained elusive. 
North Carolina macular dystrophy (NCMD) is an AD macular dystrophy with an early child-
hood onset and a stable disease course.89-91 The highly variable phenotype contains yellow 
drusen-like lesions with retinal pigmentary changes of variable severity.89,92 The corresponding 
locus, MCDR1, was identified on chromosome 6q16,93,94 but the gene and its presumed function 
are currently unknown. Benign concentric annular macular dystrophy (BCAMD) is described 
in a Dutch family and may be caused by a mutation in IMPG1.95 An early-onset AD macular 
dystrophy (MCDR3) resembling NCMD has been mapped to chromosome 5.96,97 The defect in 
a Greek family with macular dystrophy has been positioned on chromosome 19q (MCDR5).98
2.3. CliniCal and genetiC CharaCteristiCs of syndromiC Cone disorders
In a minority of cases, cone-rod disorders are not limited to a degeneration of the retina, but 
show systemic involvement as well. Ocular signs and symptoms may precede or follow the 
onset of systemic features and it is therefore recommended to incorporate a comprehensive 
ophthalmologic examination into the regular clinical work-up of patients with additional non-
ocular features.
CD can be part of a syndrome or complex disease like Danon disease, Alström syndrome, or 
Jalili syndrome. Danon is a rare genetic condition caused by mutations in the X-linked lysosome-
associated membrane protein gene (LAMP2), and consists of the triad muscle weakness, cardio-
myopathy, and mental impairment. The mortality rate in males is high; the most frequent cause 
of death is a heart arrhythmia. Female carriers can show a milder phenotype, often restricted 
to cardiomyopathy.99 Ophthalmic involvement has been reported in several cases, varying from 
macular abnormalities to CRD.100,101 In one family, with a missense mutation in LAMP2, affected 
males presented with all features of CRD. The onset in this family was relatively late (middle-
age) and visual acuity declined to legal blindness within two decades thereafter.101 
Another example is the very rare AR Alström syndrome. It is characterized by CRD, hearing 
loss, obesity, diabetes, short stature, cardiomyopathy, and a progressively failure of lungs, liver 
and kidney. The disease manifests in early childhood and leads to a reduced life expectancy. 
Age of onset, severity of symptoms and prognosis may vary depending on genetic background. 
Alström syndrome is caused by mutations in the ALMS1 gene, which codes for a ciliary protein 
present in basal bodies, centrosomes and cytosol of the cells. Patients with Alström disease 
present with a low visual acuity, nystagmus and photophobia on occasion, atrophic lesions of 
more widespread distribution of flecks.56-58 Hereafter, fundus flavimaculatus will not be men-
tioned separately. STGD1 can arise in the first decade, but can also have an onset much later 
in life (up to 70 years of age). The outcome is generally poor central vision developing only 
a few years after the age of onset, but the prognosis may be better due to foveal sparing in 
some cases.59-61 STGD1 patients show a dark choroid in ~80% of the cases upon fluorescein 
angiography due to the lipofuscin accumulation, which prevents the background fluorescence 
of the choroid.62,63
A combination of a mild and a severe, or two moderately severe mutations in ABCA4 give rise 
to STGD1,64,65 whereas the combination of two severe mutations in ABCA4 are known to cause 
panretinal, severe CRD which, at the endstage, may be difficult to discriminate from typical 
retinitis pigmentosa (RP).66 The estimated carrier frequency of ABCA4 variants in the normal 
population can be as high as 1:20.65 As described in more detail in paragraph 3.2, a deficiency 
of ABCA4 results in accumulation of lipofuscin in the RPE which can be seen in and around the 
macula as yellowish white flecks. In animals as well as in patients, it was shown that a defective 
ABCA4 protein causes accumulation of N-retinylidene-PE in the RPE, which forms a potential 
toxic component inducing photoreceptor death.67,68
In persons with CRD and ABCA4 mutations there appears to be an intrinsic and severe defect 
in photoreceptors, which directly leads to photoreceptor loss and lipid accumulations in the 
RPE are mostly absent.
2.2.6. other maCuloPathies
Mutations in PRPH2 have been associated with AD central areolar choroidal dystrophy (CACD, 
figures 2K and 2L), “pseudo-Stargardt pattern dystrophy”69, pattern dystrophies like butterfly-
shaped pigment dystrophy (BSMD, figures 2M and 2N) and adult-onset foveomacular vitel-
liform dystrophy (Figures 2O and 2P), as well as AD retinitis pigmentosa.70 The PRPH2 protein 
product RDS/peripherin is a photoreceptor-specific glycoprotein crucial in photoreceptor 
outer segment discs development and maintenance (Figure 4, left lower panel).71-73 It has been 
hypothesized that abnormal RDS/peripherin protein results in an altered cone outer segment 
structure and potentially an altered rod outer segment structure.74 This may interfere with 
the photoreceptor outer segment-RPE interaction leading to accumulation of lipofuscin and 
byproducts in the RPE cells resulting in apoptotic cell death of RPE and photoreceptor cells. 
Pattern dystrophies due to PRPH2 mutations are presumed to arise by disruption of the pho-
toreceptor disc membranes.75,76
Best vitelliform macular dystrophy (BVMD, figures 2I and 2J), a member of the group of ‘bestro-
phinopathies’, is caused by AD inherited mutations in the BEST1 (or VMD2) gene, which encodes 
the bestrophin-1 protein, a calcium-activated chloride channel located at the baso-lateral 
membrane of RPE cells, that also influences voltage-gated calcium channels within the RPE. 
Furthermore, BEST1 localized mostly to the ER close to the baso-lateral plasma membrane and 
is involved in the storage-dependent Ca-influx into RPE cells.77 The age at onset of central vision 
loss is highly variable ranging from the first to the sixth decade.78,79 The disease-course of BVMD 
begins with the asymptomatic carrier (‘pre-vitelliform’) stage, progressing to variable clump-
ing of vitelliform material in the vitelliruptive or ‘scrambled-egg’ stage, culminating in variable 
degrees of chorioretinal atrophy and subretinal scarring in the cicatricial stage. Patients with 
AR bestrophinopathy have more extensive retinal abnormalities and carry a BEST1 mutation 
on both alleles.80 Hypothetically, causes of RPE dysfunction in BVMD are related to abnormal 
ionic transport leading to the accumulation of subretinal fluid and vitelliform material originat-
ing from photoreceptor outer segment-waste products and lipofuscin loaded pigmented cells.81 
The overload of the RPE eventually leads to photoreceptor and RPE dysfunction.
PRPH2 variants have also been associated with BVMD and like BEST1 mutations, are also associ-
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Mutations in the CNGA3 and CNGB3 genes encoding the α- and β-subunits of the cone cGMP-
gated channel can cause ACHM and COD.26,113,114,121 A defect or lack of the cGMP-gated channel 
impairs the resting state dark current and the establishment of a proper cone photorecep-
tor membrane potential (Chang et al 2009), causing apoptosis by perpetual influx of calcium 
ions.34,122 The majority of CNGB3 mutations are truncating, resulting in the absence or altered 
protein levels of the β-subunit.32 Compared to the β-subunit of the pore, which mostly com-
prises truncating mutations in the CNGA3 gene, the cone α-subunit is more sensitive to changes. 
Amino acid substitutions in the highly conserved CNGA3 protein have an even more severe 
phenotypic impact. The reason may lie in the fact that CNGA3 can form a functional channel in 
the absence of CNGB3, while CNGB3 cannot establish the ion currents without the presence 
of CNGA3.123,124 CNGA3 missense mutations can lead to an interfering conformational change 
of the active channel due to an altered secondary structure.124 The impaired channel will cause 
cellular mistrafficking125,126 and altered targeting to the plasma membrane due to impaired sur-
face expression.127,128 
Remarkably, unlike COD and CRD, autosomal dominant inheritance has not been observed for 
ACHM, despite the fact that many cone-specific proteins act in multimeric complexes in which 
dominant-negative disease mechanisms would be plausible.
The KCNV2 gene encodes a voltage-gated potassium channel subunit in cone and rod photo-
receptors and mutations cause COD with supranormal rod responses on ERG. The subunit 
encoded by KCNV2 is unable to form a functional potassium channel but needs heteromeriza-
tion with other channel components, thereby altering the potassium current in the cell and 
affecting its excitability potential.129,130 It is unclear how mutations in this gene cause repolariza-
tion disturbances in rods.131,132
Specific heterozygous GUCY2D missense mutations are a cause of AD CRD, whereas homozy-
gous or compound heterozygous inactivating mutations in this gene can cause AR-LCA. GUCY2D 
encodes the membrane-bound retinal guanylyl cyclase-1 protein (RetGC-1), which is expressed 
in both types of photoreceptors but predominantly in the cone outer segment.133-136 In mam-
malian photoreceptor cells RetGC-1 and RetGC-2 together synthesize cyclic 3’, 5’-guanosine 
monophosphate (cGMP) from guanosine triphosphate. RetGC-1 restores the Ca2+-sensitive 
cGMP levels after light activation of the phototransduction cascade, together with its associ-
ated activator proteins GUCA1A and GUCA1B.137 Cyclase activity is regulated by Ca2+, which 
binds to the GC-associated proteins, GCAP1 and GCAP2 encoded by GUCA1A and GUCA1B, 
respectively. The majority of dominant missense mutations causing AD COD and AD CRD are 
found in the Ca2+-binding EF hands of the proteins. Similar to the dominant GUCY2D mutations, 
these mutations generally alter the cyclase sensitivity to inhibit the Ca2+ levels after a light flash.
3.2. retinoid CyCles
To maintain the phototransduction cascade, recycling of the chromophore all-trans-retinal to 
11-cis-retinal is required. This process is referred to as the retinoid or visual cycle. The rod and 
cone visual cycles take place in their respective outer segments, and the RPE cells (Figure 4, left 
upper panel). Moreover, part of the visual cycle of the cones takes place in the cone OS and 
the Müller cells (Figure 4, left middle panel). Although several genes encoding proteins of the 
retinoid cycles have been found to be defective in inherited retinal dystrophies, only the ABCA4 
and SEMA4A genes are implicated in CDs (Table 2).
Upon photo-excitation all-trans-retinal dissociates from opsin and is subsequently transferred 
to the cytoplasmic space by ABCA4. In rods, ABCA4 is located at the rim of the outer seg-
ments discs and essential in the transport of all-trans-retinal from the inner to the outer leaflet 
of the disks through an ABCA4-mediated flippase of N-retinylidene-phosphatidylethanolamine 
the retina, and an abnormal cone-rod ERG. Phenotypically this ciliopathy shows similarities to 
Bardet-Biedl syndrome.102 
Jalili syndrome (cone dystrophy with amelogenesis imperfecta) is caused by autosomal reces-
sive mutations in CNNM4, encoding a metal transporter protein. Patients present with a de-
mineralization of both primary and secondary dentition with or without COD. A large Arab 
family with Jalili syndrome showed low visual acuity since early childhood, photophobia and 
nystagmus in some cases, absent color vision, and a bull’s eye maculopathy or atrophic macular 
degeneration. Cone responses were more reduced than rod responses,103 consistent with a 
retinal diagnosis of CORD. 
A novel syndrome of North Carolina-like macular dystrophy with progressive sensorineural 
hearing loss (MCDR4) was linked to chromosome 14q.104
2.4. differential diagnosis
CDs form a genetically complex disease spectrum with a large phenotypic variability. Different 
mutations can result in similar phenotypes, whereas many genetic factors may contribute to 
the phenotypic variability of one causative mutation. Traditionally, Leber congenital amaurosis 
(LCA) has been considered as the congenital form of retinal dystrophy and it is typically associ-
ated with a very low vision at birth accompanied by roving nystagmus, amaurotic pupils, and 
a high hypermetropic refractive error. Visual acuity ranges from 0.10 Snellen visual acuity to 
no light perception. Eye poking (oculodigital reflex) to provoke visual stimuli can be observed 
in young children. Most often no fundus abnormalities are present, but in later stages round 
subretinal pigment clumps or bone-spicule-like pigment changes can develop. ERG responses 
are undetectable for both rods and cones before the age of one year. With an inconclusive ERG 
result, it is sometimes necessary to repeat the ERG after the age of 1 year to obtain the cor-
rect diagnosis. The prevalence of LCA varies from 1:30,000 to 1: 81,000.105,106 In most cases the 
inheritance modus is AR, but cases of AD inheritance have been described. Systemic disorders 
that are associated with LCA or a LCA-like ocular phenotype are Alström syndrome,107 Batten 
disease,108,109 Joubert syndrome,110 peroxisomal diseases ,111 and Senior Løken syndrome.112
3. Cone disorder meChanisms
3.1. PhototransduCtion CasCade
The processes involved in the conversion of light into an electric neural signal is called photo-
transduction. The phototransduction cascade takes place in the outer segments of the rod and 
cone (Figure 4, upper right panel) photoreceptors. Defects in various components of the photo-
transduction cascade can lead to CD: the red and green opsins, the cone transducin α subunit, 
the cone phosphodiesterase α’ and γ subunits, the cone-specific cGMP-gated α and β subunits, 
the retinal guanylyl cyclase-1, and the voltage-gated potassium channel subunit. 
Deletions of, or mutations in, the red and green opsin genes may cause color blindness (see 
2.2.4.). A gene conversion event in which exon 3 of the red opsin gene, carrying the p.Trp177Arg 
variant, was transferred into the red opsin gene, was shown to underlie X-linked COD.43 
Mutations in the GNAT2-encoded α-subunit of cone transducing leads to ACHM.113-115 The identi-
fied mutations are null alleles, which are predicted to prevent either the formation of the trimer-
ic transducin protein complex or its interaction with cone opsin and phosphodiesterase-γ.115,116 
Gene defects in PDE6C and PDE6H, encoding the α’ and γ subunits of the cone cGMP phospho-
diesterase, are a cause of ACHM and COD.117,118 Mutations in the PDE6C gene are null alleles 
leading to absence of the α’ subunit, or missense mutations causing a loss or reduction of the 
catalytic activity resulting in reduced hydrolysis of cGMP.119,120 The absence of transducin or 
phosphodiesterase activity can be considered functionally analogous since in both cases the 
phototransduction cascade is interrupted and the photoreceptor remains in the dark state.119 
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splicing, absence of DNA binding because of mutations in the DNA-binding domain, or impaired 
co-repressor binding because of mutations in the ligand-binding domain.158 
The rod photoreceptor outer segments represent a unique and complex example of specialized 
sensory cilia by their dense stacks of rhodopsin-laden discs. Disc renewal takes place at the 
proximal side and it has been estimated that 10% of the rod photoreceptor discs at the distal 
tips of the OS in humans are removed every day by undergoing phagocytosis by the overlying 
RPE cells.159 The process of disc morphogenesis is critical for the viability of the photoreceptor 
cells as shown by several vertebrate models, where blockage of disc morphogenesis resulted 
in cell death and retinal degeneration.160,161 A relevant difference between cone and rod photo-
receptors is the continuity of the disc membranes in cones and the presence of separate discs 
in rods. 
The transmembrane protein peripherin/RDS forms homotetramers, or heterotetramers with 
ROM1. Some heterozygous variants in the gene encoding RDS, PRPH2, are associated with AD 
cone disorders.162-165 Other heterozygous variants in PRPH2, in combination with heterozygous 
variants in ROM1, are associated with digenic RP.166-168 These molecules are proposed to play 
a critical role in disk membrane morphogenesis and to keep the rod discs in a flattened con-
figuration by connecting to similar molecules on the other side of the disc through disulphide 
bridges (Figure 4, left lower panel). Possibly, RDS has a similar function in cones to flatten the 
invaginations.
PROM1 interacts with protocadherin 21 (PCDH21) and actin filaments, which are also crucial 
for disk membrane morphogenesis. For ADAM9 it has been suggested that it may be involved in 
adhesion at the junction of the outer segments (OS) and the RPE. Alternatively, the transmem-
brane ADAM9 protein may be involved in the remodeling of the extracellular matrix between 
the RPE and the OS or in the shedding of factors essential for the maintenance of the extracel-
lular matrix.169 FSCN2 and ELOVL4, two genes involved in AD macular degeneration,170,171 are 
expressed in different parts of the photoreceptor cells and are also thought to have a role in 
maintaining the structure and/or physiological function of photoreceptor cells.
3.4. transPort ProCesses
The narrow ‘channel’ or ‘conveyer belt’ connecting the inner segment with the outer seg-
ment of the photoreceptor cells is called the connecting cilium (CC; see Figure 4, right lower 
panel). In the process of vision, transport of proteins from the inner segments critically occurs 
through docking at the basal body (or adjacent membrane) and subsequent transport via the 
CC towards the outer segment.172 Intraflagellar transport (IFT) complexes tightly regulate the 
anterograde flow of proteins necessary for the assembly, maintenance and renewal of outer 
segment discs,173 as well as the retrograde transport of proteins.
Several proteins involved in CD have been identified at the CC. These proteins include AIPL1, 
C8orf37, RAB28, RPGR, RPGRIP1, TULP1, and UNC119. Mutations in RPGR causing COD 
are localized in ORF15, a highly repetitive region coding for a glutamic acid and glycine-rich 
C-terminal domain, while mutations causing RP are found throughout the protein. It has been 
hypothesized that the phenotype is determined by the type of opsin which is mis-localized, 
depending on the type of mutation.174,175 Alternatively, the genetic background may determine 
the disease outcome to be cone-dominated or rod-dominated.176
The transition zone protein RPGR has a wide expression, but mutations predominantly affect 
photoreceptor function, with few cases of hearing loss, sino-respiratory infections and sperm 
dysfunction.177-180 RPGR binds to RAB8a,181 and via crystal modeling it was proposed that RPGR 
has an interplay with PDEδ and Arl2/3 to regulate ciliary targeting of farnesylated cargo.182 
(PE), the Schiff base conjugate of retinal and PE. In the cytoplasm, all-trans-retinal separates 
from PE and is converted to all-trans-retinol.68,138-140 In cones, N-retinylidene-PE is translocated 
from the exocytoplasmic leaflet (lumen/extracellular) to the cytoplasmic leaflet, and upon dis-
sociation from PE, all-trans-retinal is reduced to all-trans-retinol by retinol dehydrogenase 8 
(RDH8) (Figure 4, left upper panel).141,142
A defective ABCA4 protein leads to the accumulation of A2E in RPE cells which basically consists 
of all-trans-retinal conjugated to N-retinylethanolamine (N-retinylidene-N-retinylethanolamine; 
N-retinylidene-PE) and another all-trans-retinal molecule cells,143,144 which is toxic to these cells 
in higher concentrations.145
In cone and rod photoreceptors, all-trans-retinal is converted to all-trans-retinol (i.e. vitamin 
A), and absorbed by the RPE cell. In these cells, vitamin A is converted to all-cis-retinal and 
recycled to be introduced back into the phototransduction cascade.146 Under light conditions 
cones have a higher demand for vitamin A compared to rods, which can be provided through an 
alternate visual cycle between the cone photoreceptor cells and the Müller cells. In the fovea, 
Müller cells exist in a 1:1 ratio to cones. In cone-dominated retinas (from ground squirrel and 
chicken) it was found that all-trans-retinol was isomerized to 11-cis-retinol directly, without 
the intermediate molecule all-trans-retinyl.147 Recently, Kaylor and colleagues showed that all-
trans-retinol is isomerized by dihydroceramide desaturase-1 to 11-cis-retinol, 9-cis-retinol and 
13-cis-retinol, of which 11-cis-retinol is subsequently bound to cellular retinal-binding protein 
(CRALBP). The interphotoreceptor retinoid-binding protein (IRBP) transports 11-cis-retinol to 
the cone OS. 9-cis-retinol diffuses directly to the interphotoreceptor matrix and into cone OS, 
and together with 11-cis-retinol is oxized by an unknown retinol dehydrogenase to 9/11-cis-ret-
inal which subsequently is combined with apo-opsin to form a new chromophore.148 Although 
more knowledge on the cone visual cycle has been gained, compared to the rod cycle challenges 
remain regarding the differences between the cycles. More studies could possibly address these 
challenges, potentially revealing novel candidate genes for CD.
Semaphorin 4A (SEMA4A) plays a role in endosomal sorting in the RPE (Figure 4, left upper 
panel). As a response to oxidative stress, SEMA4A acts as a switch converting endosomal 
sorting in the lysosome to exosomal release, thereby preventing light-induced photoreceptor 
apoptosis. In the absence of oxidative stress, SEMA4A sorts retinoid-binding proteins with 
retinoids, a RAB11-facilitated process by which 11-cis-retinal is regenerated and transported 
back to photoreceptors.149
3.3. PhotoreCePtor develoPment and struCture
During development, photoreceptor specification is initiated by transcription factors OTX2 and 
RB by influencing the multipotent retinal neuroepithelial cells to exit the cell cycle. It is hypoth-
esized that CRX is the competence factor in photoreceptor precursor cells after mitosis.150 
Cells that only express CRX have the fate to become cone precursors, while NRL-expressing 
cells will develop into rod photoreceptor cells with subsequent expression of NR2E3.150 The 
transcription factor RAX2 (QRX) is thought to synergistically increase the transactivating func-
tion of CRX and NRL and also to interact with CRX.151 Other, as yet unknown transcription 
factors are necessary to complete the development to mature photoreceptors. 
Dominant gain-of-function mutations in CRX were found to be a cause of AD CRD,152 by 
impairing CRX-mediated transcriptional regulation of photoreceptor genes.153 Recessive loss-
of-function, and dominant mutations in NR2E3 cause enhanced S-cone syndrome, AR RP and 
rod related syndromes.154-157 The molecular mechanism underlying phenotypes due to NR2E3 
mutations involves the absence of the NR2E3 repressor function on cone-specific gene pro-
moters, either by the absence of NR2E3 protein because of nonsense mutations or aberrant 
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3.6. misCellaneous
Several other CD-associated proteins cannot be assigned to one of the five major functionalities 
of the cone photoreceptor, RPE cells, and Müller cells, and are listed below.
Sphingolipids consist of a sphingoid base linked to a variety of polar groups and fatty acid chains.201 
CERKL is an endoplasmic reticulum and golgi apparatus membrane associated protein, which 
seems to be involved in the sphingolipid metabolism due to the shared homology with CERK.202 
However its exact role is currently unknown. Knockdown mice showed reduced levels of several 
sphingolipids, such as glucosylceramide or sphingomyelin. Enzymes in the synthesis/degradation 
pathway of these sphingolipids are associated with sphingolipidoses, which among other features 
also can show retinal degeneration.203 Furthermore ceramides are involved in oxidative stress and 
apoptosis, and it has been shown that CERKL protects from induced oxidative stress in vitro.202 
CERKL has been shown to localize in mouse cone photoreceptors and ganglion cells,204-206 and 
in vitro assays suggest that CERKL interacts with GUCA1A and GUCA1B.207 Morpholino oligo-
nucleotide injected zebrafish showed abnormal eye development with lamination defects, photo-
receptor outer segment developmental abnormalities, reduced eye size and increased apoptosis 
of retinal cells, suggesting that CERKL is relevant for survival and protection of retinal tissue.208 
In humans, PITPNM3 is shown to be expressed in the brain, spleen and ovary, although the 
analysis of expressed sequence tags predicted a wider expression pattern.209,210 The zebrafish 
homologue of PITPNM3 is predominantly expressed in the inner segments of cone photorecep-
tor cells.211 In the rat expression however is seen throughout the retina in all cell layers including 
the inner segment and outer plexiform layers containing photoreceptor terminals with predomi-
nant expression in Müller cells.212 Members of the PITP-family play a role in multiple processes 
such as phospholipase C-mediated inositol signaling, ATP-dependent Ca2+-activated secretion, 
lipid metabolism, trafficking from Golgi-membranes and exocytosis.213 The importance of a PIT 
domain was observed in rdgB mutant flies with light-dependent retinal degeneration rescued by 
transfer of the PIT-domain.214 The signaling pathway for mammalian PITPNM3 is not completely 
understood.209 
Extracellular matrix components or plasma membrane components proteins encoded by BEST1, 
C1QTNF5, EFEMP1, HMCN1 and TIMP3, are expressed in the RPE. A heterozygous p.Ser163Arg 
variant in C1QTNF5, encoding the short-chain collagen CTRP5, causes late-onset macular degen-
eration. It was proposed that mutant CTRP5, which is secreted by the RPE, is unable to fulfill 
its adhesive property between the RPE and Bruch’s membrane.215 Although the functions of 
fibulin-3 (EFEMP1) and fibulin-6 (HMCN1) are unknown, interaction of fibulin-3 with TIMP3, an 
inhibitor of matrix metalloproteinases, has been demonstrated. TIMP3 mutations are a cause of 
Sorsby maculopathy, a drusen associated dystrophy.216 It has been hypothesized that misfolding 
and accumulation of mutant fibulin-3 underlies drusen formation although the protein itself is not 
a major component of the drusen.217
Another component of the rod and cone photoreceptor extracellular matrix is IMPG1 (a.k.a. 
SPACR). Although its exact function is unknown, IMPG1 could be important in RPE-photoreceptor 
attachment.218 Alternatively, mutations in IMPG1 lead to impaired metabolism of the photorecep-
tors and/or RPE resulting in an accumulation of vitelliform deposits in the retina.219
RP1L1 was shown to closely interact with RP1 via its two DCX domains, which functions in 
the assembly and stabilization of axonemal microtubules.220 Whereas autosomal recessive and 
dominant mutations in RP1 lead to rod photoreceptor dysfunction, autosomal recessive variants 
in RP1L1 lead to late-onset RP; heterozygous variants are associated with AD occult macular 
dystrophy.85,221,222
RPGRIP1 is linked to cilium integrity with RPGR via Nek4 serine/threonine kinase183 and local-
izes exclusively to the photoreceptor CC. Absence of RPGRIP1 in mice resulted in a strongly 
decreased formation of photoreceptor outer segments and a rapid degeneration of these neu-
rons, leading to vision loss.184
AIPL1 functions as a chaperone of rod PDE6 and interacts with its α-, β-, and γ-subunits 185 
and is thereby indirectly also involved in the phototransduction cascade. The cone PDE6 α’ but 
not the γ subunit carries a carboxy-terminal prenylation motif (as do the rod α and β PDE6 
subunits), and it has been hypothesized that AIPL1 also acts as a chaperone for cone PDE6.186 
It recently has been shown that AIPL1 is essential for cone PDE6 stability.187 AIPL1 is necessary 
for proper assembly of the rod PDE6-complex185 and also functions as a chaperone of other 
farnesylated proteins. The absence of AIPL1 results in disorganized rod and cone outer seg-
ments, although presence of viable rod cells may prevent a rapid degeneration.186 Interestingly, 
null mutations in RAB28 were recently found to be associated with AR CRD.188 RAB28 belongs 
to a superfamily (>60 members in humans) of small GTPases that fulfill a myriad of intracellular 
transport functions. Strikingly, RAB28 is uniquely farnesylated at its carboxy terminus, whereas 
almost all other RABs contain two geranylgeranyl groups for membrane attachment and very 
few RABs can be farnesylated or geranylgeranylated. The expression of RAB28, as is the case 
for most RABs, is not restricted to the retina. It is not known why mutations in RAB28 only 
result in a retinal phenotype.
UNC119, also known as Retina Gene 4 protein (RG4), has been shown to be crucial for transdu-
cin transport in the absence of light.189 In one mouse model UNC119 can dissociate transducin 
subunits from each other and the membrane, and subsequently inhibits rhodopsin-dependent 
activation of transducing.190 Furthermore, UNC119 has the capacity of binding myristoylated 
proteins, e.g. NPHP3, which is regulated by the small GTPase ARL3.191 
Mutations in the gene coding for RIMS1 are a cause of AD CRD, which is characterized by a 
progressive loss of photoreceptors along with retinal degeneration.192 RIMS1 was found to be 
essential to short- and long-term synaptic plasticity by affecting the readily releasable pool 
of vesicles193,194 and RIMS1 proteins were found to be required for normal Ca2+-triggering of 
exocytosis.195
3.5. synaPtiC transduCtion
A subset of genes associated with CD encode proteins that are localized in the synaptic 
region, i.e. CACNA1F, CACNA2D4, RIMS1, and UNC119. The transmission of L-glutamate at 
the photoreceptor synapses to the horizontal and bipolar cells is a calcium-dependent event. 
Transmitter release is increased with depolarization, as voltage-dependent calcium chan-
nels in a depolarized state have an increased capability of channel opening.196 CACNA1F and 
CACNA2D4 are involved in a continuous calcium-dependent transmitter release and when 
disturbed cause CD. The reduction of functional calcium-channel densities in synaptic terminals 
may lead to inefficient photoreceptor-signal transmission and may account for the electronega-
tive ERG.197 The RIMS1 protein plays a role in basic synaptic vesicle release as well as long- and 
short-term pre-synaptic plasticity.193,194,198 The RIMS1 p.Arg655His missense mutation identified 
in CRD abolishes the hyperpolarization of current activation, likely resulting in impaired synap-
tic transmission of ribbon synapses of the visual system.199 
UNC119 may also have an important function in photoreceptor neurotransmission as it also 
is localized at the ribbon synapses formed between photoreceptors and the horizontal and 
bipolar cells of the retina.200
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FSCN2, HMCN1), or because they localize to structures not shown (TIMP3). Left upper panel) 
The retinoid cycle taking place in cone photoreceptor cells and the RPE. Upon photoactivation 
(indicated by a lightning symbol), 11-cis-retinal is converted into all-trans-retinal and dissoci-
ates from activated cone opsins, OPN1LW and OPN1MW (activated opsins indicated by an 
asterix). All-trans-retinal is then recycled to 11-cis-retinal via several enzymatic steps in the 
RPE. Transport of all-trans-retinal is mediated by ABCA4. Left middle panel) Retinoid cycle 
in cones and Müller cells. Upon photoactivation, isomerization of 11-cis to all-trans-retinal in 
a cone opsin takes place. After dissociation, all-trans-retinal is reduced to all-trans-retinol by 
RDH8 and then released from the cone outer segment into the interphotoreceptor matrix 
where it is bound by IRBP and taken up by the Müller cells. All-trans-retinol is isomerized 
by dihydroceramide desaturase-1 (DES1) to 11-cis-retinol, 9-cis-retinol and 13-cis-retinol, of 
which 11-cis-retinol is subsequently bound to cellular retinal-binding protein (CRALBP). The 
interphotoreceptor retinoid-binding protein (IRBP) transports 11-cis-retinol to the cone outer 
segments. 9-cis-retinol diffuses directly to the interphotoreceptor matrix and into cone outer 
segments, and together with 11-cis-retinol is oxized by an unknown retinol dehydrogenase to 
9/11-cis-retinal which subsequently is combined with apo-opsin to form a new chromophore. 
Left lower panel) Developmental and structural proteins. Three transcription factors mutated 
in non-syndromic CDs are CRX, NR2E3 and RAX2. Other proteins important in the mor-
phogenesis and structure of the cone photoreceptor cell are EYS, IMPG1, PRPH2, PROM1, 
and PCDH21. Right upper panel) The phototransduction cascade in cone photoreceptor cells. 
Upon activation, amplification of the signal is mediated by the α-subunit of transducin and the 
α’- and γ-subunits of cone phosphodiesterase, encoded by PDE6C and PDE6H. This results 
in closure of the cGMP-gated channel composed of CNGA3 and CNGB3, a hyperpolariza-
tion of the cell and a reduction in glutamate release at the synaptic region. The KCNV2 gene 
encodes a voltage-gated potassium channel subunit together with other channel components 
and regulated the potassium current in the cell and affects its excitability potential. PDE6 and 
transducin subunits are marked as alpha (α), alpha’ (α’), beta (β), and gamma (γ). Right lower 
panel) CD-associated proteins involved in transport processes in the cone photoreceptor cell. 
AIPL1 is a chaperone of the putative farnesylated protein PDE6C. Farnesylated proteins are 
marked with a red zig-zag icon. C8orf37, RAB28, RIMS1, and TULP1, based on immunolocalisa-
tion studies act predominantly in transport processes toward and at the base of the connecting 
cilium, whereas RPGR and RPGRIP1 act throughout the connecting cilium. UNC119 is respon-
sible for ciliary delivery of myristoylated proteins as well as the dissociation of transducin in 
separate subunits in mice. ATP, adenosine-triphosphate; GTP, guanosine-5’-triphosphate; GDP, 
guanosine diphosphate; GMP, guanosine monophosphate; cGMP, cyclic GMP; IRBP, interphoto-
receptor retinol binding protein, the product of RBP3; MII, metarhodopsin II; P, phosphoryla-
tion; RAL, retinal; RE, retinyl esters; REH, retinyl ester hydrolase; ROL, retinol.
 
4. mammalian models for Cone disorders
4.1. mouse models for Cone disorders 
To learn more about the etiology, progression, underlying disease mechanisms, and to explore 
treatment of CDs, rodent animal models have been used. Rodent models have significantly 
improved our knowledge of retinal diseases as the disease process can be followed entirely, and 
invasive studies can be done. The lifespan and development of these animals permit a degenera-
tive process to be followed in a matter of weeks to months also enabling thereby the effects 
of treatment to be monitored. The largest disadvantage of the mouse as a model for CD is the 
lack of the cone-dominated region or macula in mice, as well as the fact that humans have genes 
encoding three different types of cones (long, middle and short wavelengths), whereas the mouse 
only contains cones sensitive for middle and short wavelengths.215 Therefore, retinal phenotypes 
Figure 4 Schematic representation of the roles of the non-syndromic cone disor-
der-associated proteins in the human retina
Schematic representation of five major functionalities of human cone photoreceptor cells (PC), 
Müller cells and the RPE. The locations and functions of proteins involved in non-syndromic 
CDs are depicted in different colors. Proteins which are relevant for the different cellular pro-
cesses and not mutated in CDs are given in black lettering. Some CD-associated proteins are 
not shown in this figure either because of their wide-spread localization in the retina (EFEMP1, 
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may differ significantly between mice and humans. In some cases, mice do not mimic the human 
phenotype, as is the case for the Adam9,216 Cerkl,196 Gcap1 and Gcap2217; 218 mutant mice, or have 
not been described in detail for genes like CDHR1, GUCY2D and RIMS1. Secondly, the eye of the 
mouse differs in size and anatomy from humans hindering gene delivery approaches. Finally, the 
relatively short life span of a mouse can limit the relevance of the model. The ability to genetically 
modify mouse models has increased throughout the past decades. Besides genetic modification, 
a number of spontaneous and chemically induced models have been identified. In Table 2, 42 
genes are listed that are associated with non-syndromic CDs. Natural occurring or generated 
mouse models are available for 31/42 (74%) CD-associated genes, including 33 knockouts, 14 
knock-ins, two knockdowns, eight reporter models, three chemically induced, two targeted, two 
trapped, one floxed and 10 spontaneous mouse models (Table 2). For 10 of the CD associated 
genes, no mouse model is available. This is also true for the EYS gene, which represents the only 
CD-associated gene that is absent in the mouse.16; 219 To date mouse model studies have contrib-
uted to our understanding of disease, in addition gene therapy has been successfully applied in 10 
of these models (Table 2).
Compared to rod phototransduction studies in mice, studies in cones have been limited to ERG 
studies, mainly due to the low percentage of cones (3%) and fragility of the cone outer segments. 
To further study the mechanism, function and etiology of cones, mouse models were designed to 
increase the number of cones in the mouse retina.220 The Nrl knockout forces the cell fate of rod 
photoreceptor cells into cone-like photoreceptors.212-223 In a second model, EGFP was expressed 
in mouse cones to increase detection and identification of cones,224 and in the third model, rod 
phototransduction was blocked by a knockout of the rod transducin α-subunit (Gnat1 -/-).225
4.2. other animal models of Cone disorders 
Compared to small animal models like mouse or rat, larger animal models have a few advantages. 
Anatomically, the retinas of dogs and cats are more similar to those of humans, as they have a 
cone-rich area, which is similar to the macula. Chicken have a cone-rich retina in which cones 
outnumber the rods at 6:1, while in humans the cone-rod ratio is 1:20. Chicken cones have 
a higher density in the rod-free region analogous to the human fovea.234,235 Chicken also have 
retinal glia (Müller) cells, a fully sequenced genome and relatively low maintenance costs. The 
size of the eyes makes the chick especially suitable for experimental manipulation.236 Next to 
the cone-rich retina of chickens, pigs are also equipped with a cone-dominated retina. Although 
no naturally occurring cone disease related defects have been discovered in pigs, Mussolino et al 
(2011) showed that the porcine retina is suitable for developing novel AAV-mediated therapies 
using AAV2/5 or AAV2/8 to transduce both RPE and photoreceptor cells without safety issues.237 
Xenopus laevis is an ideal animal model to study the role of the interphotoreceptor matrix in 
RPE-photoreceptor interactions,238 due the fact that 30% of its photoreceptors are cones, and 
because they have relatively large photoreceptors, which is helpful in cellular, transgenic and 
imaging studies.239 The Xenopus genome is available240,241 and strategies using morpholino oligo-
nucleotide antisense knock-down offer a powerful reverse genetics approach.242
Currently there are only few large animal models which are suitable for investigating inherited 
CDs. Canine models with gene mutations in ADAM9, BEST1, CNGB3, RPGR and RPGRIP1, are 
currently used to develop therapy models. In three dog models the retinal degeneration was 
successfully treated30,243,244 (Table 2). A great potential in the discovery of novel canine models 
for CDs resides in the several hundred dog breeds affected by progressive retinal atrophy with 
a currently unidentified gene defect (RWJ Collin (Nijmegen), K. Stieger (Giessen) and H. Lohi, 
(Helsinki), personal communications). Other large animal models for CD are sheep, which carry 
a spontaneous nonsense mutation in CNGA3 to investigate ACHM,245 and a feline model with a 
single nucleotide deletion in CRX.246
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The current status of treatment of CNGA3 and -B3-associated channelopathies in animal mod-
els have shown solid and encouraging results and hold great promises for future treatment of 
patients with similar defects.336 A human Phase 1 trial for patients with CNGA3 mutations is 
being developed (B. Wissinger, personal communication). The human situation however may be 
more complex and limitations may occur due to the age-dependent results for CNGB3, which 
argues to treat only younger patients. Possibly, the same or a similar treatment with CNTF 
could create treatment opportunities for older patients too. 
In GNAT2 knockout mice, AAV-mediated therapy has also proven to be successful.296 However, 
for those genes in which AAV-mediated therapy is not feasible due to their size, other strate-
gies need to be developed. The ABCA4 open reading frame (ORF) measures 6.8 kb and there-
fore an alternative approach using the nanoparticle (a.k.a. non-virus) mediated therapy has 
been applied. Compacted DNA nanoparticles were constructed with the human ABCA4 cDNA 
and the IRBP or mouse opsin promotor. Nanoparticles have a high transfection efficiency in 
post-mitotic cells, are biodegradable, and cause minimal toxicity even after repeated doses to 
the eye, lung and brain.248 and refs therein This non-viral approach has been performed subretinally 
on Abca4-/- mice. ABCA4 transgene expression was identified up to 8 months after injection 
resulting in significant structural and functional rescue of Stargardt disease, with improved dark 
adaptation recovery and reduced lipofuscin granules in the RPE.248 These results suggest that 
nanoparticle-mediated gene delivery has the potential to target many diseases caused by muta-
tions in large genes. Alternatively, lentiviral vectors can be used337 which can accommodate 
cDNAs up to ~10 kb. This strategy is currently also used for the development of ABCA4 gene 
therapy. Equine infectious anemia virus (EIAV)-derived lentiviral vectors expressing either the 
human ABCA4 gene or the LacZ reporter gene under the control of the constitutive (CMV) 
or photoreceptor-specific (Rho) promoters were subretinally injected in Abca4-/- mice. High 
transduction efficiency of rod and cone photoreceptors and a significant reduction of accumu-
lation of A2E were observed in these mice suggesting the potential of lentiviral gene therapy in 
treating ABCA4-associated maculopathies.249 Similar results in rabbit and macaque were shown 
in the study by Binley et al. (2013). In this study ‘StarGen’ was used, a lentivirus vector con-
taining a normal copy of the human ABCA4 gene, which is currently in a Phase I/IIa stage with 
individuals affected with STGD1 (http://clinicaltrials.gov/ct2/show/NCT01367444?term=abca4
&rank=6).338
One of the challenges for gene therapy is the limited time window to achieve a successful treat-
ment outcome. Some CDs exhibit a fast progression of disease and therefore the window of 
opportunity of treatment is smaller compared to slow or non-progressive phenotypes. Hence, 
treatment opportunities may expand beyond our initial expectations now that SD-OCT and 
adaptive optics may determine the viability of the cone cell bodies, which have shown the capa-
bility of being reactivated in mice.339 In persons with very early onset CD, gene augmentation 
therapy however should ideally start as early as possible.
5. theraPeutiCs for Cone disorders
Currently, to (partially) restore gene function in CD, several strategies are being applied with 
the use of animal models. A specific vector is always necessary to deliver the target gene into 
the cell, as naked DNA is not able to enter the cell efficiently. 
The success of retinal gene augmentation is dependent on the vector and delivery method. 
Vector choice depends on the size of the cDNA of the relevant gene, the type of targeted cells, 
stability of expression and immunogenicity. Although the eye is a complex organ, the advan-
tages of the eye are its immune privileged nature, its small size, accessibility, and functional 
assessment.
Adeno-associated viruses (AAVs) have been successfully used as vectors for gene therapy. 
AAVs enable the incorporation of a healthy copy of the gene that is defective in the patient. An 
advantage of this technology is its low toxicity due to the absence of the original viral coding 
sequences as shown in its application in muscle, brain, liver, lung, RPE and the neural retina. A 
restriction of this technology is its limited cargo size, only enabling the transport of cDNAs 
of genes up to 4.7 kb, and therefore potentially are thereby able to accommodate 36 of the 
42 CD-associated genes (see Table 3). Putative immune responses to the viral capsid may also 
limit recurrent treatments.
In Cnga3 -/- mice, AAV5-mediated gene replacement therapy restored cone function and 
thereby visual processing. The non-functional cones were capable of producing photoreceptor 
responses and transferring the generated signals to the bipolar cells. Treated mice showed 
normalized levels of cGMP in the cones as well as a delayed cone cell death, and the inflamma-
tory response typically seen in retinal degeneration was reduced.31,334 Treatment was successful 
when the subretinal injections were performed in 1- and/or 3-month-old knockout mice, and 
the therapeutic effect was still present after 8 months. Improved cone function using the AAV5 
vector was confirmed in another Cnga3 study.276 
A similar strategy was used to treat a deficiency of CNGB3-associated ACHM. In two canine 
models it was shown that long-term restoration of cone function and diurnal vision could be 
achieved by subretinal delivery of AAV5 vectors expressing human CNGB3 under the control of 
a 2.1 kb human red cone opsin promoter.30 The same authors were also able to circumvent the 
unexplained reduction in therapeutic effect after 54 weeks in dogs by administration of ciliary 
neurotrophic factor (CNTF). Administration of this neuroprotective and axogenic factor for 
retinal ganglion cells however led to immature photoreceptors with shorter outer segments 
and reduced gene expression. This effect was reversible with photoreceptors returning to 
expected developmental maturity and function thereafter. This approach to photoreceptor 
replacement enabled successful gene therapy in dogs up to 42 months.335 As the treatment with 
CNTF in the dog model showed measurable phenotypic improvements, the first clinical trials in 
humans with CNGB3 mutations using intraocular implants releasing CNTF are currently ongo-
ing (http://clinicaltrials.gov/ct2/show/NCT01648452?term=achromatopsia&rank=1).
Long-term improvement of retinal function was also found in a study using AAV8-mediated 
therapy. In both M- and S-cones, the β-subunit of the CNG-channel could be detected after 
subretinal AAV8 vector injection. In addition, increased levels of the α-subunit of the CNG-
channel were found, reduced cone death, improved density and a positive effect of the outer 
segment structure of the cone and subcellular compartmentalization of the cone opsins.33 
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Gene aa ORF (bp) Model name** Synonym** Retinal phenotype description**,+
ABCA4 2,273 6,819* tm1Ght, tm1Kpal Abcr-, Abca4- Delayed rod dark adaptation. Model for juvenile macular degeneration
ADAM9 819 2,457 tm1Bbl mdc9- No retinal phenotype
AIPL1 384 1,152 tm1Mad, tm1Tili, tm1Visu Aipl1-, Aipl1h Complete retinal degeneration and lack of ERG responses. Hypomorphic mutants display less severe retinal degenera-
tion and impaired ERG responses
BEST1 605 1,815 tm1.1Amar, tm1Lmar Best1W93C, Vmd2- Altered eye electrophysiology
C1QTNF5 243 3,914 Gt(OST522586)Lex, tm1.1Geno, 
tm1.1Itl, tm1.1(KOMP)Vlcg, rd6, rdx
C1qtnf5Ser163Arg, C1qtnf5S163R, C1qtn-
f5tm1.1Igl, CTRP5S163R, Mfrp174delG
Increased retina vasculature leakage, retinal degeneration, and features of late-onset macular degeneration Mice homo-
zygous for the same knock-in generated by a different group are normal
C8orf37 208 624 - - -
CACNA1F 1,977 5,931* tm1.1Sdie, tm1Ntbh, nob2 Cav1.4nob2, nob2, Cacna1fdeltaEx14-17, 
Cacna1fG305X
Impaired eye electrophysiology, abnormal retinal neuronal layer, bipolar cell, and horizontal cell morphology, and im-
paired retinal synapse morphology
CACNA2D4 1,137 3,411 lob - Severe loss of retinal signaling associated with abnormal photoreceptor ribbon synapses and cone-rod dysfunction
CDHR1 859 2,577 tm1(cre)Kbal, tm1Nat Pcdh21/Cre, prCAD- Progressive degeneration of retinal photoreceptor cells and a slight reduction in light responses
CERKL 558 1,674 tm1.1Geno - No photoreceptor phenotype, retinal apoptosis and decreased amplitudes and increased implicit time of oscillatory 
potentials
CNGA3 676 2,028 tm1Biel, cpfl5 CNG3- Progressive loss of cone photoreceptor cells
CNGB3 809 2,427 tm1Dgen - Cone degeneration and decreased photopic response
CRX 299 897 tm1Clc, tvrm65 Crx- A lack of photoreceptor outer segments and rod and cone activity, reduced expression of several photoreceptor- and 
pineal-specific genes, and altered circadian behavior
EFEMP1 494 1,482 tm1Eap, tm1Lex, tm1Lmar, tm2Lmar Efemp1R345W, Efemp1ki Knock-out mice display a normal phenotype. Homozygous R345W mice develop deposits below the retinal pigment 
epithelium
ELOVL4 315 945 tm1Kzh, tm1Rayy, tm1Sie, tm1Wked, 
tm2Kzh
Elovl4del, E_mut-, Elovl4270x Knock-out mice die before or around birth. Mice heterozygous for a null allele breed poorly and display mild retinal 
abnormalities
EYS 3,144 9,432* - - -
FSCN2 517 1,551 ahl8, tm1Sykk, tm2Sykk Fscn2R109H, Fscn2p neo(-), Fscn2g neo- Retinal generation with structural abnormalities of the outer segment and depressed rod and cone ERGs that worsen 
with age
GNAT2 354 1,062 cpfl3, c.518A>G - Progressive degeneration of photoreceptors and normal ERG responses
GUCA1A 202 606 tm1.1Hunt, tm1Itl, tm1Jnc COD3, GCAP-, GCAP1-GCAP2-, 
GCAPs-
Photoreceptor degeneration and loss of cone and rod function
GUCA1B 201 603 tm1Amd, tm1Jnc GCAP-, GCAP1-GCAP2-, GCAPs- Abnormal rod electrophysiology
GUCY2D 1,103 3,309 tm1Mom, tm1Sdm GCD-ITL, Gucy2d- Not analyzed for retinal phenotype
HMCN1 5,636 16,908* - - -
IMPG1 798 2,394 - - -
KCNV2 545 1,635 - - -
NR2E3 410 1,230 tm1Dgen, rd7 - Rosettes and a reduced number of nuclei in the retinal outer nuclear layer
OPN1LW 364 1,092 - - -
OPN1MW 364 1,092 tm1(OPN1LW)Nat Opn1mwR, R A knock-in allele encoding a derivative of the human red cone pigment results in hemizygous male and homozygous 
female mice with a ~45-nm red shift in retinal sensitivity
PDE6C 858 2,574 cpfl1 - Abnormal cone photoreceptor function
PDE6H 84 252 - - -
PITPNM3 974 2,922 - - -
PROM1 865 2,595 tm1.1(DTA)Toko, tm1Pec, tm1(cre/
ERT2)Gilb, tm1Rafi
Prom1lacZ,DTA, Prom1C-L Abnormal retina morphology, vasculature, and electrophysiology
Table 3 Non-syndromic cone disorder genes, their human open reading frame 
sizes, the mouse model names, synonyms, and the retinal phenotype description
Gene aa ORF (bp) Model ame** Synonym** Retinal phenotype description**,+
ABCA4 2,273 6,819* tm1Ght, tm1Kpal Abcr-, Abca4- Delayed rod dark adaptation. Model for juvenile m cula  degener tion
ADAM9 819 2,457 tm1Bbl mdc9- No retinal phenotype
AIPL1 384 1,152 tm1Mad, tm1Tili, tm1Visu Aipl1-, Aipl1h Complete retinal degeneration and lack of ERG responses. Hypomorphic mutants display less severe retinal degenera-
tion and impaired ERG responses
BEST1 605 1,815 tm1.1Amar, tm1Lmar Best1W93C, Vmd2- Altered eye electrophysiology
C1QTNF5 243 3,914 Gt(OST522586)Lex, tm1.1Geno 
tm1.1Itl, tm1.1(KOMP)Vlcg, rd6, rdx
C1qtnf5Ser163Arg, C1qtnf5S163R, C qtn-
f5tm1.1Igl, CTRP5S163R, Mfrp174delG
Increased retina vasculature leakage, reti al degener tion, and features of lat -ons t macu ar d g neration Mice homo-
zygous or the same knock-in generated by a different group are normal
C8orf37 208 624 - - -
CACNA1F 1,977 5,931* tm1.1Sdie, tm1Ntbh, nob2 Cav1.4nob2, nob2, Cacna1fdeltaEx14-17, 
Cacna1fG305X
Impaired eye electr physiology, abnormal retinal neuronal layer, bipolar ce l, and horizontal cell morphology, and im-
paired retinal synapse morphology
CACNA2D4 1,137 3,411 lob - Severe loss of retinal signaling associated with abno mal ph toreceptor ribbon ynapses and co e-rod dysfunction
CDHR1 859 2,577 tm1(cre)Kbal, tm1Nat Pcdh21/Cre, prCAD- Progressive degen ration of retinal photoreceptor c ll  and a slight reduction  light responses
CERKL 558 1,674 tm1.1Geno - No photoreceptor phenotype, retinal apoptosis and decreas d am litudes and increased implicit tim  of o cill tory 
potentials
CNGA3 676 2,028 tm1Biel, cpfl5 CNG3- Progressive loss of cone photoreceptor cells
CNGB3 809 2,427 tm1Dgen - Cone degeneration and decreased photopic resp nse
CRX 299 897 tm1Clc, tvrm65 Crx- A lack of photoreceptor outer segments and rod nd cone activity, reduced expression of several photoreceptor- an  
pineal-specific genes, and altered circadian behavior
EFEMP1 494 1,482 tm1Eap, tm1Lex, tm1Lmar, tm2Lmar Efemp1R345W, Efe p1ki Knock-out mice display a normal phenotype. Homozygous R345W mice develop d p sits bel w the retinal pigment 
epithelium
ELOVL4 315 945 tm1Kzh, tm1Rayy, tm1Sie, tm1Wked, 
tm2Kzh
Elovl4del, E_mut-, Elovl4270x Knock-out mice die before or around birth. Mice heterozygous for a null allele breed poorly and display mild retin l 
abnormalities
EYS 3,144 9,432* - - -
FSCN2 517 1,551 ahl8, tm1Sykk, tm2Sykk Fscn2R109H, Fscn2p neo(-), Fscn2g neo- Retinal generation with structural abnormalities of the outer segment and depressed rod and c ne ERGs that worsen 
with age
GNAT2 354 1,062 cpfl3, c.518A>G - Progressive degeneration of photoreceptors and normal ERG responses
GUCA1A 202 606 tm1.1Hunt, tm1Itl, tm1Jnc COD3, GCAP-, GCAP1-GCAP2-, 
GCAPs-
Photoreceptor degeneration and loss of cone and r d function
GUCA1B 201 603 tm1Amd, tm1Jnc GCAP-, GCAP1-GCAP2-, GCAPs- Abnormal rod electrophysiology
GUCY2D 1,103 3,309 tm1Mom, tm1Sdm GCD-ITL, Gucy2d- Not analyzed for retinal phenotype
HMCN1 5,636 16,908* - - -
IMPG1 798 2,394 - - -
KCNV2 545 1,635 - - -
NR2E3 410 1,230 tm1Dgen, rd7 - Rosettes and a reduced number of nuclei in the retinal outer nuclear layer
OPN1LW 364 1,092 - - -
OPN1MW 364 1,092 tm1( LW)Nat Opn1mwR, R A knock-in allele encoding a derivative of the human red con  pigment results in hemizygous male and homozy ous 
female mice with a ~45-nm red shift in retinal s nsitivity
PDE6C 858 2,574 cpfl1 - Abnormal cone photoreceptor function
PDE6H 84 252 - - -
PITPNM3 974 2,922 - - -
PROM1 865 2,595 tm1.1(DTA)Toko, tm1Pec, tm1(cre/
ERT2)Gilb, tm1Rafi
Prom1lacZ,DTA, Prom1C-L Abnormal retina morphology, vasculature, and electrophysiology
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6.2. moleCular diagnostiCs
Up to a few years ago it was not possible to, stabilize or improve impaired vision in persons 
with CD. With the emerging options for treatment of CD, early molecular diagnostics has 
become highly relevant. In addition, early molecular diagnosis may be important in cases in 
which genetic defects are associated with extra-ocular features, some of which may develop 
later in life and be amenable to pre-symptomatic management, e.g. in nephronophthisis, in 
which the kidney is involved. 
6.3. transCriPtomiCs 
Introns are riddled with rare variants that theoretically can have an impact on RNA splicing if 
they are situated in an intronic splice enhancer or inhibitor site, or if they increase the splicing 
potential of a cryptic splice site, leading to the transcription of an aberrant mRNA product. 
The latter was recently shown for ABCA4, as a few deep intronic variants led to aberrant 
splicing in persons with STGD1.345 Farkas et al (2013) identified 79,915 novel alternative splice 
events and more than one hundred novel genes expressed in human retinal tissue, which will 
aid the difficult task of discriminating benign from causal variants. 15-36% of the novel splic-
ing events resulted in mRNAs with an open reading frame and are likely be transcribed into 
protein coding transcripts.346 This demonstrates that the retinal transcriptome is more compli-
Gene aa ORF (bp) Model name** Synonym** Retinal phenotype description**,+
PRPH2 346 1,038 tm1Nmc, rd2, Nmf193 Prph2delta307, rds-307, Prph2Rds, Rd-2, 
rds, rds-,  Rds, RdsRd2
Slow retinal degeneration with thinning and loss of the outer nuclear layer, loss of photoreceptor outer segments, and 
increased numbers of Müller cells
RAB28 221 663 -
RAX2/QRX 184 552 -
RIMS1 1,692 5,076* tm1Sud , tm3.1Sud, tm2Sud, tm3Sud RIM1alpha-, RIM1alphabeta-, RIM1 
S413A-KI, fRIM1, RIM1alphabetafloxed
No retinal phenotype
RP1L1 2,401 7,203* tm1Jnz Knock-out mice exhibit retinal photoreceptor abnormalities, including scattered outer segment disorganization, re-
duced ERG amplitudes, and progressive retinal rod cell degeneration
RPGR 1,152 3,456 tm1Tili, tm1Wbrg, rd9 RPGR-, Rpgrdeltaexon4 Ectopic location of cone opsins, reduced levels of rhodopsin in rod cells, and partial degeneration of both cone and rod 
photoreceptors by 2-6 months of age
RPGRIP1 1,286 3,858 tm1Tili, nmf247 RPGRIP- Photoreceptor cell dysmorphology. By 3 months of age mutant animals show near complete loss of photoreceptor cells
SEMA4A 761 2,283 tm1Kik, Gt(OST393408)Lex Sema4aGt22Lex Severe retinal degeneration with reduced retinal vessels, depigmentation and dysfunction of both rod and cone photo-
receptors
TIMP3 212 636 tm1.1(KOMP)Vlcg, tm1Hest, 
tm1(KOMP)Vlcg, tm1Osya, tm1Rkho, 
tm1Web
timp-3-, Timp-3-null, Timp3S156C Knock-out mice die prematurely with lethargy, ruffled hair, and a hunched posture, displaying impaired bronchiole 
branching, reduced alveologenesis and abnormal mammary gland involution. S156C knock-ins provide a mouse model 
for Sorsby fundus dystrophy
TULP1 542 1,626 tm1Pjn Tulp1- Retinal degeneration
UNC119 240 720 tm1Gina Retinal degeneration characterized by thinning of the outer nuclear layer of the retinal that is visible at 6 months and 
progresses rapidly after 17 months to end-stage by 26 months
Table 3 (continue)
Gene aa ORF (bp) Model ame** Synonym** Retinal phe otype description**,+
PRPH2 346 1,038 tm1Nmc, rd2, Nmf193 Prph2delta307, rds-307, Prph2Rds, Rd-2, 
rds, rds-,  Rds, RdsRd2
Slow retinal degene ation with thinning and loss f th  outer nuclear layer, loss of photoreceptor outer segments, and 
increase  numbers of Müller cells
RAB28 221 663 -
RAX2/QRX 184 552 -
RIMS1 1,692 5,076* tm1Sud , tm3.1Sud, tm2Sud, tm3Sud RIM1alpha-, RIM1alphabeta-, RIM1 
S413A-KI, fRIM1, RIM1alphabetafloxed
No retinal phenotype
RP1L1 2,401 7,203* tm1Jnz Knock-out mice exhibit retinal photoreceptor abnormali ies, includ ng scattered uter segment disorgan zat on, re-
duced ERG amplitudes, and progressive retinal rod cell degeneration
RPGR 1,152 3,456 tm1Tili, tm1Wbrg, rd9 RPGR-, Rpgrdeltaexon4 Ectopic location of cone opsins, reduced levels of rhodopsin i  rod cells, and pa tial degeneration of b th co e and rod 
photoreceptors by 2-6 months of age
RPGRIP1 1,286 3,858 tm1Tili, nmf247 RPGRIP- Photoreceptor cell dysmorphology. By 3 months f ag  mutant animals show near complete loss of photoreceptor cells
SEMA4A 761 2,283 tm1Kik, Gt(OST393408)Lex Sema4aGt22Lex Severe r tin l degeneration with reduced retinal ssels, depigmentation and dysfunction of both rod an  cone pho -
receptors
TIMP3 212 636 tm1.1(KOMP)Vlcg, tm Hest, 
tm1(KOMP)Vlcg, tm1Osya, tm1Rkho, 
tm1Web
timp-3-, Timp-3-null, Timp3S156C Knock-out mice die prematurely with lethargy, ruffled hair, and a hunched posture, displayin  impaired bronchiole 
branching, reduced alveologenesis and abnormal mammary gland involution. S156C knock-ins provide  mouse model 
for Sorsby fundus dystrophy
TULP1 542 1,626 tm1Pjn Tulp1- Retinal degeneration
UNC119 240 720 tm1Gina Retinal degeneration characterized by thinning of the outer nuclear laye  of the retinal that is visibl at 6 months and 
progresses rapidly after 17 months to end-stage by 26 months
*ORF sizes in italics are larger than 4.7 kb and therefore not suitable targets for adeno-associ-
ated virus-therapy. **Data collected from MGI Jackson lab, +phenotype among different mod-
els can vary; aa, amino acids; bp, basepair; ERG, electroretinogram; ORF, open reading frame.
6. future PersPeCtives 
6.1. identifiCation of Cd-assoCiated genes
WES, combined with homozygosity mapping or linkage analysis, has proven successful in the 
discovery of novel retinal disease genes.340-342 In a recent Saudi Arabian study of predominantly 
AR inherited retinal dystrophies, ~80% of DNA samples analyzed using homozygosity mapping 
and/or WES were solved by the identification of mutations in either known or novel genes.343 
In six of 86 families with causal variants, mutations in different new genes were found. This sug-
gests that most of the undiscovered CD genes (Figure 3) are mutated in very low percentages 
of affected individuals.
In the next few years, WES and whole genome sequencing (WGS) will facilitate the identifica-
tion of novel gene defects in individuals for which WES could not identify the pathologic defect. 
WGS can robustly identify heterozygous deletions, duplications, inversions, and intronic vari-
ants.344 However, proving causality of rare variants in candidate CD genes will be challenging, 
as in most cases only few family members are available for segregation analysis. This may be 
partially solved by testing large patient cohorts through collaborative efforts. In addition, the 
causality of novel variants can be tested through cellular and animal model studies. 
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Supplemental tables 1-5
A thorough investigation of all public available literature resulted in estimates of the current 
frequencies and genetic causes of CD. Corrections were made for patient cohorts reported 
repetitively.
Supplemental Table 1 Occurrences and frequency of mutations in achromatopsia
Study CNGA3 CNGB3 GNAT2 PDE6C PDE6H
353 12/36 12/36 0/36
27 3/63 55/63 0/63
354 4/16 8/16 2/16
123 9/22 9/22
355 4/9 5/9
356 3/16 10/16
357 1 1
358 9/19 5/19
121 5
126 21
359 1/5
360 4
113 3/13
114 53/162
361 1/14
362 1
26 9/11
363 163/256
115 5/77
116 1
364 1
365 1
119 6/26
118 3/10
120 7/77
117 1/217
Overall mutation  
frequency
165/407 
(35.5%)
273/449 
(58.7%)
10/195 
(2.2%)
16/113 
(3.3%)
1/217 
(0.2%)
cated than previously thought, and the knowledge of naturally occurring splice events may aid 
the interpretation of RNA analysis of known retinal disease genes in patients. Importantly, only 
approximately 35% of the genes involved in retinal dystrophies are expressed at high enough 
levels in lymphoblastoid cells to scrutinize the transcriptome from an individual’s blood sample 
(K. Neveling, unpublished data).
Alternatively, photoreceptor precursor cells can be differentiated from patient’s keratinocytes 
through generation of induced pluripotent stem cells (iPSC).347 iPSCs can be generated from 
adult somatic cells by expressing a set of transcription factors, and subsequently can be dif-
ferentiated into retinal cells.348 and refs therein. RNA analysis of such cells is likely to more closely 
mimic the situation in the diseased tissue, enabling the detection of splice defects that might 
not be detectable in lymphoblastoid cells. The generation of a homogeneous population of fully 
differentiated cells remains a challenge, in particular regarding the neural retina.
6.4. alternative Cone resCue strategies
A great promise in treating early onset degenerative diseases, like CD, are cell replacement 
therapies using retinal progenitor cells derived from embryonic stem cells (ESCs) or induced 
pluripotent stem cells (iPSCs). iPSCs can be generated from adult somatic cells by express-
ing a set of transcription factors, and subsequently can be differentiated into retinal cells.349 
These cells could be very valuable in cell-based therapies. Proof of concept using mouse retinal 
progenitor cells harvested in a specific developmental time window (postnatal day 4-8) was 
obtained recently.349 It is critical to transplant a sufficient number of cells that can populate 
a significant fraction of the diseased retina. The transplanted cells differentiated into adult 
photoreceptor cells, were positioned at the correct location, and formed connections with 
bipolar cells,349-352 demonstrating the potential of this approach to rescue retinal function in 
future clinical trials.
7. ConClusions
The early aim of CD research has been the identification of the genetic bases of CD. Advances 
in this field compounded by technologies such as WES and WGS technologies have created a 
new era for molecular diagnostics in CD. In the next few years, the remaining genetic causes 
of CD will most likely be elucidated representing an enormous achievement. The prevalence of 
novel genetic defects however will be very low, and in particular regarding rare missense vari-
ants, functional modeling of their effects in animal models or cellular systems will be crucial to 
understand their mode of action. The ultimate aim remains the development of therapies that 
rescue cone photoreceptors. For the 31/42 CD-associated genes in which mammalian models 
are available, 14 have successfully been used for gene augmentation studies and a few human 
trials are underway. Nevertheless, large naturally occurring animal models, In particular canine 
models with progressive retinal atrophy, need to be identified for CDs as they can more closely 
mimic the human diseases and are a more relevant model with respect to the development of 
gene therapy. The rescue of cone photoreceptors not only is important to treat cone dysfunc-
tions, but also will be crucial to maintain vision in rod-dominated diseases.
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Supplemental Table 3 Occurrences and frequency of mutations in autosomal 
recessive cone rod dystrophy
Study ABCA4 ADAM9 C8orf37 CDHR1 CERKL CNGB3
374† 33/123 2/123
41 1/47 3/47
66 1
375 13/55
40 13/20
376 4/8
377 11/37
378 5/8
379 2
380 1
381 16/30
382 18/54
383 1
384 1
385 2
386 1
387 1
388 2/14
366 3
389 1
367 16/46
390 3
391 1
392 1/5
34 17/65
358 16/34
393 26/86
169 4
340 4
394 1
395 2
396 1
397 7/21
398 1
399 3
400
401
402
403
404
188
405
372*
Overall mutation
frequency
176/542
(15.7%)
4/4
(0.4)
4/4
(0.4%)
4/4
(0.4%)
11/25
(1.0%)
3/47
(0.3%)
Supplemental Table 2 Occurrences and frequency of mutations in autosomal 
recessive cone dystrophy
Study CNGA3 CNGB3 GNAT2 PDE6C PDE6H
353 12/36 12/36 0/36
27 3/63 55/63 0/63
354 4/16 8/16 2/16
123 9/22 9/22
355 4/9 5/9
356 3/16 10/16
357 1 1
358 9/19 5/19
121 5
126 21
359 1/5
360 4
113 3/13
114 53/162
361 1/14
362 1
26 9/11
363 163/256
115 5/77
116 1
364 1
365 1
119 6/26
118 3/10
120 7/77
117 1/217
Overall mutation  
frequency
165/407 
(35.5%)
273/449 
(58.7%)
10/195 
(2.2%)
16/113 
(3.3%)
1/217 
(0.2%)
Study ABCA4 CACNA2D4 CNGA3 CNGB3 KCNV2 PDE6C PDE6H TULP1
34 8/90 3/90 4/90
366 1
367 4/18
197 1/34
114 3/48
24 4
368 3/60
131 10/11
369 8
370 3
132 11
371 4/154
36 4
118 1/104
372* 1/159
373 1
Overall mutation 
frequency
13/109
(3.9%)
1/34
(0.3%)
3/48
(0.9%)
10/154
(3.0%)
44/277
(13.1%)
1/104
(0.3%)
1/1
(0.3%)
1/159
(0.3%)
*Roosing et al. (2013) only analyzed one variant of TULP1 in this cohort.
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Study CRB1 CRX EYS FSCN2 GUCY2D KCNV2
374† 1/123 1
41
66
375
40
376
377
378
379
380
381
382
383
384
385
386
387
388
366
389
367
390
391
392
34
358
393
169
340
394
395
396
397
398
399
400 2/29 1/29
401 29/186
402 1/47
403 1
404
188
405
372*
Overall mutation
frequency
2/29
(0.2%)
1/29
(0.1%)
29/186
(2.6%)
1/47
(0.1%)
1/1
(0.1%)
1/1
(0.1%)
Supplemental Table 3 (continue)
Study ABCA4 ADAM9 C8orf37 CDHR1 CERKL CNGB3
374† 33/123 2/123
41 1/47 3/47
66 1
375 13/55
40 13/20
376 4/8
377 11/37
378 5/8
379 2
380 1
381 16/30
382 18/54
383 1
384 1
385 2
386 1
387 1
388 2/14
366 3
389 1
367 16/46
390 3
391 1
392 1/5
34 17/65
358 16/34
393 26/86
169 4
340 4
394 1
395 2
396 1
397 7/21
398 1
399 3
400
401
402
403
404
188
405
372*
Overall mutation
frequency
176/542
(15.7%)
4/4
(0.4)
4/4
(0.4%)
4/4
(0.4%)
11/25
(1.0%)
3/47
(0.3%)
Study CRB1 CRX EYS FSCN2 GUCY2D KCNV2
374† 1/123 1
41
66
375
40
376
377
378
379
380
381
382
383
384
385
386
387
388
366
389
367
390
391
392
34
358
393
169
340
394
395
396
397
398
399
400 2/29 1/29
401 29/186
402 1/47
403 1
404
188
405
372*
Overall mutation
frequency
2/29
(0.2%)
1/29
(0.1%)
29/186
(2.6%)
1/47
(0.1%)
1/1
(0.1%)
1/1
(0.1%)
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Supplemental Table 4 Occurrences and frequency of mutations in autosomal dom-
inant cone and cone-rod dystrophy
Study AIPL1 CRX GUCA1A GUCY2D PITPNM3
406 1/15
162 1/7 3/22 3/7
407 3
408 1
400 1/29
409 1
410 0/88
411 4/67
412 1
413 1
414 3/30
415 4
152 2/30
416 1
417 1
418 1
419 3
420 1
421 1/119
422 1
423 1
424 1
425 1
426 4/24
133 4
427 1
134 1
428 1
429 4
135 3/40
430 2
431 2
432 3/38
433 1
434 1
136 11/27
435 1
436 2/22
437 1
438 1
439 1
209 2
440 5/163
441
442
163
164
165
443
444
200
Overall mutation
frequency
1/15
(0.2%)
24/260
(4.3%)
17/173
(3.0%)
43/155
(7.7%)
7/165
(1.2%)
Supplemental Table 3 (continue)
Study CRB1 CRX EYS FSCN2 GUCY2D KCNV2
374† 1/123 1
41
66
375
40
376
377
378
379
380
381
382
383
384
385
386
387
388
366
389
367
390
391
392
34
358
393
169
340
394
395
396
397
398
399
400 2/29 1/29
401 29/186
402 1/47
403 1
404
188
405
372*
Overall mutation
frequency
2/29
(0.2%)
1/29
(0.1%)
29/186
(2.6%)
1/47
(0.1%)
1/1
(0.1%)
1/1
(0.1%)
Study PDE6C PROM1 RAB28 RPE65 RPGRIP1 TULP1
374† 1/123
41 2/47 1/47
66
375
40
376
377
378
379
380
381
382
383
384
385
386
387
388
366
389
367
390
391
392
34
358
393
169
340
394
395
396
397
398
399
400 1/29 0/29
401
402
403
404 1
188 2/617
405 2
372* 1/91
Overall mutation
frequency
2/47
(0.2%)
1/1
(0.1%)
2/617
(0.2%)
1/29
(0.1%)
3/76(
0.3%)
1/91
(0.1%)
 †Littink et al. (2010) was excluded in the statistics. In this study the samples had been scanned 
with homozygosity mapping only without the addition of Sanger sequencing, *Roosing et al. 
(2013) only analyzed one variant of TULP1 in this cohort.
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Supplemental Table 5 Occurrences and frequency of mutations in X-linked cone 
and cone-rod dystrophy
Study CACNA1F OPN1LW/OPN1MW RPGR
445 1
43 2
44 1
446 3
447 2
448 2/6
449 3
34 7/8
358 2/10
Overall mutation 
frequency
1/1 
(2.78%)
3/3 
(8.34%)
19/32 
(52.8%)
Supplemental Table 4 (continue)
Study AIPL1 CRX GUCA1A GUCY2D PITPNM3
406 1/15
162 1/7 3/22 3/7
407 3
408 1
400 1/29
409 1
410 0/88
411 4/67
412 1
413 1
414 3/30
415 4
152 2/30
416 1
417 1
418 1
419 3
420 1
421 1/119
422 1
423 1
424 1
425 1
426 4/24
133 4
427 1
134 1
428 1
429 4
135 3/40
430 2
431 2
432 3/38
433 1
434 1
136 11/27
435 1
436 2/22
437 1
438 1
439 1
209 2
440 5/163
441
442
163
164
165
443
444
200
Overall mutation
frequency
1/15
(0.2%)
24/260
(4.3%)
17/173
(3.0%)
43/155
(7.7%)
7/165
(1.2%)
Study PROM1 PRPH2 RIMS1 SEMA4A UNC119
406
162 2/22
407
408
400
409
410
411
412
413
414
415
152
416
417
418
419
420
421
422
423
424
425
426
133
427
134
428
429
135
430
431
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1.4
Outline and aim of this thesis
The leading causes of hereditary blindness worldwide are retinal disorders, primarily affecting 
the photoreceptors leading to severe visual impairment. Early-onset cone-dominated pheno-
types such as achromatopsia (ACHM), cone dystrophy (COD) and cone-rod dystrophy (CRD) 
are grouped as cone dysfunctions (CD). In order to develop effective therapeutic approaches 
the genetic etiology of CD needs to be elucidated. Throughout the years, dozens of genes have 
been found to cause CD, but still significant percentages of CD cases are unexplained. The 
aim of this thesis was to elucidate and characterize genetic aberrations underlying autosomal 
recessive cone dystrophies. The identification of the genetic defects was facilitated by using 
homozygosity mapping and next generation sequencing.
Chapter 1 provides an introduction into the fascinating process of vision and the technologies 
homozygosity mapping and next generation sequencing, which were used to unravel genetic 
defects in CD. Furthermore, it contains a comprehensive description of all clinical phenotypes, 
the cellular processes in which CD-associated proteins are involved, the animal models and the 
current status of gene therapy for CDs.
Chapter 2 describes the prevalence and novel discovered association of mutations in CNGA3 
and CNGB3 with progressive COD. 
Chapter 3 summarizes the novel genotype-phenotype correlations that we have established. 
Maternal uniparental isodisomy allowed the discovery of TULP1 mutations in a COD and a 
CRD case, and in an case of oligocone trichromacy CEP290 mutations were identified, which 
are associated to a wide spectrum of phenotypes. 
Chapter 4 presents three novel genes to be involved in CD. Mutations in PDE6C were discov-
ered using homozygosity mapping, whereas mutations in RAB28 and MFSD8 were discovered 
using genetic linkage studies and WES.
Chapter 5 provides the general discussion of this thesis. It covers the novel disease mecha-
nisms underlying PDE6C, RAB28 and MFSD8-associated CDs and future considerations when 
elucidating novel CD-associated genes. Furthermore, a review is given of all prenylated retinal 
proteins that are mutated in persons with inherited retinal diseases (IRD). Moreover, other 
IRD-associated proteins involved in the process of prenylation are described and discussed 
with respect to putative overlap in mechanisms of disease. 
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Cone dystrophy (COD) is a progressive cone disorder with an estimated prevalence of 
1:30,000-1:40,000. Patients have normal cone function initially, but present with visual loss and 
color vision disturbances in the first or second decade.1-3 Macular abnormalities can be pres-
ent, and the optic nerve may show a variable degree of temporal pallor. On electroretinogram 
(ERG), cone responses progressively deteriorate and rod responses are initially normal, but 
can diminish slightly over time. Although the course of disease may vary, the visual acuity gen-
erally worsens to legal blindness before middle age. 
For COD, several genes have been identified for the autosomal dominant4-6 and X-linked 
forms,7; 8 but little is known about the genetic causes of the most prevalent autosomal reces-
sive (arCOD) form. Three genes have been implicated in this form: the ABCA4, CACNA2D4 and 
the KCNV2 genes.9-12 They play a role in only a fraction of patients, thus, most AR COD patients 
have an unknown genetic cause.
In contrast to the progressive nature of COD, achromatopsia is a congenital cone disorder. 
The estimated prevalence is 1:30,000, and the inheritance is autosomal recessive.13; 14 The clini-
cal course is characterized by low visual acuity, nystagmus, photophobia, severe color vision 
defects, and no recordable or only residual cone function on ERG. The genetic basis of achro-
matopsia has been elucidated to a large extent during the last decade. Three genes have been 
implicated: CNGA3, CNGB3, and GNAT2.15-18 The contribution of the CNGB3 gene in achroma-
topsia varies per population, but it explains the vast majority of achromatopsia cases (50-80%) 
in the Netherlands and Germany.19; 20
The CNGA3 and CNGB3 genes are cone-specific, and code for the α and β subunits of the cyclic 
nucleotide gated channel type 3 (CNG3), respectively. They are located on the membrane of 
cone outer segments, and play an important role during the phototransduction cascade. In the 
dark, high levels of cGMP open the channel, facilitate free flow of ions, and prohibit formation 
of an action potential. In the presence of light, cGMP levels decrease, resulting in closure of the 
channel, hyperpolarization of the cell, and initiation of phototransduction.21 We hypothesize 
that genes with such a vital role for cone function may also be involved in other disorders in 
which cones are primarily affected. On this subject, only one study reported mutations in 
CNGB3 in three relatives with AR COD;22 and one study described a heterozygous CNGA3 
mutation in one patient with COD.16 In our study, we expanded the possible role of CNGA3 
and CNGB3 in cone photoreceptor disorder by investigating a large series of AR COD patients 
for mutations in these genes. 
Patients and methods
Study population
Patients (N=60; 65% males, range 10-79 years, mean age 39 years, SD 16 years) who had been 
diagnosed with autosomal recessive COD were ascertained from various ophthalmogenetic 
centers in the Netherlands. Inclusion criteria for the study were: progressively deteriorating 
visual acuity, color vision disturbances in three axes, decreasing cone responses over time with 
normal or only slightly reduced rod responses on ERG, and no presence of nystagmus. The 
study was approved by the Medical Ethics Committee of Erasmus Medical Center and adhered 
to the tenets of the Declaration of Helsinki. All participants provided signed, informed consent 
for participation in the study, retrieval of medical records, and use of blood and DNA for 
research.
Clinical examination
All patients received a questionnaire which addressed the medical history and family pedi-
gree. Medical charts were retrieved from their ophthalmologists, and all available data on 
Snellen visual acuity, color vision (American Optical Hardy-Rand-Rittler Test, Ishihara Test 
for Color Blindness, or Farnsworth Panel D15 Test), slitlamp and fundus examination, and 
abstraCt 
Objective: To investigate whether the major achromatopsia genes (CNGA3 and CNGB3) play a 
role in the etiology of progressive cone dystrophy (COD).
Design: Prospective multicenter study. 
Participants: Probands (N=60) with autosomal recessive (AR) COD from various ophthalmoge-
netic clinics in the Netherlands.
Methods: All available ophthalmologic data from the AR COD probands were registered from 
medical charts and updated by an additional ophthalmologic examination. Mutations in the 
CNGA3 and CNGB3 genes were analyzed by direct sequencing.
Main outcome measure: CNGA3 and CNGB3 mutations and clinical course in AR COD probands.
Results: In three AR COD probands (3/60; 5%) we found two mutations in the CNGB3 gene. 
Two of these probands had compound heterozygous mutations (p.R296Yfs*9 / p.R274Vfs*12 
and p.R296Yfs*9 / c.991-3T>G). The third proband revealed homozygous missense mutations 
(p.R403Q) with two additional variants in the CNGA3 gene (p.E228K and p.V266M). These pro-
bands did not have a congenital nystagmus, but had a progressive deterioration of visual acuity, 
color vision, and photopic electroretinogram, with onset in the second decade. In six other 
unrelated probands, we found six different heterozygous amino acid changes in the CNGA3 
(N=4) and CNGB3 (N=2) gene.
Conclusions: The CNGB3 gene accounts for a small fraction of the later onset progressive form 
of cone photoreceptor disorders, and CNGA3 may have an additive causative effect. Our data 
indicate that these genes are involved in a broader spectrum of cone dysfunction, and it remains 
intriguing why initial cone function can be spared despite similar gene defects.
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sis software (Vector NTI Advance, version 10; Invitrogen Corp., Carlsbad, CA). Segregation 
analysis was performed when mutations were detected.
results
Mutation analysis 
Table 1 shows the mutations that were detected. We found two variants in the CNGB3 gene 
in 3/60 (5%) patients, and confirmed their independent segregation in the families (Figure 1). 
In two patients, the mutations affected exonic splicing and caused a frameshift; and in one 
patient the mutation caused an aminoacid change mutation, p.R403Q. This variant could not be 
detected in 100 ethnically matched control subjects. One patient had two additional variants in 
the CNGA3 gene. Segregation analysis in this family (Figure 1) showed that the unaffected sister 
of the proband had the two CNGA3 variants without a CNGB3 variant, while the unaffected 
children were heterozygous for the CNGB3 variant and one CNGA3 variant. This suggests that 
the pathogenicity was predominantly caused by the CNGB3 variants. One missense variant, 
p.V266M, was novel. Neither CNGA3 variant could be detected in 100 ethnically matched 
control subjects. In two other unrelated probands, we found two different heterozygous 
mutations in the CNGB3 gene: c.1148delC (p.T383Ifs*13) and c.1208G>A (p.R403Q). In four 
other unrelated probands we detected four different CNGA3 variants: c.1856C>T (p.A619V); 
c.284C>T (p.P95L); c.1618G>A (p.V540I) and c.1694C>T (p.T565M). In these patients, we did 
not find a second variant on the other allele in the coding region of the CNGA3, CNGB3 and 
GNAT2 gene, despite complete sequencing (Table 1).
Clinical findings
Clinical findings are summarized in Table 2. The three probands with two variants had a pro-
gressive deterioration of visual acuity, color vision, and photopic ERG since their teens. Two 
patients had passed their driving exam at age 18 years, with a best corrected visual acuity 
(BCVA) of at least 0.50 decimals Snellen. In all three patients, the BCVA deteriorated rapidly in 
the second decade. They did not have a congenital nystagmus. The macular appearance varied in 
each patient. Two patients showed degeneration of the macula over time; one had progressive 
pigmentary changes since age 10, one developed a bull’s eye maculopathy in the second decade 
and one patient still had a normal macular appearance at the age of 45 years. The optic discs did 
not show any abnormalities in the three probands; no temporal pallor was apparent (Figure 2). 
Figure 2 Fundus appearance 
of probands with progres-
sive cone dystrophy and 
mutations in the CNGA3 and CNGB3 genes.
A) Fundus photograph of the left eye of proband A-II-1, per-
formed at age 45 years. No macular abnormalities are appar-
ent. B) Fundus photograph of the left eye of proband B-II-1, 
performed at age 57 years, showing pigmentary changes in the 
macular region. C) Fundus photograph of the left eye of proband 
C-II-3, performed at age 47 years, showing a bull’s eye maculopa-
thy with atrophy of retinal pigment epithelium.
ERGs were collected. Color vision defects were classified as mild, moderate or severe in the 
three color axes (red, green and blue). Patients with incomplete or unavailable data from the 
last five years were invited for an additional ophthalmologic examination, ERG, and fundus 
photography. ERGs incorporated the recommendations of the International Society for Clinical 
Electrophysiology of Vision.23
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p.R274Vfs*12/+ p.R274Vfs*12/+
p.R274Vfs*12/+
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Figure 1 Pedigrees of three families with autosomal recessive progressive cone 
dystrophy showing segregation of CNGA3 and CNGB3 gene mutations 
Open square and circle, unaffected males and females; black square and circle, affected males 
and females; dashed symbols denote deceased individuals.
Molecular Genetic Analysis
Blood samples were obtained from probands, affected relatives, and parents. DNA was isolat-
ed from peripheral blood lymphocytes by standard procedures. The coding region and intron/
exon boundaries of the CNGA3 and CNGB3 genes were amplified by PCR using the conditions 
and primer sequences provided in Supplemental Table 1. Direct sequencing was performed on 
sequence analyzer 3730 (Applied Biosystems, Inc. [ABI], Foster City, CA) with sequence analy-
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disCussion
It has been well established that mutations in the CNGA3 and CNGB3 genes are a common cause 
of achromatopsia. We now report that mutations in these genes can also cause a progressive 
cone disorder. In contrast to achromatopsia, the AR COD patients with these mutations had 
no clinical signs of cone dysfunction at birth, but developed progressive loss of cone function 
during the first two decades of life. 
The truncating mutations in CNGB3 were described earlier in patients with achromatopsia, as 
was the combination of the splice defect in exon 9 and the frameshift mutation p.R296Yfs*9.19 
The combination of p.R296Yfs*9 and p.R274Vfs*12 has not been reported earlier. Our 
observed mutations in the CNGB3 gene were all located in the transmembrane helices (Figure 
3). This is likely to lead to defective pore formation and may ultimately lead to apoptosis by 
the continuous influx of Ca2+ ions.24 The question remains why the severe mutations in these 
patients did not disturb initial cone function, but caused deterioration only after the first 
decade. There are no functional studies of absent β-subunits of the CNG3 channel, but mice 
lacking the α-subunits due to CNGA3 deficiency have been described.25 These mice never had 
recordable cone responses on ERG. However, histology showed presence of cones at birth 
and progressive cone cell loss only after the second postnatal week. Residual cones could 
still be identified after 22 months.25 Apparently, there is functional redundancy of an unidenti-
fied cGMP-dependent protein, particularly early in development, which is also capable of ion 
transport and initiation of an action potential. Another explanation could be that the CNGA3 
protein can compensate initially for some function of CNGB3.
Pore
1
-
Figure 3 Localization of the mutations with respect to the topological model of the 
CNGB3 and CNGA3 polypeptides
(http://smart.embl-heidelberg.de,October 2008). CaM = Ca2+ calmodulin domains; COOH = carbox-
ylic acids; cGMP = cyclic guanosine monophosphate.
The third patient had a homozygous missense mutation in CNGB3 (p.R403Q) in combination 
with a compound heterozygous variant in CNGA3 (p.E228K; p.V266M). In a previous report, 
Nishiguchi et al. found a homozygous p.R403Q mutation without CNGA3 mutations, in a 
31-year-old patient with few macular drusen, a slightly decreased visual acuity, normal color 
vision, and normal cone responses on full-field ERG.26 p.R403Q has also been described in a 
patient with COD in a compound heterozygous genotype with p.T383Ifs*13.22 Although this 
combination is more pathogenic, the phenotype was comparable to our patient. p.R403Q is 
located in a well conserved domain of the cone β-subunit in the middle of the pore domain T
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Supplemental table 1 Primers used for sequencing of CNGB3 and CNGA3
Sequence (5’3’)
 Gene & exon Forward Reverse
Product size 
(basepairs)
CNGB3
Exon 1 ggcacagtcataaatacagaggg ggagactatactaggatttgg 393
Exon 2 agtacatcataaacagtcaattt gcattttcatcacctgacatg 425
Exon 3 ttggcctgaaggtgtctacc gctcaaatatccactctcccc 400
Exon 4 tgccccaccatctgtagc ccaaaagcagaccctgagaa 561
Exon 5 cggtgtttggttaagaaattc ccctgtgactcaaagtcacag 309
Exon 6 acagtccagaggcagaatgg caattatccatgcagatagcc 481
Exon 7 gagattggaaggaaccaacc ttgagaggcagaaacttcagg 298
Exon 8 gccttaaaaagccccatgc ccatctttctgccctcatca 397
Exon 9 ctataactacagggtagcaat tcatatccctgccaaattcc 388
Exon 10 cagtcaagacattgccatcag gcatttaccagccattgaatgg 430
Exon 11 cccaagaatagtggtctttcg gatcaacagtgcttttccatt 385
Exon 12 cagggcattagaaggaagta ctgtaaggtagcagagactag 340
Exon 13 aggtatggaggtccaataga cctagagaaattatgtgga 405
Exon 14 cacacccaagtctatctgagc actctgagagcacgttattgc 468
Exon 15 ggaggcaaacagtactcacg ggtttgattgtgctgagagc 472
Exon 16 aatcacctggaccctcacc ctctgagatagggagaaccg 357
Exon 17 cttgatcacagtgagatatg acgcccactctaattccatt 410
Exon 18 tcttggtggtgatcttagcc ccttgagaaacgaaaggcaa 543
CNGA3
Exon 2 cttgatgagctgggtttgc cccccacagtctagatcagc 283
Exon 3 tctcactcctggctgtgtcc ccccatctagcactttttcc 279
Exon 4 agggaaagactggggtttgg caaacaggatggagcaaagc 335
Exon 5 gtaatcccctggtgaaatgg gggagcaggagcactaagg 228
Exon 6 gccctaggctctctaaaacc gggagaggtggagctctgg 274
Exon 7 ttacatgatccagcgtcttcc taatgtcccatccaccatgc 294
Exon 8.1 gcatactgtgtagccgtgagg ggttttgggacagactcctg 655
Exon 8.2 gttcaggattgggaacttgg ccgtgaggcattcatattcg 331
Exon 8.3 gtgggtgttctgatttttgc cccaatatctcccttcttgc 390
Exon 8.4 gacacgctgaagaaggttcg gctgcttcatcttcatctgg 559
Exon 8.5 ctggacaccctgcagacc ttcaaccctgaccaagttcc 271
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi, April 2007) or using Exon Primer from the Genome Browser (http://genome.ucsc.edu, 
April 2007). Exon 1 of the CNGA3 gene is non-coding.
of the CNG-channel (Figure 3). This mutation replaces the positively charged residue arginine 
by a neutral glutamine. The substitution may directly affect ion transfer through the channel 
pore,27 or may change the electrostatic environment of the pore region and influence Ca2+ bind-
ing.27 Both will result in dysfunction of the channel. Evidence for channelopathy was provided 
by an in vitro study which investigated the effect of p.R403Q in recombinant cone CNG-
channels.27 p.R403Q appeared to increase sensitivity for cGMP. This will sustain the opening of 
the channel, cause increased Ca2+ entry, and eventually cause cell dysfunction and apoptosis.24 
Remarkably, cGMP affinity of CNGB3 containing the p.R403Q variant was more comparable 
to the wild-type protein than cGMP affinity of CNGB3 containing p.F525N, a variant associated 
with achromatopsia.27 
Whether the heterozygous CNGA3 mutations have an additional pathogenic effect in the third 
patient is unclear. p.E228K is located in a fully conserved site in the transmembrane region 
of the cone α-subunit (Figure 3), and was found homozygously without CNGB3 mutations in 
a proband with achromatopsia.28 This observation indicates that the p.E228K variant can be 
pathogenic, and suggests that this variant could have an additive effect to the AR COD phe-
notype in our proband. The eldest daughter of this proband, who is a heterozygous carrier of 
this CNGA3 variant and of a CNGB3 variant, is still unaffected at the age of nine years. The next 
decade will show whether she will develop any cone dysfunction, and provide further proof of 
a true digenic disease model. The newly identified p.V266M variant appears to be well tolerated 
and is unlikely to affect protein function. What may be the consequences of mutations in both 
CNGB3 and CNGA3? The CNG-channels in the cone are heterotetramers with two α- and two 
β-subunits. In a mouse model inter-subunit interaction between CNGA3 and CNGB3 was 
identified with immunolabeling. Matveev et al. concluded that this interaction was necessary 
to obtain a heterotetrameric complex in the cone CNG-channels.29 Our hypothesis is that a 
missense mutation in the CNGA3 gene in the presence of two missense mutations in CNGB3 
further deteriorates an already compromised CNG3 channel. 
The single CNGA3 and CNGB3 variants that we found in six probands all reside in evolutionary 
conserved areas.30 If a second mutation is present, it could be located in an area of the CNGA3, 
CNGB3 or GNAT2 gene that was not analyzed (deep intronic, promotor), or it may have been a 
large deletion that was missed due to the nature of our PCR-based analysis. However, a second 
mutation may not be present. In this scenario, the heterozygous variant does not contribute to 
the COD phenotype. In conclusion, the CNGB3 gene accounts for only a small fraction of the 
later onset progressive form of cone photoreceptor disorders, and CNGA3 may have an addi-
tive causative effect. It is likely that the majority of AR COD is due to other genetic causes. The 
finding that cone function can be maintained in the early years of life despite mutations coding 
for essential proteins of the cell suggests that protective mechanisms are present. Identification 
of these pathways may help develop strategies to prolong the life of the cone photoreceptor 
cell.
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3.1
A novel TULP1 mutation as a cause of cone dysfunction 
introduCtion
Cone dystrophy ( COD) and cone-rod dystrophy (CRD) are progressive retinal cone disorders 
with an estimated prevalence of 1:30.000-1:40.000 worldwide.1-3 Individuals with COD have 
normal cone function at birth, but develop progressive loss of cones and central vision in the 
first or second decade of life.4 Most persons develop severe visual acuity loss before the age 
of 40.4 Clinical features of cone dystrophy are poor visual acuity, disturbances in color vision, 
a fundus appearance varying from normal, a bull’s eye maculopathy or total atrophy of the 
macular region, with a variable degree of temporal pallor of the optic nerve. Visual fields display 
a central scotoma and full-field electroretinography (ERG) records a progressive deterioration 
of cone derived amplitude responses. Both diseases are characterized by loss of cone photo-
receptors and progressive visual decline, but CRD can be distinguished from COD by early 
involvement of rod photoreceptors. Symptoms of CRD resemble those of COD, although 
patients with CRD may also experience nyctalopia owing to rod dysfunction.5 Multiple genes 
have been shown to be involved in both disorders. The most prevalent mode of inheritance 
is autosomal recessive; Seven genes have been implicated in AR COD (ABCA4, CACNA2D4, 
CNGA3, CNGB3, GNAT2, KCNV2, PDE6C); and six in AR CRD (ABCA4, ADAM9, CERKL, EYS, 
PROM1 and RPGRIP1). In both disorders mutations in these genes explain disease in only a 
minority of all patients, and most genetic causes are currently still unknown.6; 7 
The goal of this study was to identify novel causes of AR COD and CRD using homozygosity 
mapping. Homozygosity mapping has proven itself to be an effective tool in elucidating genetic 
defects in recessive traits in consanguineous as well as non-consanguineous families.8-10 This 
study demonstrates that homozygosity mapping can reveal uniparental disomy, facilitating the 
identification of a novel gene for cone disorders.
methods
Subjects and clinical evaluation
Patients (COD N= 159; CRD N= 91) were ascertained from various ophthalmic centers in the 
Netherlands, Belgium, the United Kingdom, and Canada. Individuals with COD were included 
when they showed a progressive decline of visual acuity, color vision disturbances, and reduced 
cone amplitude responses on ERG, with normal rod responses for ~5 years. Inclusion criteria for 
CRD were a progressive decline of visual acuity, color vision disturbances, and on ERG a reduc-
tion of both cone and rod responses, with cones equally or more severely reduced.5 
After identification of the genetic defect, the medical history of the respective patients was 
reviewed and additional ophthalmic examinations were performed. This included best-corrected 
visual acuity (BCVA; Snellen chart), slit-lamp biomicroscopy, ophthalmoscopy, color vision test-
ing (Hardy–Rand–Rittler color vision test and Lanthony Panel D-15 tests), and Goldmann kinetic 
perimetry (targets V-4e, and I-4e to I-1e). Electroretinography (ERG) was performed accord-
ing to the extended protocol for the full-field ERG (ERG, Rod- and Cone b-wave series) of 
the International Society for Clinical Electrophysiology of Vision (ISCEV).11 In addition we also 
did S-cone-specific ERG testing in one patient.12; 13 After one-minute adaptation to an amber 
background to deactivate the L- and M-cones, blue light-flashes were delivered once every two 
seconds to stimulate the S-cones. This process was repeated, but instead patients followed a 
one-minute adaptation to a blue background to deactivate the S-cones and amber light-flashes 
were delivered to stimulate the L- and M-cones. Spectral-domain optical coherence tomography 
(SD-OCT; Heidelberg Spectralis HRA+OCT, Heidelberg Engineering, Germany) was used to 
obtain cross-sectional images of the macular region through dilated pupils, one horizontally and 
one vertically (30° wide, 51 frames per line). In addition we performed a volume scan (20x15°, 
37 lines, 36 frames per line). Fundus autofluorescence (FAF) imaging (Heidelberg Spectralis 
HRA+OCT, Heidelberg Engineering, Germany) of the macula was performed with 488 nm wave-
length using a 30° lens: a mean image out of 16 single images was calculated. Fundus photographs 
abstraCt
Purpose: The majority of the genetic causes of autosomal recessive (AR) cone dystrophy 
(COD) and cone-rod dystrophy (CRD) are currently unknown. We employed a high-resolution 
homozygosity mapping approach in a cohort of patients with COD or CRD to identify new 
genes for autosomal recessive (AR) cone disorders.
Design: Case series
Participants: A cohort of 159 AR COD and 91 CRD patients 
Methods: The genomes of 83 AR COD and 73 CRD patients were analyzed for homozygous 
regions using single nucleotide polymorphism (SNP) microarrays. One patient showed homo-
zygosity of SNPs across chromosome 6 and segregation analysis was performed using micro-
satellite markers. Direct sequencing of all retinal disease genes on chromosome 6 revealed a 
novel pathogenic TULP1 mutation in this patient. A cohort of 159 COD and 91 CRD individuals 
was screened for this particular mutation using the restriction enzyme HhaI. The medical his-
tory of patients carrying the TULP1 mutation was reviewed and additional ophthalmic exami-
nations were performed, including electroretinography (ERG), perimetry, optical coherence 
tomography (OCT), fundus autofluorescence (FAF), and fundus photography.
Main Outcome Measures: TULP1 mutations, age at diagnosis, visual acuity, fundus appearance, 
color vision defects, visual field, ERG, FAF and OCT findings. 
Results: In one patient homozygosity mapping and subsequent segregation analysis revealed 
maternal uniparental disomy (UPD) of chromosome 6. A novel homozygous missense muta-
tion (p.Arg420Ser) was identified in TULP1, while no mutations were detected in other retinal 
disease genes on chromosome 6. The mutation affects a highly conserved amino acid residue 
in the Tubby domain, and is predicted to be pathogenic. The same homozygous mutation was 
also identified in an additional, unrelated CRD patient. Both patients carrying the p.Arg420Ser 
mutation presented with a bull’s eye maculopathy. The first patient had progressive loss of 
visual acuity with a relatively preserved ERG, while the second patient developed loss of visual 
acuity, peripheral degeneration and severely reduced ERG responses in a cone-rod pattern. 
Conclusions: Maternal UPD of chromosome 6 unmasked a mutation in the TULP1 gene as a novel 
cause of cone dysfunction. This expands the disease spectrum of TULP1 mutations from Leber 
congenital amaurosis and early-onset retinitis pigmentosa to cone-dominated disease.
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copies of the mutated allele from his mother. Segregation analysis in five unaffected siblings and 
the unaffected mother confirmed the presence of the mutation on the maternal allele. The 
patient’s mother was 45 years old when he was born, had a normal pregnancy with a normal 
gestational period, although the patient was born with a very low birth weight. 
A cohort of 159 unrelated individuals with COD and 91 with CRD (including individuals who 
were previously genotyped with SNP microarrays) was screened for this particular mutation, 
which lead to the identification of another Dutch individual (patient 2) carrying p.Arg420Ser in 
a homozygous state. TULP1 was located in the largest homozygous region (43.2 Mb) of patient 
2 (Supplemental Table 3). Patients 1 and 2 shared a common 8.2-Mb homozygous haplotype 
surrounding the TULP1 mutation, suggesting that they are related through a common ancestor. 
Segregation analysis confirmed that both parents of patient 2, who are first cousins, carry the 
p.Arg420Ser mutation in heterozygous state (Figure 1B). The mutation was not detected in 159 
healthy ethnically matched control individuals nor in our in-house exome (n=672) database and 
online exome (Exome Variant Server, http://evs.gs.washington.edu/EVS/, 1 October 2012) and 
mutation databases (HGMD, www.hgmd.cf.ac.uk/ac/index.php 1 October 2012; 1000genomes 
project, www.1000genomes.org, 1 October 2012). 
Figure 1 Pedigrees with two Dutch patients with cone dysfunction due to a novel 
mutation (c.1258C>A; p.Arg420Ser) in the TULP1 gene
A) Microsatellite analysis in patient 1 and his family members demonstrated maternal UPD of 
chromosome 6. The patient inherited two copies of the maternal chromosome carrying the 
TULP1 mutation p.Arg420Ser. Microsatellite marker positions are based on the UCSC human 
genome reference sequence, version hg19. B) Segregation analysis of the same TULP1 mutation 
in family members of patient 2. Both parents, who are first cousins, carry the p.Arg420Ser muta-
tion in heterozygous state. 
In silico analysis of the p.Arg420Ser mutation in TULP1
The p.Arg420Ser mutation identified in TULP1 affects a residue which is located in the C-terminal 
Tubby-domain (Figure 2A). The arginine residue at position 420 is highly conserved among mam-
malian and fish TULP1 orthologs, but is not conserved in chicken and frog nor in the homologous 
proteins TULP2, TULP3 and TUB. To evaluate the pathogenicity of the mutation, in silico analysis 
centered on the macular area as well as on the four peripheral quadrants was performed using 
standard procedures.
This study was approved by the Institutional Review Board, and adhered to the tenets of the 
declaration of Helsinki. All subjects provided written informed consent prior to participation in 
the study. 
Molecular Genetic Analysis
Blood samples were obtained of all probands, and (if possible) their parents, affected and 
unaffected siblings. DNA was isolated from peripheral blood lymphocytes by standard proce-
dures. After exclusion of mutations in the known genes CNGA3, CNGB3, KCNV2, and PDE6C, 
genome-wide homozygosity mapping was performed in 83 individuals affected by COD using the 
Affymetrix GeneChip Genome-Wide Human Mapping 5.0 (Affymetrix, Santa Clara, CA, USA). 
Homozygosity mapping in another 73 individuals with CRD was performed using the Affymetrix 
GeneChip Human Mapping 250K NspI array (Affymetrix, Santa Clara, CA,USA, N=32) and 
Affymetrix GeneChip Genome-Wide Human Mapping 6.0 (Affymetrix, Santa Clara, CA,USA, 
N=41).7 Genotypes were called with Genotype Console software (Affymetrix), and homozygous 
regions were calculated with Partek Genomic Suite software (Partek Inc., St. Louis, MO, USA). 
For one Dutch patient and all his available family members, microsatellite analysis was performed 
for selected markers on chromosome 6. Microsatellites D6S291, D6S963, D6S1552, D6S1568, 
D6S1582, D6S1611, D6S1618, D6S1645 and were amplified with primers containing a M13 for-
ward and reverse tail. A second PCR was performed with a fluorescently labelled M13-forward 
primer and an unlabelled M13-reverse primer. Polymerase chain reaction (PCR) products were 
mixed with a fluorescent size marker (Applied Biosystems), and samples were analyzed on a 3100 
or 3730 DNA Analyzer (Applied Biosystems). Fragment lengths were analyzed with GeneMapper 
software (Applied Biosystems). Haplotypes were constructed based upon the size of the alleles 
of the microsatellites. 
Sequence analysis of all exons and intron-exon boundaries was performed for ELOVL4, EYS, 
IMPG1, LCA5, RDS and TULP1 with the Big Dye terminator cycle sequencing kit (PE Applied 
Biosystems, Foster City, CA, USA). Primers were designed with Primer3 software, and primer 
sequences are listed in Supplemental Table 1. Screening of patients and controls for the observed 
TULP1 mutation p.Arg420Ser was performed by amplification of exons 12 and 13 (499 basepairs 
(bp)) followed by HhaI digestion of the amplified products. Wildtype alleles were digested into 
355 bp and 145 bp fragments, whereas mutant alleles remained undigested. 
The pathogenicity of the mutation was determined in silico using the Grantham- and PhyloP-score 
(phylogenetic P-value), SIFT, and Polyphen-2 (v2.1.0r367). The 3D-structure of TULP1 (residues 
290-542) was determined experimentally and can be found in PDB-file 2FIM. YASARA was used 
to visualize this structure and to study the effect of the mutation.14 
results
Molecular genetic analysis
Homozygous SNP calls across the entire chromosome 6 were observed in one single Dutch 
patient (patient 1; Supplemental Table 2), suggesting uniparental disomy (UPD), a phenomenon 
involving the inheritance of two homologous chromosomes from one parent.15 Considering the 
high chance of identifying the causative mutation on chromosome 6, all relevant retinal disease 
genes located on this chromosome were analyzed. Screening of ELOVL4, EYS, IMPG1, LCA5, and 
RDS did not reveal a pathogenic mutation. Analysis of TULP1 identified a novel homozygous mis-
sense mutation that substitutes the amino acid arginine by a serine (c.1258C>A; p.Arg420Ser). To 
determine the origin of the patient’s UPD, haplotype analysis using eight microsatellite markers 
surrounding TULP1 was performed (Figure 1). This demonstrated that patient 1 inherited two 
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Table 1 Clinical evaluation of cone disorders with TULP1 mutation
Patient 1 (52 yrs) Patient 2  (36 yrs)
Origin The Netherlands The Netherlands
Age at  
diagnosis
43 24
Visual acuity
(refraction)
At onset:
RE: 80/200
LE: 120/200 
Current age:
RE: CF
LE: 10/200 
Mild myopia
(SE-3D)
At onset:
RE: 50/200
LE: 32/200 
Current age:
RE: 10/200 
LE : 10/200 
High myopia
(SE -12.5D)
Fundus -Macular bull’s eye 
-Peripheral mottling 
-Vessels slightly attenuated 
-Optic disc mild pallor
Macular bull’s eye 
-Mid-periphery subtle RPE changes and
 far-periphery bone-spicules 
-Vessels severely attenuated
-Optic disc moderate pallor
Autofluore­
scence
Central hyperfluorescence, paracentral ring of 
nonfluorescence surrounded by hyperfluore-
scence
Hypofluorescent macula surrounded by hyper-
fluorescent ring
OCT Thinned retina; decreased photoreceptor layer 
in fovea and paracentral loss of RPE
Thinned retina; photoreceptor layer absent in 
posterior pole and loss of RPE
Color vision Errors in all color axes (Ishihara, Panel D15) Errors in all color axes (Panel D15, HRR)
Visual field
(Goldmann)
-Central scotoma 
-Periphery normal
-Large central scotoma 
-Peripheral field loss and constriction
ERG Responses within normal limits Scotopic and photopic responses significantly 
reduced
CF = counting fingers, D = diopters, ERG = electroretinogram, HRR = Hardy-Rand-Rittler 
color vision test, LE = left eye, OCT = optical coherence tomography, RE = right eye, RPE = 
retinal pigment epithelium, SE = spherical equivalent
Clinical features of patients with TULP1 mutations
Table 1 shows a summary of the clinical findings in both patients with the TULP1 mutations. 
Both were re-invited to the clinic for a complete ophthalmologic examination. Patient 1 had 
experienced a rapid visual decline from 80/200 RE and 120/200 LE at age 43 to counting fingers 
RE and 10/200 LE at age 52 with a myopic refraction (SE-3D). Fundoscopy detected a slight bull’s 
eye maculopathy, which is more apparent on the autofluorescence image, and psychophysical 
testing showed severe color vision defects without a specific axis of confusion. Goldmann 
perimetry revealed a central scotoma with an intact periphery. Dark adapted electrophysiol-
ogy showed a mild delay of the onset of the b-wave of the isolated rod responses. The rod 
b-wave amplitudes and latencies were normal. Mixed dark adapted responses and light adapted 
responses, including 30-Hz flicker were in the low range of two standard deviations. OCT 
imaging revealed general thinning of the retina, and parafoveally, loss of RPE and photorecep-
tors. FAF showed a distinct hyperfluorescent ring (Figure 3A-D, and 3I). 
using a variety of prediction programs was performed. Arginine shows a moderate physico-
chemical dissimilarity with serine (Grantham score: 110 [0-215]). SIFT predicts that no other 
residue than the wildtype arginine is tolerated at this position, and Polyphen-2 predicts that the 
substitution is possibly damaging, with a score of 0.925 (sensitivity: 0.80; specificity: 0.94). At 
nucleotide level, position 1258 is moderately high conserved with a phyloP score of 2.20. 
The 3D-structure of TULP1 residues 290-542 consists of a beta-barrel with the last C-terminal 
residues forming an alpha-helix centered at the core of this barrel. Arginine 420 is located in one 
of the beta-sheets that surrounds the central helix (Figure 2B). Its side chain is located on the 
protein surface where it can make a hydrogen bond to residue Asn411 and a saltbridge to residue 
Glu409. These interactions stabilize the beta-sheet domain, which might be required for the 
correct positioning of the central helix and could be involved in interactions with other proteins. 
Due to the differences in charge and size between Arginine and Serine, mutation p.Arg420Ser 
will lead to a change at the protein surface which will affect the stability of the domain (Figure 2C). 
Figure 2 Evolutionary conservation and effect on the TULP1 structure of the TULP1 
mutation p.Arg420Ser
A) Alignment of a part of the C-terminal Tubby domain of TULP1 orthologs and TULP1 family 
members. The arginine residue at position 420 is highly conserved among mammalian and fish 
TULP1 orthologs, but is not conserved in chicken and frog nor in the homologous proteins 
TULP2, TULP3 and TUB. Identical amino acids are indicated in black boxes, conserved residues 
in gray boxes. B) Visualization of the beta-barrel in the TULP1 structure using the PDB-file 2FIM. 
Red represents the arginine residue at position 420 and the magenta dots indicate unknown 
parts of the structure. C) Visualization of the p.Arg420Ser mutation in the TULP1 structure. The 
wildtype amino acid is shown in green, whereas the mutant amino acid is depicted in red. The 
structure will be destabilized due to the change of the positively charged arginine to the neutral 
serine. D) Visualization of the p.Arg420Pro mutation in the TULP1 structure. Destabilization of 
the structure will occur by the change of the positive arginine to the neutrally charged proline 
and by the introduction of a more rigid residue.
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pattern. The fundus showed a macular bull’s eye with subtle RPE changes, bone spicules in the 
far periphery, severely attenuated vessels and a moderate pallor optic disc. The autofluores-
cencence image pointed to central hypofluorescence surrounded by a hyperfluorescent area. 
The OCT revealed thinned retinal layers with absent RPE and photoreceptor layer in the fovea 
(Figure 3E-I).
disCussion
In the present study, we describe two unrelated individuals with cone dysfunction due to 
a novel homozygous TULP1 mutation (p.Arg420Ser). Both patients presented with progres-
sive loss of visual acuity, bull’s eye maculopathy, color vision deficiencies, central scotomas, 
abnormal imaging of the central retina, and progressive loss of cone function on ERG, indicat-
ing predominantly cone-mediated disease. This mutation occurred in 0.4% of our COD/CRD 
cohort, indicating that it is an infrequent cause of cone dysfunction. Previous studies have asso-
ciated TULP1 mutations with predominantly rod-mediated diseases such as Leber congenital 
amaurosis (LCA) and early-onset retinitis pigmentosa (RP).16-18 Hanein et al. (2004) considered 
TULP1 mutations to cause type 2 LCA, which is a severe and progressive form of rod-cone 
dystrophy with nightblindness and peripheral involvement19. Several other studies described 
TULP1 mutations in RP and LCA with extinguished rod and cone ERG responses, who at early 
stages presented with nightblindness, a hallmark of initial loss of rod photoreceptors.10; 16; 20-22 
All missense mutations that were identified in early-onset AR RP and LCA affect residues in the 
highly conserved C-terminal Tubby domain, which underlines the importance of this region for 
the physiology of photoreceptor cells. Interestingly, a different mutation (p.Arg420Pro, Figure 
2D) affecting the same arginine residue of TULP1 was described in two siblings with early-onset 
RP.16 In that family, p.Arg420Pro was present in a compound heterozygous state with another 
missense mutation (p.Phe491Leu), which also affects a conserved residue in the C-terminal 
Tubby domain. The mutation p.Arg420Pro is predicted to also result in loss of interactions 
and affect the stability in a similar way to p.Arg420Ser. The wide spectrum of phenotypes 
attributed to TULP1 missense mutations suggests that the Tubby domain, and in particular the 
region spanning the Arg420 residue, may exert important functions specific to either rods or 
cones.23; 24 Indeed, previous studies have shown that TULP1 is expressed in both photorecep-
tor subtypes.23 Several cellular functions have been suggested for TULP1. TULP1 has been 
shown to enhance phagocytosis by the retinal pigment epithelium (RPE), an important process 
for the removal of apoptotic cells and cellular debris.25; 26 A reduced phagocytosis is shown 
for TULP1 mutations located towards the C-terminus, but p.Arg420Pro appeared to have no 
effect on RPE phagocytosis.25 TULP1 has also been suggested to be involved in vesicular traf-
ficking of photoreceptor proteins, like rhodopsin,27 both at the nerve terminal during synaptic 
transmission and at the inner segment during protein translocation at the other segment.28; 29 
Tulp1 interacts with Actin and Dynamin-1, both known to be crucial in the scaffold of the cyto-
skeleton, vesicle docking/cycling at the synaptic terminals of photoreceptors, and in vesicular 
protein transport from the inner to the outer segment. The latter is supported by the abnor-
mal distribution of two rhodopsin transport machinery proteins, Rab8 and Rab11, and the 
mislocalization of guanylate cyclase activation proteins GCAP1 and GCAP2 in Tulp1-/- mice.30 
Interestingly, synaptic malfunction after photoreceptor degradation was also observed in these 
mice, indicating that Tulp1 may also play a role in photoreceptor synapse development.31 Both 
rod and cone opsins are mislocalized in Tulp1-/- mice.32 Although the exact region involved in 
opsin transport remains to be elucidated, we speculate that the p.Arg420Ser mutation may 
have a more pronounced effect on cone opsin transport and a lesser effect on rhodopsin trans-
port in rod photoreceptors, opposed to p.Arg420Pro and other missense mutations that cause 
early-onset RP or LCA. As the p.Arg420Ser and p.Arg420Pro mutations introduce different 
Figure 3 Clinical evaluation of cone dysfunctions caused by the TULP1 mutation
A-D Clinical characteristics of patient 1. A) The fundus photograph showed a slight macu-
lar bull’s eye, peripheral mottling, slightly attenuated vessels and a mild pallor optic disc; B) 
Autofluorescence revealed a more apparent macular bull’s eye, central hyperfluorescence and 
a paracentral ring of nonfluorescence surrounded by hyperfluorescence; C) optical coherence 
tomography (OCT) displayed a thinned retina and a decreased inner and outer segmental 
region in the fovea and paracentral loss of RPE; D) Goldmann perimetry showed a central 
scotoma and a normal periphery; E-H Clinical characteristics of the patient 2: E) Fundus pho-
tographs revealed a macular bull’s eye, subtle mid-peripheral retinal pigment epithelium (RPE) 
changes, bone-spicules in the far periphery, severely attenuated vessels and a moderate pal-
lor of the optic disc; F) Autofluorescence showed a hypofluorescent macula surrounded by a 
hyperfluorescent ring; G) OCT displayed a thinned retina and absence of the inner and outer 
segments. Also note the posterior staphyloma around the optic disc; H) Goldmann perimetry 
revealed a large scotoma and peripheral field loss; I) Electroretinogram (ERG) of patient 1 and 
2. In patient 1 dark adapted electrophysiology showed a mild delay of the onset of the b-wave 
of the isolated rod responses. The rod b-wave amplitudes and latencies were normal. Mixed 
dark adapted responses and light adapted responses, including 30-Hz flicker were in the low 
range of two standard deviations. In patient 2 ERG responses showed significantly reduced 
cone and rod responses.
Patient 2 also had progressive visual decline, as the visual acuity dropped from 50/200 RE and 
32/200 LE at age 24 to 10/200 RE and 10/200 LE at age 36 with a myopic refraction (SE-12.5D). 
Psychophysical testing showed color vision without a specific axis. Goldmann perimetry 
revealed a large central scotoma, with constriction of peripheral isopters as well. ERG respons-
es deteriorated over the years from mild cone dysfunction to a significantly reduced cone-rod 
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Supplemental Table 1 Chromosome 6 retinal disease gene primers
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Gene & exon Forward Reverse Product size (bp)
TULP1
1-2 gtgaagttgagccgagattag taccctgcgtgggtttac 368
3 ctgcggttatttctggcggc gcttccattcagcttcccac 408
4 gaagtgttgaaagtggaaacc ccttctctccttagctccac 364
5 cggttcttgtttcagaagg cctcaatcgctgtgtctc 376
6-7 gactataggcaggacaagagg tccttacctagcactgtcttg 481
8 gaagcactttgcaaaccag tctaggctcccaagtccag 238
9-10-11 ccagagcctcctaacttgg cacagcaggacagagatgac 733
12-13 tgaattgctcagtcctaactc agttggctatttcctaagctg 499
14 agccatctcagccatctc cttgaatgaaggtcagcatc 296
15 gtgttgagtaactgagatggtg gacacaggagcagttttcc 384
ELOVL4
 1 ttgaggagcaggagaagacg tgatccgcagcatccgaaag 374
 2 ttgggactcaaaggacagtg atgccagaacagctaataagg 570
 3 cacagtaacttctagcaatcg cataccactgcacttcagtc 412
 4 ccatgccttgtacattttgtg tgacagagcgagactccatc 477
 5 acaactgtgaaagtcctttgc ataactgcgatatagctggag 520
 6 aaatttgggcctgtgatagc tcctttgcttctgttttccc 458
EYS
 1 ttatgtcagcctgcacatgg gtagttgtgttcagctaggc 286
 2 agctaaaggcaggatactgg atggaaagcagggaatgagg 315
 3 gaagactcattctaggttagtc cactgcaaagatagtgtcacc 472
 4A cttaaaacaccattttgcagc atgtgtcccaacactcagcc 498
 4B acttctacagagattgctgg agattcctggcagaactgc 376
 4C gtggtccatcaccttgtcc tagagacggggtttcaccg 486
 5 agaattgagggaaaactgatgg cataaaagagttcagtatatatacc 485
 6 tctatgctcatttcttctttccttc aaaataagtagaccgttcttgttcg 403
 7 ttctccaggtaagaacccattc ttaagtaaaagttagggttaaaaccag 311
 8 ttggaataatgttaataggcttttc tggctaagattaataagagcatttg 285
 9 ggcttttgaacatggatatgac agatttcctaggatgtagttggtg 559
 10 ggaacttattttgtggcagatg gactgttgagaatttgtttacgaag 427
 11 ggtttcatcttagtagacagagaggc cattgttaccatgaaacagttcg 368
 12 tgcaccccacaactatcttc aattgcccaaagaagcaatc 570
 13 ttcagatgtcatcctaagtgg cagacaagagacagaagtgc 293
 14 ggatattttcattgttgctttgc tgaatccaataagtgaacagtttg 655
 15 gagatatcaaaatggccaggag atcccaaggacactgagcac 273
 16 caccacatactattagttcaag attttaggaggccatcatcc 447
 17-18 attctttagactaccactgattc acataatgagcacatgtgtgc 551
side chains at the protein surface, they might have a different effect on protein interactions 
involved in either rod or cone opsin transport. 
Both patients carrying the p.Arg420Ser mutation had similarities in their clinical presenta-
tion, but we also noted several remarkable differences. Patient 2 had a ounger age of onset 
(age 24) than patient 1 (age 43), was more severely affected, and his ERG showed significantly 
reduced cone and rod responses (Figure 3I), whereas patient 1 showed a mild delay, but nor-
mal amplitudes and latencies in the b-wave responses. Maybe the presence of high myopia 
may have deteriorated the clinical course in patient 2. Alternatively, patient 2 may carry addi-
tional deleterious alleles in other genes which contribute to the pathology, or patient 1 may 
carry protective alleles reducing photoreceptor degeneration. Interestingly, a recent screen 
for modifier loci identified a protective allele near Mtap1a, which reduces photoreceptor loss 
in Tulp1-/- mice.33 Patient 1 had a significant hyperautofluorescent macular ring, which was even 
observed on the nasal side of the optic disc. A macular ring has been described in many RP 
patients,34-36 but to our knowledge has not been described in patients with TULP1 mutations. 
The ring is considered to be the result of abnormal accumulation of the fluorophore lipofuscin 
in the RPE due to outer segment degeneration. The size and growth of this ring appears to 
correspond to the degree of abnormal retinal function and visual prognosis.34 
In this study, UPD facilitated the finding of the causal TULP1 mutation in patient 1. UPD is a 
phenomenon involving the inheritance of two homologous chromosomes from one parent.15 
UPD allows two copies of a recessive mutation to be transmitted from a heterozygous carrier 
parent.37 The majority of such cases appear to be associated with advanced maternal age.38 This 
is in agreement with the observed UPD in this report, as the patient’s mother was 45 years old 
when he was born. UPD is a rare phenomenon, with an estimation of 1 in 5,000 or even less.39 
This is confirmed by the fact that of 156 COD/CRD, 186 RP and 93 LCA patients that were 
genotyped with SNP microarrays, the patient described in this study is the only case in which 
we detected homozygosity across an entire chr mosome.8; 10 To date, seven cases of maternal 
UPD of chromosome 6 have been reported in literature.40-46 In several of these cases intra-
uterine growth retardation was observed. The mother of patient 1 had a normal pregnancy, 
but the patient was born with a very low birth weight, indeed suggesting intrauterine growth 
retardation. Chromosome 1 and 2 UPD’s were found in which mutations in MERTK, RPE65, 
USH2A were associated with retinal dystrophies.47-49
In conclusion, through homozygosity mapping of patients with cone disorders, a case with 
maternal UPD of chromosome 6 was identified. This unmasked a mutation in TULP1 as a novel 
cause of cone dysfunction in two unrelated patients. Our study expands the disease spectrum 
of TULP1 mutations from early-onset RP to cone-dominated disease. The observed phenotypic 
difference in patients carrying mutations affecting the same amino acid residue (p.Arg420Ser 
and p.Arg420Pro), may be a result of different structural alterations at the TULP1 protein 
surface, leading to defective opsin transport in either cones and/or rods. Further research is 
required to decipher the molecular mechanisms associated with the different diseases caused 
by TULP1 mutations, and will aid a better understanding of the function of TULP1 in cones and 
rods. 
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Gene & exon Forward Reverse Product size (bp)
 19 agcagaacaaaattttgcaagg catctggcagattatttcagg 425
 20 agagaggtcttcatttcttgg agctcttgttttatgaaagagc 395
 21 aaacccaggaataaactctgc ggaagaaatgactctgaaacc 322
 22 gtcaaacaagtttgcacatcag gaaagcaaaacatgggagtg 531
 23 aactcattgtcaccccaagg tcctgatgaaagcctaagtgc 486
 24 aatggcaccacggataagag gaggaatgccgagaaaagtg 572
 25 gagctatccaatatgtctatgg gcagaaaatatgcttttaccac 378
 26A ttatcccagtgccaaagtgg agtaatgactgcctgtttagc 525
 26B actgttgctttatctgctacc gaacatgttgcacatgtttgg 434
 26C tactgaggcttcaagcaacc gtgggtcccatagttatgcc 549
 26D atccattgtcccttcacaaac tacagacatggaggaagacg 439
 26E gatttttcagaagtcaccacc ctgattacaatgaggctgttc 410
 27 aaagaggcaggaaagagacg aggaagagacatcctggtgg 443
 28 acttcatgtctctccaaagtg attgttagggatagcctttgc 273
 29 tgcttctggctttgttttattg tggaaaaacagactgacattgg 521
 30 tgcataccctgaccagtttg cgtaggaatgtgaagcaaaaac 335
 31 gttaaaccttgatcagtattgg acagctgtttcttgtttgtgc 475
 32 tgcttcatgcactggtctgg gtgttaccttttcaaatgaatgc 552
 33 ctaatagcactcctaccaacc tctgtagtcccaactacttgg 465
 34 cttgaaaatgtccacacttgg tttctggtgctttgttgagag 405
 35 aactagccaacaatagcaacc ctctcagaggacaatactgc 447
 36 agtggaaagcacacagctac ttgatcagtcaagtgctatcc 458
 37 ttagttgctcaatgctgaagg caattagagtgtccctgagg 410
 38 cagccagttgcacatatacc gtgaacttcgtggatgtagg 438
 39 agcagagaattgagtggtatc gaaagcaatccatatagctgg 410
 40 tctctgcgcatttctgtattc atgtgcatctgtttgtgttcc 438
 41 aaattgacaagttagcatcagg aagtactagtctatctgtgaag 432
 42 gaactgcaggacagatgtac cctaattctaagctccaatcc 323
 43 ttgatgtactcacctacaagc acgcatacacttgcagtgac 444
 44A cacaattgtgctcaagatctg tacatttgagccaccttttgc 511
 44B tgaacctgtaggttttcaagg tgaactggaggtttctcattc 422
 44C ttcttacagttgcctgtgtac tttatgtggatcaatatcctcg 424
 44D ttctgttgtaataaatggcacc acaatcagaaccttcagtgac 394
IMPG1
 1 tgacagatgctcctccagaa tcaattggtagccttgttgg 435
 2 tagcagttgcaccacggtag tgaatgaaagggaagggatg 430
 3 actttgcttgggattgggta cccttacgttgtggaaacca 329
 4 ggtttccacaacgtaagggtta acacagctcttagtggctgaca 346
 5 tgcttacggaaaacactggag catgatggttgtttccaaactg 543
 6 aaaagatgagttcagaaggcac cccctcagtacctaggaagaag 422
Gene & exon Forward Reverse Product size (bp)
 7 ttgattgcaaaacacttaagcc tatgtcctatcggctcccac 335
 8 ccattttcagctgttcccc tccaggatttggcagagc 294
 9 ccattcaaattctgatggcag cattgaccttggaaa ggagc 620
 10 gagcccatcaggaaagagg acacaggaaggagtgagaaaag 533
 11 ggactgttttattgtcccaacc tctttggtggaaggttttgag 212
 12 aggcagattcagttatccgag aaggaaggatgctgtggatg 508
 13-1 aatgatctacgcaaatgctatg ctgggacagaaacatattcgc 459
 13-2 tgcatcttcagatgacagcc gcttggcggtttgtttctac 443
 14 aattagcagcagctgagcac tgtggcctaaagattgaaacg 375
 15 ggtctcttgcctttgactgc aaccatgggttgaaaggacc 381
 16 ctcaaacggaagacacctgc tgcactagaaaatgtcacccc 368
 17 tggcaagcacatcctcttatc tgtctggattttgatgaccc 288
LCA5
 1 caatgggagctcgggtag tccctgctttaagaaccacc 499
 2 tcctaggagtggtctcatttcc tctgttctcgcattactgagg 248
 3 tgtggagaaaatagattgcacag cctataaaacgtaaatcagcccac 465
 4.1 acggacccacttgtgttagg gttgcccgttctttctcttg 477
 4.2 aggtcaagttagctgagctgc tccaagcaaataccaaactgc 457
 5 ttggtaaatctgtttcccagc ttataccaacaaaccttttctaagtg 461
 6 tgacaaagtgaggggttttg tcaatgaggttcttttccttcc 269
 7 ccaagctgagcaaaacatgc ttaggtatatctcctaaaagccaaag 538
 8 tctgtgttgcttagttcccc tttctttctcaagggatgctg 256
 9.1 aaatatggtggttttatgaaagttg ttttgactaaatggatttgacctc 578
 9.2 gaagccccaaaacatacagg ttggcaaactatctatgtggtg 765
RDS
 1A gtgggaagcaacccggac agatcttcccagccagcg 276
 1B tgatagggatgggggtgc ctgtgtcccggtagtacttc 243
 1C gctcgctggagaacaccct tctgaccccaggactggaag 239
 2 aagcccatctccagctgtct cttaccctctacccccagctg 314
 3 agattgcctctaaatctcctc tgcactatttctcagtgttcg 290
Supplemental Table 1 (continue)
Gene & exon Forward Reverse Product size (bp)
 19 agcagaacaaaattttgcaagg catctggcag ttatttcagg 425
 20 agagaggtcttcatttcttgg agctcttgttttatgaaagagc 395
 21 aaacccaggaataaactctgc ggaagaaatg ct tgaaacc 322
 22 gtcaaacaagtttgcacatcag gaaagcaaaacatgggagt 531
 23 aactcattgtcaccccaagg tcctgatgaaagcctaagtg 486
 24 aatggcaccacggataagag gaggaatgccg gaaa gtg 572
 25 gagctatccaatatgtctatgg gcagaaaatatgcttttaccac 378
 26A ttatcccagtgccaaagtgg agtaatgactgcc gtttagc 525
 26B actgttgctttatctgctacc gaacatgttgcaca gtttgg 434
 26C tactgaggcttcaagcaacc gtgggtccca g tatgcc 549
 26D atccattgtcccttcacaaac tacagacatggagg aga g 439
 26E gatttttcagaagtcaccacc ctgattacaatgaggctgttc 410
 27 aaagaggcaggaaagagacg aggaagagac tcct tgg 443
 28 acttcatgtctctccaaagtg attgttagggatagcctttgc 273
 29 tgcttctggctttgttttattg tggaaaaacaga tgacattgg 521
 30 tgcataccctgaccagtttg cgtaggaatg a gcaaaaac 335
 31 gttaaaccttgatcagtattgg acagctgtttct gtttgtgc 475
 32 tgcttcatgcactggtctgg gtgttaccttt caaatgaatg 552
 33 ctaatagcactcctaccaacc tctgtagtccca ct cttgg 465
 34 cttgaaaatgtccacacttgg tttctggtgctt gttgaga 405
 35 aactagccaacaatagcaacc ctctcagagg caata tgc 447
 36 agtggaaagcacacagctac ttgatcagtcaagtgct tc 458
 37 ttagttgctcaatgctgaagg caattagagtg ccc agg 410
 38 cagccagttgcacatatacc gtgaacttcgtggatgtagg 438
 39 agcagagaattgagtggtatc gaaagcaatccat tagctgg 410
 40 tctctgcgcatttctgtattc atgtgcatctgtt g tt c 438
 41 aaattgacaagttagcatcagg aagtactagtctatctgtg 432
 42 gaactgcaggacagatgtac cctaattctaagct caatcc 323
 43 ttgatgtactcacctacaagc acgcatacac cagtgac 444
 44A cacaattgtgctcaagatctg tacatttgagccacct tgc 511
 44B tgaacctgtaggttttcaagg tgaactggaggtttct at c 422
 44C ttcttacagttgcctgtgtac tttatgtggatcaatatcctcg 424
 44D ttctgttgtaataaatggcacc acaatcagaaccttca g c 394
IMPG1
 1 tgacagatgctcctccagaa tcaattggtagccttgttg 435
 2 tagcagttgcaccacggtag tgaatgaaagggaag gatg 430
 3 actttgcttgggattgggta cccttacgttgtggaaacca 329
 4 ggtttccacaacgtaagggtta acacagctcttag gg tg ca 346
 5 tgcttacggaaaacactggag catgatggttgtttccaaactg 543
 6 aaaagatgagttcagaaggcac cccctcagtacct gaagaag 422
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Supplemental table 2 Homozygous regions identified in patient 1
Ranking Chromosome Start position End position Size (Mb) # Homozygous SNPs
1 6 67,106,320 170,719,369 170.6 27168
2 11 46,212,732 57,489,108 11.3 779
3 6 56,930,577 67,061,694 10.1 762
4 10 105,661,099 107,446,812 1.8 413
5 13 78,334,621 79,781,601 1.4 258
6 5 113,437,540 114,518,218 1.1 220
7 3 109,214,236 110,409,180 1.2 217
8 13 56,453,118 58,215,268 1.8 211
9 5 112,050,154 113,057,813 1.0 210
Ranking Chromosome Start position End position Size (Mb) # Homozygous SNPs
1 6 3,906,287 47,108,480 43.2 8165
2 1 212,339,909 239,532,850 27.2 5038
3 4 76,059,943 105,721,548 29.7 4427
4 6 85,585,248 115,108,714 29.5 4389
5 1 57,173,572 81,551,203 24.4 4346
6 14 62,239,467 87,333,478 25.1 4122
7 8 23,760,240 47,043,376 23.3 3229
8 15 64,757,325 85,923,635 21.2 3099
9 10 118,369,943 127,815,378 9.4 2016
10 4 135,645,476 148,658,165 13.0 1854
11 2 128,991,071 138,407,083 9.4 1459
12 2 117,702,425 122,959,129 5.3 891
13 13 22,173,106 25,198,128 3.0 657
14 8 48,367,867 52,695,154 4.3 563
15 6 1,841,598 3,813,951 2.0 449
16 14 25,382,609 28,102,584 2.7 367
17 3 78,696,092 81,235,379 2.5 308
18 12 33,620,575 38,489,062 4.9 297
19 20 53,707,089 54,918,720 1.2 287
20 9 10,417,491 12,008,371 1.6 285
21 1 150,071,531 151,464,242 1.4 282
22 18 52,879,681 53,963,968 1.1 264
23 10 58,845,146 60,201,267 1.4 263
24 6 57,270,662 63,224,267 6.0 255
25 5 58,984,219 60,612,388 1.6 214
26 11 47,841,423 50,234,746 2.4 207
27 12 80,592,770 82,065,456 1.5 206
28 10 25,222,938 26,215,931 1.0 203
Supplemental table 3 Homozygous regions identified in patient 2
Ranking Chromosome Start position End position Size (Mb) # Homozygous SNPs
1 6 3,906,287 47,108,480 43.2 8165
2 1 212,339,909 239,532,850 27.2 5038
3 4 76,059,943 105,721,548 29.7 4427
4 6 85,585,248 115,108,714 29.5 4389
5 1 57,173,572 81,551,203 24.4 4346
6 14 62,239,467 87,333,478 25.1 4122
7 8 23,760,240 47,043,376 23.3 3229
8 15 64,757,325 85,923,635 21.2 3099
9 10 118,369,943 127,815,378 9.4 2016
10 4 135,645,476 148,658,165 13.0 1854
11 2 128,991,071 138,407,083 9.4 1459
12 2 117,702,425 122,959,129 5.3 891
13 13 22,173,106 25,198,128 3.0 657
14 8 48,367,867 52,695,154 4.3 563
15 6 1,841,598 3,813,951 2.0 449
16 14 25,382,609 28,102,584 2.7 367
17 3 78,696,092 81,235,379 2.5 308
18 12 33,620,575 38,489,062 4.9 297
19 20 53,707,089 54,918,720 1.2 287
20 9 10,417,491 12,008,371 1.6 285
21 1 150,071,531 151,464,242 1.4 282
22 18 52,879,681 53,963,968 1.1 264
23 10 58,845,146 60,201,267 1.4 263
24 6 57,270,662 63,224,267 6.0 255
25 5 58,984,219 60,612,388 1.6 214
26 11 47,841,423 50,234,746 2.4 207
27 12 80,592,770 82,065,456 1.5 206
28 10 25,222,938 26,215,931 1.0 203
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introduCtion 
Centrosomal protein 290 (CEP290, MIM#610142) encodes a centrosomal and ciliary protein of 
290 kDa that is expressed in a variety of tissues. CEP290 has been shown to play an important 
role in ciliary trafficking and cilium assembly.1; 2 In the photoreceptor, CEP290 localizes to the con-
necting cilium, the transitional zone linking the inner and outer segments of rods and cones.1; 3-5 
To date, more than one 100 CEP290 mutations have been identified leading to a spectrum of 
phenotypes ranging from isolated early-onset retinal dystrophy and Leber congential amauro-
sis (LCA, MIM#611755) to more severe syndromes like Senior-Loken, Bardet-Biedl, Joubert, 
and Meckel-Gruber syndromes.4; 6-9 Hypomorphic CEP290 mutations are generally associated 
with non-syndromic forms of LCA, and account for an estimated 15% of all LCA cases in the 
Caucasian population.4; 10; 11
Clinically most of these LCA patients, but not all, present with blindness from birth with non-
recordable electroretinograms.11-13 Littink et al. described a family with better preserved cen-
tral vision; these patients were heterozygous carriers of the frequently occurring deep-intronic 
c.2991+1655A>G variant, which is a hypomorphic variant, as about 50% of the resulting mRNA 
contains a stopmutation in the inserted intronic sequence.4 On the other allele, the c. 451C>T 
(p.Arg151*) variant was identified.14 The latter was found to result in nonsense-associated 
altered splicing with an intact reading frame, possibly explaining the milder phenotype. In 
two patients of the family residual rod function was measured on eletroretinography (ERG). 
Coppieters and Perrault also suggested that CEP290-associated LCA is of the cone-rod type 
(LCA type I), despite the relatively well-preserved central macula.11; 15
In this study we describe a family with an unusual form of cone dysfunction evolving into a pro-
gressive dystrophy caused by hypomorphic CEP290 mutations. The two siblings were diagnosed 
as oligocone trichromates by Van Lith who described oligocone trichromacy (OT) as ‘general 
cone-dysfunction without achromatopsia (ACHM)’ in 1973.16 At that time, he described a boy 
of 13 years with nystagmus, photophobia, severely reduced visual acuity, normal fundi, normal 
rod responses and a remnant of cone function on ERG, suggesting a form of achromatopsia. 
Color vision however was unremarkable, leading Van Lith to postulate that all three types of 
cones must be present but reduced in number. Since then, eleven cases of OT with a simi-
lar clinical presentation have been described with severely reduced or non-recordable cone 
responses on ERG and normal or near normal trichromatic color vision. Concomitant signs 
may include nystagmus and photophobia.
Mutations in CNGA3 (MIM#600053)17, CNGB3 (MIM#605080),18 GNAT2 (MIM#139340),19 and 
PDE6C (MIM#600827)18 have been detected in cases with OT, all of which encoding cone 
phototransduction pathway proteins,18 suggesting a pathomechanistic overlap with ACHM. In 
a number of these cases a single heterozygous missense variant has been identified, indicat-
ing that these cases may not be explained by mutations in these genes.18; 19 Unlike ACHM, no 
progressive deterioration of cones and visual function has been reported in the small number 
of described OT cases, so far.
Here, we report 40 years follow-up of two siblings initially diagnosed with OT, but over time 
developed a progressive retinal dystrophy. The disease in these siblings was found to be caused 
by two hypomorphic variants in CEP290, and subsequently broadening the spectrum of CEP290-
associated disease.
methods
The research procedures followed the tenets of the Declaration of Helsinki (1983) and were 
approved by the local ethics committee. Written informed consent was obtained from the 
subjects after explanation of the nature of the study. The father was Dutch and the mother 
originated from Belgium.
abstraCt
Objectives: To identify the gene defect and to study the clinical characteristics and natural 
course of disease in a family diagnosed with oligocone trichromacy (OT).
Methods: Extensive clinical and ophthalmologic assessment was performed for two siblings with 
OT. Subsequently, next generation sequencing (NGS) and Sanger sequence analysis of CEP290 
was performed in the two siblings. Additionally, the identified CEP290 mutations were analyzed 
in persons with ACHM (n=23) and autosomal recessive or isolated cone dystrophy (n=145). 
Results: In the first decade of life, the siblings were diagnosed with OT based on low visual acu-
ity, photoavesion, nystagmus, an absent cone response on electroretinography (ERG), but with 
normal color vision. Over time, the degenerative phenotype progressed from the periphery 
towards the macula. The siblings did not reveal any CEP290 associated non-ocular features. In 
both siblings NGS yielded a heterozygous nonsense mutation (c.451C>T; p.(Arg151*)) in CEP290. 
Subsequent Sanger sequencing revealed a second nonsense mutation (c.4723A>T; p.(Lys1575*)) 
in CEP290. mRNA analysis demonstrated nonsense-mediated altered splicing, confirming a sus-
pected hypomorphic character of p.(Lys1575*), as exon 36 skipping was observed in a small 
fraction of CEP290 mRNA, which has previously also been demonstrated for the c.451C>T 
(p.Arg151*; p.Leu148_Glu165del) mutation. No additional cases carrying these variants were 
identified in the ACHM and CD cohorts.
Conclusions: Compound heterozygous hypomorphic mutations in CEP290 may lead to OT, a 
novel phenotype belonging to the CEP290-associated spectrum of ciliopathies.
Clinical relevance: These findings provide insight into the effect of CEP290 mutations on the 
clinical phenotype.
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Figure 1 Retinal imaging of two individuals with CEP290 variants
A–B, Clinical characteristics of patient II-1 of family A. A) The fundus photograph showed a 
pink optic disc and mildly attenuated vessels. The retinal pigment epithelium (RPE) had a coarse-
grained aspect in the posterior pole and mid-periphery, and a faintly recognizable foveola reflex 
with a subtle indication for bull’s eye maculopathy. B) Fundus autofluorescence (FAF) revealed 
a relatively normal appearance. D–F, C) Fundoscopy displayed a pink, myopic optic disc, mildly 
attenuated vessels and subtle RPE changes in the macula. A faintly recognizable foveola reflex 
Clinical examination
The first ophthalmic examinations of the subjects date from 1971, at ages 2 and 3. Since then they 
were followed regularly and underwent electrophysiology and color vision testing (Hardy Rand 
Rittler (HRR), Pseudoisochromatic Plates and Farnsworth Panel D-15 Test, saturated and desatu-
rated version) at several occasions. Recent examination included best corrected visual acuity (Early 
Treatment Diabetic Retinopathy Study charts, Precision Vision Inc., La Salle, IL, USA), biomicros-
copy, ophthalmoscopy, fundus photography, color vision testing (Panel D-15), and Goldmann kinetic 
perimetry. Extended ERG testing was performed according to the protocol of the International 
Society for Clinical Electrophysiology of Vision (ISCEV).20 Spectral domain optical coherence tomog-
raphy (OCT) and fundus autofluorescence (FAF, Heidelberg Spectralis HRA+OCT, Heidelberg, 
Germany) were carried out as described previously,21 but failed partially due to photophobia and 
nystagmus. Both individuals were also seen by an internist to evaluate the presence of extra-ocular 
features. This included physical examination and extensive laboratory testing.
Genetic testing
To determine the genetic defect in the family with two affected siblings, blood samples for molecu-
lar genetic analysis were collected from all family members (Figure 3A). Genomic DNA was isolated 
from lymphocytes by standard procedures.22 DNA samples of both affected individuals was analyzed 
using GeneChip Genome-Wide Human single nucleotide polymorphism array 5.0 NspI (Affymetrix, 
Santa Clara, CA, USA), genotypes were called using Genotype Console (Affymetrix, Santa Clara, 
CA, USA) and homozygous regions were calculated with Partek Genomics Suite software (Partek, 
St. Louis, MO, USA). Using Sanger sequencing six genes known to be mutated in ACHM and cone 
dystrophy (CD, MIM#120970), (ABCA4 (MIM#601691), CNGA3, CNGB3, KCNV2 (MIM#607604), 
PDE6C and PDE6H (MIM#601190)), were excluded as the cause of their disease. Subsequently, DNA 
samples of the affected siblings, were analyzed by exome sequencing. The exomes were enriched 
according to the manufacturer’s protocol using Agilents’ SureSelect Human All Exon v.2 Kit (50Mb), 
which contains the exonic sequences of approximately 21,000 genes (Agilent Technologies, Inc., 
Santa Clara, CA, USA), and next generation sequencing was performed on a SOLiD4 sequenc-
ing platform (Life Technologies, Carlsbad, CA, USA). LifeScope software v2.1 (Life Technologies, 
Carlsbad, CA, USA), was used to map color space reads along the hg19 reference genome assembly. 
The DiBayes algorithm, with high-stringency calling, was used for single-nucleotide variant calling. 
The small Indel Tool was used to detect small insertions and deletions.
Sequence analysis of the CEP290 gene
The 54 exons and exon-intron boundaries of CEP290 (GenBank NM_025114) were screened 
in the DNA of the individuals for the presence of a second mutation using the primers previ-
ously described.23 Sequencing and segregation analysis was performed by Sanger sequencing. 
Subsequently, a subset of 23 ACHM and 145 CD individuals, mainly from the Netherlands, were 
specifically analyzed for the occurrence of the c.451C>T and c.4723T>A mutations.
Analysis of hypomorphic character of the c.4723T>A variant
The determine the effect of c.4723T>A on the CEP290 mRNA, RNA was isolated from EBV-
transformed lymphocytes of the affected persons and three control individuals according to 
manufacturer’s protocol (Qiagen, Venlo, The Netherlands). The lymphocytes of the affected 
individuals were grown with or without cycloheximide to visualize the effect of the mutation 
and possible degradation of nonsense-containing mRNAs by nonsense mediated decay (NMD).24 
Reverse transcription with iScript (Biorad, Veenendaal, The Netherlands) was performed on 
total RNA (1 µg) to obtain cDNA. RT-PCR experiments were performed using 2.5 µl cDNA 
with primers in exon 34 and 37 (35 cycles), with a subsequent nested PCR using 0.5 µl of the 
PCR-product and initial primers (15 cycles), followed by Sanger sequencing.
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test. A few years later, they were capable of executing the HRR, and Panel D-15 test correctly, 
leading to the diagnosis of OT. A remnant of cone function was measured on ERG of the youngest 
sib at the age of 13. Visual acuity was between 20/200 and 20/125 and remained stable over the 
years, while the youngest sibling developed myopia. Around the age of 27, color vision with the 
Panel D-15 test was still normal, but they developed more difficulties with pseudoisochromatic 
plates. ERG rod function was also reduced and perimetry revealed mild visual field defects. At 
the age of 39, the youngest patient presented with altitudinal visual field defects, threatening 
the macular area of the left eye. His sister had in the meantime developed tunnel vision. On 
funduscopy, both individuals had degenerative changes mainly in the inferior quadrants consisting 
of RPE atrophy with bone-spicule pigmentations. In the youngest patient, the degeneration had 
progressed towards the macula and small atrophic spots around the fovea were observed in the 
left eye imposing as a bull’s eye-like maculopathy (Figure 1C). It has to be taken into account 
that his myopia might also have played a role in the atrophic changes. In the past six years, a 
further deterioration of the visual fields and rod ERGs was observed, whereas visual acuity and 
color vision were still relatively well preserved. The data of the most recent examination are 
presented in Table 1, Figure 1 and 2. Due to photophobia and nystagmus, OCT and FAF failed 
partially. Interestingly, a double ring sign was observed on the FAF of the youngest patient, indi-
cating the transitional zone between present and absent photoreceptors on OCT (Figure 1D). 
Examinations by an internist did not reveal any extra-ocular abnormalities that might be associ-
ated with the CEP290 variants.
Genetic analysis 
Homozygosity mapping in the two affected siblings revealed two small overlapping homozygous 
regions of 1.1 Mb on chromosome 8 and a 1.0 Mb on chromosome 11 (Supplemental table 1). 
For the exomes of person II-1 and II-2, 49,732,464 and 55,772,367 reads were uniquely mapped 
to the gene-coding regions. The analysis uncovered 36,457 variants for individual I-11 and 37,944 
variants for individual II-2. 
A total of 3,525 functionally relevant variants, occurring with a frequency of less than 1% in 1,302 
individuals in an in-house exome database, were shared by both individuals (data not shown). As 
a control for initial sequencing analysis, genes known to be involved in ACHM were checked for 
pathogenic variants, but none were observed. Variants were included for further analysis when 
they met our criteria of a frequency <0.5% in genetic variant databases, as well as the in-house 
controls (n=2,604 alleles), and resulted in a nonsense, frame shift, (canonical) splice site or mis-
sense variant with a PhyloP >2.7. Under the hypothesis of autosomal recessive inheritance, we did 
not identify two heterozygous variants in one gene (>20% variation) in the shared variants among 
the siblings and also no homozygous (>80% variation) variants based were identified. Analysis of 
the two small overlapping homozygous regions (1.0 Mb and 0.9 Mb) in the NGS data showed a 
single variant in the largest region, which was excluded to be functionally relevant as it resided 
in a non-genic region. The second overlapping region for the siblings contained four variants 
present in both individuals, which were all discarded for functional relevance and high frequency. 
An expanded analysis of variants in known retinal disease genes for CD, cone-rod dystrophy 
(CRD, MIM#120977), LCA and retinitis pigmentosa (MIM#268000) yielded a single heterozygous 
nonsense variant (c.4723T>A; p.(Lys1575*)) in exon 36 of CEP290 in both affected persons, which 
was confirmed by Sanger sequencing. Further analysis of CEP290 in the exome data did not 
reveal a second hit, but as coverage of CEP290 was incomplete, all coding exons and intron-exon 
boundaries were analyzed by Sanger sequencing. This resulted in the identification of a second 
nonsense mutation (c.451C>T; p.(Arg151*)) in exon 7 in both siblings which segregated with the 
disease in the family (Figure 3A). Both mutations were not identified in the exome variant server 
(EVS, http://evs.gs.washington.edu/EVS/).
was noted, as well as perimacular RPE atrophy. Clinical characteristics of patient II-2 of family A. 
D) Autofluorescence of the right eye revealed a double hyperfluorescent ring and hypofluores-
cent spots along and inferior of the inferior vascular arcade. E) Optical coherence tomography 
(OCT) displayed no discernible photoreceptor complexes at the macula, but they were present 
at the peripheral part of the scan. F) Autofluorescence of the left eye revealed a double hyper-
fluorescent ring and hypofluorescent spots along and inferior of the inferior vascular arcade as 
well as the macula.Figure 3
Figure 2 Peripheral fundus imaging of individual II-2
A compilation of fundus photographs of the left eye of II-2 showed a pink and myopic optic disc. 
Mildly attenuated vessels and a bull’s eye maculopathy. A faintly recognizable foveola reflex was 
noted, as well as perimacular RPE atrophy, mild RPE changes in the superior quadrants. More 
pronounced RPE atrophy in inferior quadrants with bone-spicule pigmentations was documented.
results
Clinical findings 
The patients were initially examined at the ages of 2 and 3 years, and presented with low visual 
acuity, severe photophobia and pronounced nystagmus. ERGs were performed under general 
anesthesia and revealed normal rod responses with absent cone responses. The fact that they 
could name colors correctly puzzled Van Lith, but they were too young to perform a color vision 
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analysis of the normal sized product bands showed only a fraction of the mutant allele, while the 
smaller sized product showed and absence of exon 36 (Figure 3C). The mutant allele was recov-
ered to the normal levels due to the cell treatment with cycloheximide, which inhibits nonsense 
mediated decay (Figure 3D).
B
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Figure 3 mRNA analysis of individuals with OT carrying CEP290 c.4723A>T variant
A) The pedigree with OT and the segregation of CEP290 variants c.415C>T (p.(Arg151*), M1) 
and c.4723A>T (p.(Lys1575*), M2); B) CEP290 cDNA analysis of the effect of the c.4723A>T 
variant on splicing of exon 36 in the patient cell lines treated with (+) or without (-) cyclohexi-
mide (CHX) to prevent degradation by nonsense-mediated decay (NMD) versus non-treated 
control cell lines. Agarose gel electrophoresis revealed a major 432 bp product representing 
the normal transcript in all tested samples. Hence, the difference (Δ) between treated and 
untreated samples in the affected individuals can be explained by the partial effect of NMD. 
An aberrant product (*) is seen in the affected persons at 324 bp, whereas this product is not 
found in controls. This product size corresponds to a transcript lacking exon 36. The lower 
products represent nonspecific product as observed by sequencing. The comparison for input 
was made by the analysis of the housekeeping gene GUSB; C) Sequence analysis of the abundant 
cDNA product in the CHX treated samples shows the exon transition from 35 to 36 with the 
recovered mutant allele at wild-type level. The right panel shows sequences of the aberrant 
product from exon 35 to 37, skipping exon 36; D) Sequence analysis of the untreated normal 
mRNA product shows a reduced presence of the mutant allele due to partial NMD, visible by 
a reduced peak size of the mutant T-allele (M2Δ) compared to the wildtype A-allele.
Table 1 Clinical characteristics of two patients with variants in CEP290 
Patient ID II-1 II-2
Sex Female Male
Age at diagnosis 3 2
Age recent examination 46 45
Nystagmus Present Present
Visual acuity RE 20/100+ 20/80-
Visual acuity LE 20/1002+ 20/160
Refraction RE +1.25-2.25x19; LE: -0.25-3.00x170 RE: -14.25-1.75x5; LE: -10.25-2.25x155
Lens Clear Clear
Fundus Pink optic discs, mildly attenuated 
aterioles, coarse-grained aspect RPE 
posterior pole and mid-periphery 
superior quadrants, faintly recognizable 
foveola reflex BE with subtle indication 
for bull’s-eye maculopathy, RPE atrophy 
in far periphery of superior quadrants, 
RPE atrophy in mid- and far periphery 
of inferior quadrants with scarce bone-
spicule pigmentations
Pink, myopic optic discs, mildly attenu-
ated arterioles, subtle RPE alterations 
macula RE, bull’s-eye maculopathy LE, 
faintly recognizable foveola reflex BE, 
perimacular RPE atrophy, mild RPE 
changes superior quadrants, RPE atrophy 
inferior quadrants with bone-spicule 
pigmentations
Fundus  
autofluorescence
Relatively normal Double hyperfluorescent ring, hypo-
fluorescent spots along and inferior to 
the inferior vascular arcade BE, and in 
macula LE
OCT Failed No discernible photoreceptor com-
plexes at the macula, but present at the 
peripheral part of the scan. 
Color vision  
(Panel D-15)
Saturated: normal  
Desaturated: minor errors RE, multiple 
errors. LE, no specific axis
RE: de- and saturated: multiple errors 
mainly in tritan axis 
LE: failed
Visual field  
(Goldmann)
Radius < 100 Altitudinal defect BE, partially including 
the centre RE, central scotoma LE
ERG
Dark adapted
Mildly reduced isolated rod responses 
with significantly reduced rod derived 
‘mixed’ responses
Significantly reduced isolated rod and 
rod derived ‘mixed’ responses
ERG
Light adapted
Non-recordable Non-recordable
Miscellaneous Anorexia, depressions, followed by the 
diagnosis of schizofrenia at age 29
None
BE = both eyes, ERG = electroretinogram, LE = left eye, OCT = optical coherence tomography, 
RE = right eye, RPE = retinal pigment epithelium.
Analysis of the hypomorphic character of c.4723A>T.
Compared to the thus far described phenotypes associated to CEP290 mutations, the affected 
individuals of this family showed a relatively mild non-syndromic retinal phenotype. We hypoth-
esized that the c.4723A>T variant potentially had a hypomorphic character as was already experi-
mentally proven for this families’ other allele (c.415C>T)14, because the exon consists of 108 bp. 
If deleted, the resulting open reading frame will miss the coding information for 36 amino acids 
(aa), but will be in frame. Analysis of the cDNA for both siblings using primers surrounding the 
mutated exon 36, confirmed the hypothesis of the hypomorphic character (Figure 3B). Sequence 
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Comment
This is the first report on long term follow-up in two patients with OT, showing the transi-
tion of a supposedly stationary cone dysfunction syndrome into a progressive degenerative 
disease, and thereby stressing the importance of studying the natural course of rare diseases. 
We also discovered that the genetic defect was located in CEP290, a gene primarily involved in 
syndromic and non-syndromic LCA.
OT is a group of clinically and genetic heterogeneous disorders, since certain symptoms like 
nystagmus and photophobia are not present in all of them, and visual acuity may vary. In a few 
individuals, mutations were discovered in phototransduction genes suggesting an overlap with 
ACHM.17-19 Neuhann et al.25 described one OT patient and mentioned that a far relative in 
the same village suffered from sector retinal dystrophy. It is highly speculative to assume that 
this might have also been a case of progressive OT. Andersen et al.18 and Michaelides et al.26 
reported on OT patients with subnormal rod specific response, a feature that our patients 
also displayed. Subnormal rod function has also been observed in patients with ACHM, due 
to CNGA3 and CNGB3 mutations. Today, we know that ACHM is a progressive diseases evolv-
ing into cone dystrophy. In ACHM patients, progressive loss of cones is observed on OCT in 
the macula after the first decade.27 There are no reports on progressive rod degeneration in 
ACHM. In our patients, the degeneration started in the inferior quadrants progressing towards 
the posterior pole , and was coupled by progressive visual field loss and deterioration of rod 
derived ERG responses. The cone function, at age 46, in our eldest patient was still relatively 
well preserved given the stable visual acuity and the preserved color vision. 
In the original report on OT by Van Lith, it was postulated that all three types of cones must be 
present but reduced in number. Michaelides and colleagues investigated this presumption and 
studied the cone photoreceptor mosaic with adaptive optics in four relatively young patients. 
It was found that in three out of four subjects indeed a sparse mosaic of cones remained at 
the fovea with no structure visible outside the fovea. These patients also showed decreased 
length of the outer segments on OCT. Only one patient seemed to have a normal cone mosaic. 
It is impossible to compare the OCTs of our youngest subject with the ones published by 
Andersen et al.18 and Michaelides et al.,24 since our patient had atrophic changes around the 
fovea and in the posterior pole. More to the periphery, however, three layers seemed visible. 
In individual II-1 imaging failed due to the nystagmus and photoaversion. There was a (double) 
ring sign observed on FAF in individual II-2 indicating the transitional zone between intact and 
absent photoreceptor inner and outer segments, a phenomenon also observed in other retinal 
dystrophies.28, 29
We tried to find an explanation for the cone dominated disease in these two patients since 
gene expression of CEP290 is seen in the connecting cilia of both photoreceptor cells. CEP290 
plays a role in primary ciliary assembly30; 31 and has been shown to recruit small GTPase Rab8a 
(MIM#165040) to the centrosomes and cilia for ciliary membrane elongation.30 The retinal 
architecture of CEP290-mutant retinas displayed clear remodeling in the rod-dominated 
periphery visualized by thickening of the inner retina, whereas the cone-dominated foveal 
region remained unaltered. The difference observed in cone and rod degeneration may indicate 
different functions in both cell types.32 As the clinical examinations in our patients uncovered 
cone defects with late onset progressive peripheral degeneration one could argue that the 
cones are more vulnerable compared to rods due their higher metabolism.33 The secondary 
impairment of rods as to CEP290 mutations is also seen in the Cnga3-/- mice and a zebrafish 
model, both models for cone degeneration.34;35 It was hypothesized that the cell density plays 
a role in determining whether there will be secondary rod degeneration. Subsequent to cone 
degeneration, loss of rod photoreceptor cells occurs in retinal regions characterized by a low 
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Finally, our cohort was also tested for the prevalence of the most frequently found mutation 
in CEP290 causing nonsyndromic LCA, the deep intronic c.2991+1655A>G mutation causing a 
cryptic splice site with a premature stop codon. This screening did not yield any mutations in 
our cohort. 
A literature analysis revealed that the frequent mutation c.4706_4812+1del, is described in 
16 cases, besides our family, of which nine homozygous cases (See Table 2).10; 11; 45; 46 In two 
cases abnormal respiratory cilia were observed.46 All cases were diagnosed with LCA, with 
the exception of one case with JBTS. We suspect that this exception may potentially be a 
carrier of a third (modifier) allele, potentially residing in one of the ciliary genes. In this study, 
we expanded phenotypes that can be caused by CEP290 mutations and it would be interesting 
to investigate whether other OT cases also carry mutations in this gene. Why genes that are 
expressed in both photoreceptor cells, can generate a cone- or rod-dominated disease is still 
unknown.
With the use of NGS, we were able to identify the causative defect in this family, which hold 
great promises for elucidation of other subtle but distinct phenotypes in the coming years. 
Not only will NGS solve many phenotypic entities, it will also likely uncover more cases with 
multigenic inheritance pattern. The identification of current CEP290 variants as a cause of OT, 
due to the rare frequency, will on their own not shed more light on the progression of the 
phenotype in these individuals. Nevertheless, the identification of hypomorphic variants in 
CEP290 will raise new hypotheses on the occurrence of ‘milder than presumed’ phenotypes 
due to CEP290 mutations, which also may be true for other genes. This study also stresses the 
importance of clinical observations and descriptions over longer period of time, which enables, 
even when imaging tools where less advanced, to follow the disease course. Also in presumed 
stationary phenotypes, clinical observations remain of great value and may elucidate potential 
progressive nature of disease. 
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Supplemental table 1 Overlapping homozygous regions detected in both affected 
siblings by SNP microarray analysis
Patient Chromosome Start position End position Size (Mb) #SNPs
II-1, II-2 8 33,792,672 34,880,118 1,09 208
II-1, II-2 11 113,018,709 114,000,208 0,99 218
density of rods, while the high rod density retinal regions remain intact.35 A third hypothesis 
on secondary rod degeneration resides in aberrant gap junction coupling of the photorecep-
tors.36 Gap junctions are crucial for photoreceptors survival31 and provides coupling between 
cones and rods,38; 39 enabling transmission of signals among the photoreceptor terminals, which 
subsequently can be transmitted to the inner retina. Whether damage due to light exposure, as 
shown for rhodopsin mutations in rodents,40;41 may play a role in the second type of degenera-
tion is speculative. 
Defects in CEP290 can cause a wide range of severe ciliary phenotypes, like Joubert syndrome 
(JBTS, MIM#610188),7 Senior Løken syndrome(SLSN, MIM#610189)6, cerebello-oculo-renal 
syndrome (CORS, MIM#608091),15 Meckel-Gruber syndrome (MKS, MIM#611134),8 a single 
case of Bardet Biedl syndrome (BBS, MIM#209900),9 LCA4 , and early-onset retinal degenera-
tion14. The phenotype observed in our two subjects showed overlap with ACHM, but muta-
tions in the ACHM genes were not detected. Up to date, 136 unique mutations are described in 
the 2,479 aa protein and limited genotype-phenotype correlations have been made.10; 42 These 
genotypes and subsequent phenotypes are recorded in the database CEP290base (http://
medgen.ugent.be/cep290base/index.php; http://grenada.lumc.nl/LOVD2/eye/home.php?select_
db=CEP290). Strikingly though, the deep intronic c.2991+1655A>G hypomorphic variant has 
been described to cause nonsyndromic LCA both in a homozygous state and in a compound 
heterozygous state together with null alleles.4 Littink et al. (2010)14 showed that c.451C>T 
produced two aberrant transcripts lacking exon 7 and exon 7-8, thereby escaping NMD. The 
skipping of exon 7, keeping the reading frame intact, leads to a deletion of 94 aa, which contains 
part of the 506 aa coiled-coil domain, but only represents a small fraction of the mutant 2,479 
aa full length/normal CEP290 protein. In these patients, the mild c.2991+1655A>G variant 
was found on the other allele, thereby causing early onset severe retinal dystrophy. Leich et 
al (2008)9 described a single case in which a C-terminal homozygous p.(Glu1903*) mutation in 
CEP290, together with a hypomorphic variant in MKS3 (MIM#607361), are the cause of BBS. 
The strong genetic interaction between these genes, and the mutational load in closely inter-
acting proteins are possible explanations to the clinical variability of the CEP290 genotypes. 
The identification of the hypomorphic nature of three CEP290 variants (c.442_495del, p.Leu148_
Glu165del; c.2991+1655A>G, r.2991_2992ins2991+1525_2991+1650; and c.4706_4812+1del, 
p.Glu1569Glyfs) due to nonsense-associated altered splicing in this and other studies,4; 14 
warrants the question whether this could be an underappreciated phenomenon in CEP290-
associated diseases. Eligible exons should contain a multiple of 3 bps as their deletion would 
result in restoration of the open reading frame. Surprisingly, an analysis on all CEP290 exons 
showed that 27 out of 54 exons (50%) are in-frame, which, if this would be random, one would 
expect one-third of the exons to contain a multiple of 3 bps. In general, many genes evolve in 
evolution through intragenic duplications.43; 44 The products of such duplications are more likely 
to evolve in functionally relevant variants if the exons contain a multiple of 3 bps. For CEP290, 
this mechanism may have amplified the number of coiled coil domain modules.
The c.4723A>T variant is a founder mutation in Belgium and France,11; 15; 45 which is in line 
with the ancestry of our patients as the mother originated from Belgium. Taking the northern 
European founder effect as a hypothesis we accordingly screened our ACHM and CD cohort 
on this mutation as well as the c.442_495del mutation, which was also found in a Dutch fam-
ily. In our cohort of 23 ACHM and 145 CD individuals we did not identify additional persons 
carrying the c.4706_4812_1del or c.442_495del mutation. Previously, Littink et al. (2010)14 did 
not identify additional CRD or RP patients with c.442_495del. It seems that this combina-
tion of nonsense mutations, causing a dystrophy milder than LCA, has a very low prevalence. 
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Impairment or death of the cone photoreceptor cells is the clinical hallmark of cone disorders 
which have an estimated prevalence of 1:30,000-1:40,000.1; 2 Achromatopsia (ACHM) (MIM 
*600827) is a stationary congenital autosomal recessive cone disorder, characterized by low 
visual acuity (0.10-0.20 decimal Snellen equivalent), photophobia, nystagmus, and severe color 
vision defects. Patients with the complete ACHM subtype have no cone function on electro-
retinogram (ERG), whereas those with incomplete ACHM have residual cone function. Cone 
dystrophy (COD) (MIM *600827) is a progressive cone disorder in which patients may initially 
have normal cone function but develop progressive visual acuity loss, increasing photophobia, 
color vision disturbances, and diminished cone responses on ERG, usually in the first or second 
decade of life. The visual acuity of these patients generally worsens to legal blindness before 
the fourth decade of life.3 
The genetic basis of these disorders has been partly elucidated during the last decade. Three 
genes have been implicated in ACHM: CNGA3 (MIM *600053), CNGB3 (MIM *605080), and 
GNAT2 (MIM *139340). Mutations in these genes explain a large part of this disease, but a frac-
tion still remains unsolved.4-7 For COD, several genes have been identified for the autosomal 
dominant3; 8; 9 and X-linked forms,10; 11 but little is known about the genetic causes of the most 
prevalent autosomal recessive (arCOD) form. Four genes have been implicated in this form: 
ABCA4 (MIM *601691),12 CACNA2D4 (MIM *608171)13 CNGB3,14 and KCNV2 (MIM *607604),15; 16 
which together explain only ~10% of all cases.
We aimed to identify disease genes for cone photoreceptor disorders, and investigated 
patients with ACHM and AR COD. Patients were ascertained from various ophthalmic centers 
in the Netherlands, Belgium, the United Kingdom and Canada. This study was approved by 
the local and national medical ethics committees and adhered to the tenets of the Declaration 
of Helsinki. All participants provided signed, informed consent for participation in the study, 
retrieval of medical records, and use of blood and DNA for research. All available data on 
visual acuity, color vision, fundus appearance, and ERGs were retrieved from medical charts, 
and updated by additional examinations including ocular coherence tomography (OCT) and 
fundus photography. Recent ERGs were performed according to the recommendations of the 
International Society for Clinical Electrophysiology of Vision.17 Patients could be stratified into 
three clinical categories: ACHM (n=75 probands), AR COD (n=97 probands), and a group 
who had clear documentation of progressive cone dysfunction, but already had impaired visual 
acuity in early childhood (early-onset AR COD, n=20 probands). We tested for the presence 
of known gene mutations in all probands in ABCA4 (A.A.H.J.T., unpublished data), and for the 
presence of CNGB3 variants in all probands by sequence analysis.5; 7 When CNGB3 variants 
were absent, all ACHM patients were analyzed for CNGA3 and GNAT2 variants using sequence 
analysis.5; 7 Finally, most of the AR COD patients were analyzed for KCNV2 variants by sequence 
analysis (A.A.H.J.T., unpublished data). These studies resulted in 116 probands, i.e. 11 ACHM, 
85 AR COD, and 20 early-onset AR COD, with unknown etiology who form the basis of the 
present genetic analyses.
We performed high-resolution SNP analysis (Affymetrix GeneChip Genome-Wide Human 
Array 5.0) on a subset of 76 patients of 64 families with autosomal recessive cone dysfunc-
tion from whom DNA was available. In 8 of these 64 families the parents were consanguine-
ous. Genotyping was performed with Genotype Console software (Affymetrix), and regions 
of homozygosity were calculated with Partek Genomics Solution software (Partek). Large 
identity-by-descent (IBD) regions (i.e. > 5 Mb) were found in all consanguineous families and in 
34 of the non-consanguineous probands. In these 34 non-consanguineous patients, we found a 
total of 57 IBD regions larger than 5 Mb, with an average size of 9 Mb (range 5 – 31 Mb). 
abstraCt
Cone photoreceptor disorders form a clinical spectrum of diseases which include progressive 
cone dystrophy (COD), and complete and incomplete achromatopsia (ACHM). The underly-
ing disease mechanisms of autosomal recessive (AR)COD are largely unknown. Our aim was 
to identify causative genes for these disorders by genome-wide homozygosity mapping. We 
investigated 75 ACHM, 97 AR COD, and 20 early-onset AR COD probands, and excluded 
the involvement of known genes for ACHM and AR COD. Subsequently, we performed high-
resolution SNP analysis, and identified large homozygous regions spanning the PDE6C gene in 
one sibling pair with early-onset AR COD, and in one sibling pair with incomplete ACHM. The 
PDE6C gene encodes the cone a-subunit of cyclic huanosine monophosphate (cGMP) phospho-
diesterase, which converts cGMP to 5’ GMP, and thereby plays an essential role in cone photo-
transduction. Sequence analysis of the coding region of PDE6C revealed homozygous missense 
mutations (p.R29W, p.Y323N) in both sibling pairs. Sequence analysis of 104 probands with 
AR COD and 10 probands with ACHM revealed compound heterozygous PDE6C mutations 
in three complete ACHM patients from two families. One patient had a frameshift muta-
tion and a splice defect, the other two had a splice defect and a missense variant (p.M455V). 
Cross-sectional retinal imaging using optical coherence tomography (OCT) revealed a more 
pronounced absence of cone photoreceptors in patients with ACHM compared to early-onset 
AR COD. Our findings reveal PDE6C as a gene for cone photoreceptor disorders, and show 
that AR COD and ACHM constitute genetically and clinically overlapping phenotypes.
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D), and segregation analysis of the respective PDE6C variants. The parents of family A are not 
related to each other in the last three generations. BI-1 and BI-2 are first cousins. E) Evolutionary 
conservation of the altered amino acid residues in three families. PDE6A and PDE6C are rod 
and cone α-subunits respectively; PDE6B is the rod β-subunit. Using the Swiss-Prot database, 
we searched for their orthologues in as many species as possible, and included, with the excep-
tion of Danio rerio, those present in all species. White lettered residues on a black background 
are fully conserved between different species in all three subunits. White lettered residues on 
a grey background are conserved in most sequences. Black lettered residues with light grey 
background are similar to amino acid residues in other orthologues and homologues. The argi-
nine residue at position 29 is fully conserved in all orthologues of both α-subunits (PDE6C and 
PDE6A), except for bovine and canine PDE6C. The aspartic acid residue in the GAF-A domain 
at position 211 is conserved or replaced by a functionally conserved glutamic acid residue in 
19 of 20 orthologues and homologues. This observation strongly suggests that the predicted 
p.E211D substitution in family D is neutral and that the effect of c.633G>C on the splice site 
is pathologic. The tyrosine residue located in the GAF-B domain at position 323 is completely 
conserved among all three PDE6 subunits. The methionine residue at position 455 is conserved 
or substituted by a functionally conserved isoleucine in all PDE6 molecules.
In a sibling pair from a consanguineous marriage (family B) and in a sibling pair from an non-
consanguineous family (family A), we identified large homozygous regions on chromosome 10 
(11 Mb and 26 Mb, respectively) (Figure 1A). The common 26 Mb homozygous region in the 
sibs from family A was the largest homozygous region (SNP boundaries: SNP_A-2260521 and 
SNP_A-1892358); the second, third and fourth largest regions measured 8, 4.3 and 4.2 Mb. 
The overlapping 11 Mb homozygous region in the affected sibs of family B was the seond larg-
est homozygous region (SNP boundaries: SNP_A-2003359 and SNP_A-1804692). The largest 
region in this family spanned 25 Mb; the third and fourth largest regions measured 10 and 6 
Mb. The overlapping homozygous region in both families spanned the PDE6C gene but no other 
obvious candidate genes (Figure 1A; see also Supplemental table 1). These regions were not 
found in other patients. 
PDE6C encodes the cone a-subunit of cyclic guanosine monophosphate (cGMP) phospho-
diesterase, an enzyme consisting of two α and two γ-subunits that is essential in the cone 
phototransduction cascade. It converts the second messenger cGMP to 5’ GMP during light 
exposure. This results in closure of the cGMP-gated ion-channel in the cone outer segment 
membrane leading to hyperpolarization of the cell.18 
Because PDE6C appeared to be an excellent candidate for cone photoreceptor disorders, we 
performed direct sequencing of all 22 exons (Figure 1B). We detected homozygous missense 
mutations in exon 1 in both sibling pairs of family A (Figure 1B-D). The first proband (AII-1) and 
his brother (AII-2) carried a homozygous missense mutation (p.R29W) affecting a conserved 
residue just upstream of the first GAF (GAF-A) domain (acronym derived from proteins in 
which these domains were initially identified) (Figure 1B). The arginine residue at position 
29 is fully conserved in all depicted orthologues of the cone and rod α-subunits (PDE6C and 
PDE6A), except for bovine and canine PDE6C (Figure 1E). The second proband (BII-1) and her 
brother (BII-2) carried the homozygous missense mutation p.Y323N (Figure 1C and 1D). This 
mutation affects a fully conserved residue located in the second GAF (GAF-B) domain (Figure 
1B and 1E, mutation M4), a region of the protein which binds cGMP and regulates the activity 
of the enzyme.19 Protein homology modeling of the GAF-B domain on the basis of a recent 
GAF-A crystal structure19 shows that the p.Y323N mutation is located near the cGMP bind-
ing site. Altough not directly interacting with cGMP, Y323 neighbors D322 which is in direct 
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Figure 1 Molecular genetic characterization of the PDE6C gene in four families 
with autosomal recessive cone photoreceptor disorders
A) The 10q22-q25 region and the homozygous regions identified in patients of families A and 
B. The SNPs flanking the homozygous regions and their genomic positions, using the March 
2006 UCSC genome build (hg18), are indicated. B) Protein and genomic structure of PDE6C. 
GAF: acronym derived from proteins in which these domains were initially identified (cGMP-
regulated mammalian phosphodiesterases, cyanobacterial adenylyl cyclases, and a formate-
hydrogen lyase transcriptional activator); HDc: domain with highly conserved histidines (H) 
and aspartic acids (D); cc, coiled-coil domain. The six mutations are depicted M1 through M6. 
C) Chromatograms showing the PDE6C mutations. D) Pedigrees of early-onset cone dystrophy 
(family A), incomplete achromatopsia (family B), and complete achromatopsia (families C and 
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contact with bound cGMP, as shown in Figure 2. D322 tightly interacts with cGMP by means 
of two hydrogen bonds, one originating from the peptide main chain and one originating from 
the aspartic acid side chain. Mutation of Y323 to N is likely to alter the local backbone confor-
mation and mobility, and is also likely to affect D322 and its interaction with cGMP. Both the 
orientation as well as the mobility of the amino acids equivalent to D322 in other GAF domains 
have been suggested to be of crucial importance in determining affinity and selectivity of these 
domains for cGMP.19 We hypothesize that the p.Y323N mutation will probably alter the affinity 
of cGMP for the regulatory GAF-B domain. 
Figure 2 Molecular modeling of Y323 in the GAF-B 
domain of PDE6C
The individual side chain orientations of D322 and Y323 are 
shown in magenta. A peptide backbone trace of the remainder 
of the model is shown, with beta-sheets colored orange and 
alpha-helices colored blue. The mutation site Y323 is located 
adjacent to D322. The latter amino acid is shown interact-
ing with bound cGMP via two hydrogen bonds, one originat-
ing from the peptide main chain and one originating from the 
aspartic acid side chain. Hydrogen bonds are indicated by yel-
low dashed lines.
Subsequently, we analyzed the remaining patients (n=114) for additional mutations in the PDE6C 
gene by direct sequencing of the coding region. Compound heterozygous mutations were 
detected in two additional probands. Patient CII-1 was compound heterozygous for a frameshift 
mutation (c.257_258dupAG; p.L87Gfs*57) in exon 1 and a 5-bp deletion (c.2367+1delGTAAG), 
which removes the first five nucleotides of intron 20 including the splice donor site (Figure 
1C and 1D). An alternative splice donor site is predicted at position 2366 (splice prediction 
score 0.80, BGDP Splice Site Prediction by Neural Network).20 Use of this splice site would 
lead to a shift in the open reading frame and premature termination of the phosphodiesterase 
6C protein (p.E790Sfs*12). Patient DII-1 and her affected sister (DII-2), revealed two missense 
variants (c.633G>C [p.E211D] and c.1363A>G [p.M455V]) (Figure 1C). The glutamic acid at 
position 211 is changed to the functionally conserved aspartic acid in five of six homologous 
rod PDE β-subunits, and in frog PDE6C, strongly suggesting that the predicted amino acid 
change is a functionally neutral variant. The c.633G>C variant does however affect the last 
nucleotide of exon 2, and is predicted to completely abolish the splice donor site (BGDP Splice 
Site Prediction by Neural Network).20 As no alternative splice donor sites are predicted, the 
mutation may either result in removal of exon 2 from the mRNA, or in non-splicing of intron 
2 (106 bp). In both options, this would result in a disruption of the open reading frame. The 
p.M455V mutation affects a conserved residue located just downstream of the GAF-B domain 
(Figure 1B and 1E). In those families in which DNA was available from parents (families B and 
D), mutations M3, M4, and M5 segregated as expected for pathologic variants (Figure 1D). 
None of the six PDE6C mutations were found in 180 ethnically matched controls. 
In four other unrelated patients with AR COD, we found four different heterozygous amino 
acid changes (c.413T>C [p.L138S]; c.696G>A [p.M232I]; c.2096A>G [p.E699G]; c.2477T>C 
[p.I826T]). In these patients, we did not find a second mutation on the other allele in the 
coding region of this gene, despite complete PDE6C sequencing. We considered the possibility 
of a digenic disease model, with mutations in both PDE6C and an interacting gene, and per-
formed sequence analysis of the gene encoding the cone γ-subunit of cGMP phosphodiesterase 
(PDE6H). We did not detect mutations in this gene. 
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4D. The area of absent cone photoreceptors in patient DII-1, which spans almost the entire 
fovea, is significantly larger than the lesion in patient AII-2 (Figure 4B and 4D). We hypothesize 
that the missense variant in family A, which is located outside functionally important domains, 
may have a less severe effect on the function of PDE6C than the mutations observed in the 
other families. 
In zebrafish, mutations in the ortholog of PDE6C are responsible for progressive cone photore-
ceptor degeneration.21; 22 An intron 11 splice acceptor site mutation,21 and a p.M175R missense 
mutation in the GAF-A domain22 lead to rapid degeneration of cone photoreceptors soon 
after their formation. Unlike in humans, zebrafish photoreceptors are continuously generated 
at the retinal margin by a population of mitotic progenitor cells, so cone photoreceptors can 
be found at the periphery throughout the life of these mutant fish. The splice site mutation in 
the zebrafish also resulted in the degeneration of rod photoreceptors in the central part of the 
retina.21 In zebrafish with the p.M175R missense mutation, rods show an abnormal morphology 
and rhodopsin mislocalization, but otherwise function normally.22 These findings suggest that 
the effect of the zebrafish Pde6c p.M175R mutation is more cone-specific than that of the Pde6c 
splice defect. 
Figure 4 Retinal phenotypes of early onset cone dystrophy and complete achroma-
topsia in families A and D
A) Fundus photography of the right eye of patient AII-2, performed at age 51 years, showing 
myopic changes in the peripapillary region. In the macular region mild pigmentary changes are 
present. The arrow denotes the position of the OCT image in B. B) The Heidelberg Spectralis 
optical coherence tomography (OCT) of this patient reveals a serous detachment of the pho-
toreceptor layer in the central fovea. The retinal pigment epithelium is intact, but the outer 
and inner segments of the photoreceptors are absent. The length of the lesion is ~500 µm. 
The OCT cross section is not fully perpendicular. C) Fundus picture of the left eye of patient 
DII-1, performed at age 37 years, showing mild pigmentary changes in the macula. The arrow 
denotes the position of the OCT image in D. D) The Heidelberg Spectralis OCT of this patient 
displays a large area of ~1300 µm with absent cone photoreceptors, which involves almost the 
entire fovea
The four heterozygous variants in PDE6C were not detected in 180 ethnically matched control 
individuals. The missense variants p.M232I, p.E699A and p.I826T were predicted by SIFT soft-
ware, to be tolerated; only variant p.L138S was predicted not to be tolerated. Moreover, the 
isoleucine at position 826 is substituted by a threonine in the mouse and rat orthologues, ren-
dering this very likely a benign amino acid change. The patients carrying the p.L138S, p.E699A 
and p.I826T variants were part of the 5.0 Affymetrix SNP screening. A copy number variant 
analysis of the SNP data with Partek GS software did not reveal a deletion or duplication of 
twenty intragenic SNPs and five copy number variant probes evenly spaced across the PDE6C 
gene (Supplemental table 1). Though very small deletions encompassing single exons or part of 
the promotor cannot be excluded, these data strongly suggest that the heterozygous PDE6C 
missense variants represent rare benign sequence variants. 
Table 1 shows a summary of the clinical findings of all patients with PDE6C mutations on both 
alleles. Patients AII-1 and AII-2 carried a homozygous missense mutation, located just upstream 
of the GAF-A domain (Figure 1A). They showed an early-onset COD; their visual acuity and 
cone ERG progressively declined in early teens. Patients BII-1 and BII-2 had a homozygous 
missense mutation in the GAF-B domain, which presumably affects the interaction with cGMP. 
This sibling pair presented with an incomplete ACHM; the cone ERG responses were signifi-
cantly reduced but measurable both in childhood as on recent examination, whereas the rod 
ERG parameters were normal. Patient CII-1, carrying a protein-truncating mutation and a 
splice defect, had the most severe cone phenotype. At four years of age, the visual acuity was 
0.10, the cone ERG was non-recordable and the rod function was completely normal (Figure 3). 
Patients DII-1 and DII-2, each carrying a splice defect and a p.M455V missense mutation, were 
clinically diagnosed as complete ACHM because they exhibited a low visual acuity of 0.16 with 
nystagmus since early childhood and absent cone responses on ERG. 
Figure 3 Electroretinogram of 
patient CII-1
An ERG performed with an abbreviated 
protocol of standard ISCEV, performed 
at the age of four years, without seda-
tion, is shown at top with normal con-
trol traces at bottom, for purposes of 
comparison. Note normal rod-specific 
response (top trace at left), with no 
significant contribution of cones to 
combined rod-cone response (bottom 
trace at left); dark-adapted oscillatory 
responses as seen on ascending limb of 
the b-wave are residual at most. The 
absence of cone-specific function was 
proven by the absence of cone-specific 
response to 30Hz flicker stimulation 
(at right).
In the adult patients, we performed Heidelberg Spectralis optical coherence tomography 
(OCT) at the most recent ophthalmologic examination. The absence of the photoreceptor 
cell layer in the fovea, a site with predominantly cone photoreceptor cells, was apparent in all 
patients. A typical OCT picture for patients from family A (patient AII-2) is shown in Figure 4B; 
a characteristic OCT image for patients from families B and D (patient DII-1) is shown in Figure 
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To test the involvement of rod photoreceptors in human patients, we repeated the ERG on the 
two oldest patients with PDE6C mutations (AII-1 and AII-2, 47 and 51 years old, respectively), and 
did not find abnormal rod responses. Normal rod responses were also observed in patients CII-1, 
DII-1, and DII-2. We concluded that rod involvement does not appear to be a major consequence 
of PDE6C mutations in humans, although some dysfunction of rods may still occur later in life.
In conclusion, through homozygosity mapping of patients with cone photoreceptor disorders 
from non-consanguineous and consanguineous families, we identified another causative gene: 
PDE6C. PDE6C has a crucial role in the cone phototransduction cascade. Similar to the other 
disease genes in this cascade (CNGA3, CNGB, and GNAT2),4-6 PDE6C mutations result in a severe 
early-onset cone disorder. We show that early-onset COD, incomplete ACHM, and complete 
ACHM form a continuous spectrum of a similar etiology. The observed variability in phenotypes 
may be due to differences in the functional effects of PDE6C mutations. Our findings will improve 
diagnosis and counseling of patients and their families, and add another step to solving the etiol-
ogy of cone photoreceptor disorders.
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Supplemental table 1 Homozygous regions for families A and B
Chr.  Start  End Sample ID(s) Length region (Mb)  # SNPs
10 80,888,184 107,352,036 A II-1 26,5 4.399
11 48,125,240 56,227,770 A II-1 8,1 434
12 33,234,603 37,599,402 A II-1 4,4 271
14 89,229,236 93,489,863 A II-1 4,3 677
6 34,180,193 36,208,710 A II-1 2,0 214
2 188,650,371 190,654,845 A II-1 2,0 236
5 155,393,372 157,303,002 A II-1 1,9 359
6 102,266,106 103,917,101 A II-1 1,7 211
11 37,664,444 39,256,145 A II-1 1,6 217
14 39,393,635 40,642,718 A II-1 1,2 231
5 65,087,560 66,311,040 A II-1 1,2 258
8 126,936,549 127,965,642 A II-1 1,0 216
1 159,531,547 160,529,894 A II-1 1,0 215
13 42,822,997 43,692,360 A II-1 0,9 202
16 25,380,356 49,895,689 B II-1 and -2 24,5 1.394
10 84,963,195 95,977,303 B II-1 and -2 11,0 1.975
4 7,188,532 16,863,548 B II-1 and -2 9,7 2.164
18 19,088,173 25,421,520 B II-1 and -2 6,3 1.010
19 48,854,873 54,922,139 B II-1 and -2 6,1 534
9 2,293,782 5,834,807 B II-1 and -2 3,5 870
12 127,192,344 129,994,218 B II-1 and -2 2,8 674
17 40,825,939 42,234,514 B II-1 and -2 1,4 219
11 82,983,190 84,287,750 B II-1 and -2 1,3 210
6 26,233,321 26,715,651 B II-1 and -2 0,5 274
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Cone-rod dystrophy (CRD, MIM *120970) is characterized by primary loss of cone photore-
ceptors and subsequent or simultaneous loss of rod photoreceptors. The symptoms include 
poor visual acuity, disturbances in color vision, decreased sensitivity of the central visual field, 
and photo aversion. Because rods are also involved, impairment of night vision and peripheral 
vision loss can occur. The fundus appearance can vary from normal to a bull’s eye maculopa-
thy, or to marked atrophy of the macular region, with a variable degree of temporal pallor of 
the optic disc.1 Visual fields display a central scotoma and full-field electroretinography (ERG) 
records a progressive deterioration of cone-derived amplitude responses, which are more 
reduced than, or equally reduced as, rod-derived responses. 
CRD has an estimated prevalence of 1:30,000 to 1:40,000,1-3 and displays all types of Mendelian 
inheritance. Seven genes have been implicated in the autosomal recessive (AR) form, the most 
prevalent mode of inheritance, i.e., ABCA4 (MIM *601691),4  ADAM9 (MIM *602713),5 C8orf37 
(MIM *614477),6 CERKL (MIM *608381),7 EYS (MIM *612424),8; 9 RPGRIP1 (MIM *605446),10 and 
TULP1 (MIM *602280)11. However, mutations in these genes explain only a minority of the 
cases.12
The goal in this study was to identify genes underlying AR CRD using a combined approach of 
homozygosity mapping and exome sequencing. Such an approach has proven to be very effec-
tive in the discovery of genetic defects in several rare autosomal recessive diseases.13-16 This 
study was approved by the local medical ethics committees and adhered to the tenets of the 
Declaration of Helsinki. All participants provided written informed consent prior to participa-
tion in the study.
 
To localize the genetic defect in a German family with three siblings affected by CRD (Family 
A; Figure 1), the DNA of all three affected individuals was analyzed using Affymetrix GeneChip 
Human Mapping 250K SNP arrays (Affymetrix, Santa Clara, CA, USA) and regions of homo-
zygosity were calculated with Partek Genomics Suite software (Partek, St. Louis, MO, USA). 
This analysis revealed a shared homozygous region of 4.68 Mb on chromosome 4 in all three 
affected siblings (see Supplemental Table 1) containing 15 genes. Subsequently, exome sequenc-
ing was performed in two out of three affected siblings (A-II:1 and A-II:2). Exome sequencing 
was performed on a SOLiD4 sequencing platform (Life Technologies, Carlsbad, CA, USA) and 
the exomes were enriched according to the manufacturer’s protocol using Agilent’s SureSelect 
Human All Exon v.2 Kit (50Mb), containing the exonic sequences of approximately 21,000 genes 
(Agilent Technologies, Inc., Santa Clara, CA, USA). LifeScope software v2.1 (Life Technologies, 
Carlsbad, CA, USA) was used to map color space reads along the hg19 reference genome 
assembly. The DiBayes algorithm, with high-stringency calling, was used for single-nucleotide 
variant calling. The small Indel Tool was used to detect small insertions and deletions. For 
the analyzed individuals, a total of 83,287,089 and 76,841,552 reads were uniquely mapped to 
the gene-coding regions, respectively, with a median coverage of 67.3x in person A-II:1 and 
61.9x in person A-II:2. The analysis uncovered 39,561 variants for individual A-II:1 and 39,029 
variants for individual A-II:2. Ninety-six non-synonymous exonic and canonical splice-site vari-
ants, occurring with a frequency of less than 1% in 1154 unrelated individuals (in-house exome 
database), were shared by both individuals (data not shown). No pathogenic variants in the 
genes known to be mutated in AR CRD (ABCA4, ADAM9, C8orf37, CERKL, EYS, RPGRIP1, and 
TULP1) were observed among the shared variants. Under the hypothesis of autosomal reces-
sive inheritance, we did not identify two heterozygous variants in a single gene (>20-<80% 
variation) in both affected individuals and only a single homozygous (>80% variation) variant, 
p.Glu189*(c.565C>T [NM_001017979.2]), in RAB28 (MIM *612994). This variant is located in 
the largest shared homozygous region in family A (Figure 1A and Supplemental Table 1). 
abstraCt
The majority of the genetic causes of autosomal recessive (AR) cone-rod dystrophy (CRD) 
are currently unknown. A combined approach of homozygosity mapping and exome sequenc-
ing revealed a homozygous nonsense mutation (c.565C>T; p.Glu189*) in RAB28 in a German 
family with three siblings with AR CRD. Another homozygous nonsense mutation (c.409C>T; 
p.Arg137*) was identified in a family of Moroccan Jewish descent with two siblings affected by 
AR CRD. All five affected individuals presented with hyperpigmentation in the macula, progres-
sive loss of the visual acuity, atrophy of the retinal pigment epithelium, and severely reduced 
cone and rod responses on the electroretinogram. RAB28 encodes a member of the Rab 
subfamily of the RAS-related small GTPases. Alternative RNA splicing yields three predicted 
protein isoforms with alternative C-termini, which are all truncated by the nonsense muta-
tions identified in the AR CRD families in this report. Opposed to other Rab GTPases which 
are generally geranylgeranylated, RAB28 is predicted to be farnesylated. Staining of rat retina 
showed localization of RAB28 to the basal body and the ciliary rootlet of the photoreceptors. 
Analogous to the function of other RAB family members, RAB28 might be involved in ciliary 
transport in photoreceptor cells. This study reveals a crucial role for RAB28 in photoreceptor 
function, and suggests that mutations in other Rab proteins may also be associated with retinal 
dystrophies.
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Sanger sequencing confirmed the homozygous presence of c.565C>T in the three affected sib-
lings (Figures 1C and 1D). The mutation was not identified in 176 ethnically matched controls, 
nor in the Exome Variant Server (EVS) database (release ESP6500).
Primers to amplify all coding exons and their exon-intron boundaries were designed using 
Primer 3 software (Supplemental Table 2). Sanger sequencing of all coding exons of RAB28 
in 468 unrelated CRD and 149 unrelated individuals with cone dystrophy did not identify 
additional likely pathogenic mutations. We assessed SNP data of >400 unrelated individuals 
with AR CRD, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) through the 
European Retinal Disease Consortium,6; 17 and identified seven families with conspicuously large 
homozygous regions spanning RAB28. Sanger sequencing of RAB28 in these families revealed 
a homozygous nonsense mutation (c.409C>T; p.Arg137*) in a consanguineous family (family 
B) of Moroccan Jewish ancestry. The two affected siblings in family B (II:1 and II:2; Figure 
1) shared four homozygous genomic regions (over 10 Mb) by whole-genome SNP analysis 
(Supplemental Table 1). The largest region was on chromosome 7 and the second largest region 
was on chromosome 4, the latter including 315 genes among which OPN1SW (MIM *613522), 
and RAB28. Mutation analysis of OPN1SW did not yield causative variants. Segregation analysis 
confirmed the presence of the homozygous nonsense mutation in RAB28 in both siblings with 
CRD (Figures 1C and 1D). This mutation was not identified in 118 ethnically matched controls, 
nor in the EVS database
The clinical features of the affected individuals of both families are described in Table 1. Members 
of family A were diagnosed with CRD in the second decade of life, with rapidly deteriorating 
visual acuities and high myopia. At their last visit, fundoscopy showed hyperpigmention of 
the fovea and autofluorescence revealed a slight hyperfluorescent fovea (Figures 2A and 2B). 
Optical coherence tomography (OCT) displayed altered photoreceptors in the fovea whereas 
the peripheral photoreceptors are intact (Figure 2C). Color vision tests revealed defects in 
all axes, and visual field testing showed a central scotoma. On ERG photopic responses were 
non-detectable and scotopic responses reduced in all three siblings. The clinical presentation 
of both affected individuals of family B was comparable to that of family A. Individual B-II:1 pre-
sented with low vision since early childhood, with progressive deterioration of the visual acuity 
and high myopia. The retinal pigment epithelium showed foveal atrophy, hypofluorescence 
was observed in the fovea and a hyperfluorescent ring was noted around the fovea (Figures 
2D and 2E, respectively). OCT imaging confirmed absence of photoreceptors in the central 
fovea, while the photoreceptor layer further out appears largely intact (Figure 2F). Color 
vision defects were noted in both siblings. Photopic ERG responses were non-detectable, and 
scotopic responses were moderately reduced.
RAB28 encodes a member of the Rab (‘Ras-related in brain’)18 subfamily of the RAS-related small 
GTPases. Rab GTPases are key regulators in trafficking of proteins, and function as molecular 
switches to regulate fusion steps in vesicle transport, vesicle budding, motility, tethering19 and 
membrane fission.20 Proper membrane-association and subcellular localization of Rab proteins 
requires post-translational prenylation of cysteine motif(s) at the carboxyl terminus, which for 
the majority of Rabs involves the attachment of a geranylgeranyl (20 carbons) anchor by gera-
nylgeranyltransferase II (GGT2 or RabGGT). RAB28 is a rather distant relative of the at least 
60 different Rabs,21 standing out because of its limited similarity (32% amino acid identity) to 
other Rab GTPases and its specific amino acid motifs. 21-23 RAB28 expresses three mRNA vari-
ants encoding different RAB28 isoforms with alternative C-termini (see Figure 1B).22 Another 
unique feature of RAB28 is that isoforms 1 and 2 are predicted to be farnesylated at their 
CaaX-motifs,22-25 which was experimentally proven for isoform 1 of RAB28.25 The third iso 
form does not contain a CaaX-motif and therefore cannot be prenylated.
Figure 1 Chromosome 4 homozygous regions and RAB28 mutations in two families 
with AR CRD 
A) Chromosomal position of RAB28, and location of the homozygous regions identified in fami-
lies A and B using homozygosity mapping. B) Genomic structure and mRNA variants of RAB28. 
Variant 1 (V1) encodes a 221 amino acid (aa) protein isoform (RAB28S, NM_001017979.2), 
variant 2 (V2) encodes a 220 aa protein isoform (RAB28L, NM_004249.3), and variant 3 (V3) 
encodes a predicted 204 aa protein (HST03798, NM_001159601.1). The location of the non-
sense mutations found in families A (mutation M1) and B (mutation M2) are indicated. C) Sanger 
sequencing confirmed the segregation of the homozygous nonsense mutations M1 (c.565C>T; 
p.Glu189*) in family A and M2 (c.409C>T; p.Arg137*) in family B. D) Pedigrees of family A of 
German ancestry and family B of Moroccan Jewish ancestry, demonstrating the segregation of 
the nonsense mutations in RAB28.
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Family Individual Ancestry Diagnosis
Age at 
diagnosis
Age at 
last visit
Refractive 
error
at last visit
Visual acuity
at last visit Fundus
Auto- 
fluorescence OCT Color vision
Visual field 
(Goldmann) ERG
A A-II:1 German CRD 14 years 28 RE -16D SE
LE -15.5D SE
RE 20/320 
LE 20/200 
Hyper- 
pigmented 
foveal region
Hyperfluorescent 
area at foveal 
region
Irregular inner and 
outer segments in fovea, 
thinning of other retinal 
layers of fovea
D-15 Panel: tritan and 
defects in scotopic 
lines
Concentric reduc-
tion to 15-20 
degrees (III/4)
Age 16: non-detectable cone 
function and reduced rod 
responses
A-II:2 German CRD 12 years 25 RE -19D SE
LE -22D SE
RE 20/320
LE 20/50 
Hyper- 
pigmented 
foveal region
Hyperfluorescent 
area at foveal 
region 
Irregular inner and 
outer segments in fovea, 
thinning of other retinal 
layers of fovea
D-15 Panel saturated: 
tritan defects,  
desaturated: marked 
protan defects
Concentric reduc-
tion to 30-40 
degrees (III/4)
Age 13: non-detectable  
photopic and markedly 
reduced scotopic ERG
  A-II:3 German CRD 10 years 16 RE -6.5D SE
LE -7.0D SE
RE 20/80 
LE 20/60
Hyper- 
pigmented 
foveal region
NA NA   Diffuse errors Central scotoma Age 10: non-detectable cone 
responses under photopic 
conditions, rod responses under 
scotopic conditions slightly 
reduced; age 15: scotopic  
markedly reduced
B B-II:1 Moroccan 
Jewish
CRD Early child-
hood
33 BE -11D SE BE 20/125 Atrophy 
(geographic 
atrophy-like) 
in fovea. 
White without 
pressure in 
periphery. 
Tilted optic 
discs (LE>RE) 
with temporal 
pallor LE.
Ring of hyper- 
fluorescence
Atrophy in fovea; retinal 
layers absent at foveal 
region
D-15 Panel: RE 
scotopic lines; 
LE Tritan and Deutan 
defect
NA Age 30: non-detectable cone 
responses under photopic 
response; rod responses under 
scotopic responses moderately 
reduced (30% below normal). 
Mixed cone-rod response 
moderately to severely reduced 
(~50-60% below normal)
  B-II:2 Moroccan 
Jewish
COD/CRD  NA 30 NA NA     D-15 Panel: Deutan 
defect and scotopic 
lines, more severe 
in OS
NA  Age 30: non-detectable cone 
responses under photopic 
condition; rod responses under 
scotopic response at below 
normal in RE and within normal 
limits in OS. Mixed cone-rod 
response moderately reduced 
(~25-35% below normal)
Table 1 Summary of the clinical data of five individuals of two families associated 
with RAB28 mutations
Family Individual Ancestry Diagnosis
Age at 
diagnosis
Age at 
last visit
Refractive 
error
at last vis t
Visual acuity
at last v sit Fundus
Auto- 
fluorescence OCT Color vision
Visual field 
(Goldmann) ERG
A A-II:1 German CRD 14 years 28 RE -16D SE
LE -15.5D SE
RE 20/320 
LE 20/200 
Hyper- 
pigmented 
foveal region
Hyperfluorescent 
area at foveal 
region
Irregular inner and
outer segments in fovea, 
thinning of oth r retinal 
layers of fovea
D-15 Panel: trita  and 
defects in scotopic 
lines
Conce tric re uc-
tion to 15-20 
degrees (III/4)
Age 16: non-d tectable cone 
function and reduced rod 
respo ses
A-II:2 German CRD 12 years 25 RE -19D SE
LE -22D SE
RE 20/320
LE 20/50 
Hyper- 
pigmented 
foveal region
Hyperfluorescent 
area at foveal 
region 
Irregular inner and
outer segments in fovea, 
thinning of oth r retinal 
layers of fovea
D-15 Panel saturated: 
tritan defects,  
d saturated: marked 
protan defects
Conce tric re uc-
tion to 30-40 
degrees (III/4)
Age 13: non-d tec able  
photopic and markedly 
reduc d scotopic ERG
  A-II:3 German CRD 10 years 16 RE -6.5D SE
LE -7.0D SE
RE 20/80 
LE 20/60
Hyper- 
pigmented 
foveal region
NA NA   Diffuse errors Central scotoma Age 10: non-detectable cone 
responses under photopic 
conditions, rod responses under 
scotopic conditions slightly 
reduced; age 15: scotopic  
markedly reduced
B B-II:1 Moroccan 
Jewish
CRD Early child-
hood
33 BE -11D SE BE 20/125 Atrophy 
(geographic 
atrophy-like) 
in fovea. 
White without 
pressure in 
periphery. 
Tilted optic 
discs (LE>RE) 
with temporal 
pallor LE.
Ring of hyper- 
fluorescence
Atrophy in fovea; retinal 
layers absent at foveal 
region
D-15 Panel: RE 
scotopi  lines; 
LE Tritan and Deutan 
defect
NA Age 30: non-d tectable cone 
responses under photopic 
response; rod responses under 
scotopic responses moderately 
reduced (30% below normal). 
Mixed cone-rod response 
moderately to severely reduced 
(~50-60% below normal)
  B-II:2 Moroccan 
Jewish
COD/CRD  NA 30 NA NA     D-15 Panel: Deutan 
defect and scotopic 
lines, more severe 
in OS
NA  Age 30: non-d tectable cone 
respons s under ph topic 
condition; rod responses under 
scotopic response at below 
normal in RE and within normal 
limits in OS. Mixed cone-rod 
response moderately reduced 
(~25-35% below normal)
BE = both eyes, D = diopters, ERG = electroretinogram, OCT = optical coherence tomogra-
phy, OS = left eye, RE = right eye, RPE = retinal pigment epithelium, SE = spherical equivalent
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Figure 3 Subcellular localization of RAB28 in rat retina
Cryosections of rat photoreceptor cells from day P20 were assessed by immunohistochem-
istry using mouse polyclonal α-RAB28 antibodies raised against aa 1-96 of human RAB28. 
These antibodies recognize all RAB28 isoforms (Sigma-Aldrich, SAB1406812, validated as 
shown in Supplemental Figure 3). Affinity purified guinea pig-α-RPGRIP1L (SNC040) was 
used as a marker of the basal body of the connecting cilium, as shown previously.26; 27 (A) 
Rat retinal sections from P20 were stained with DAPI (blue, first panel), α-RAB28 (green, 
second panel) and α-RPGRIP1L (red, third panel). The merged image in the right panel 
shows the co-localization of RAB28 and RPGRIP1L. (B) Enlargement of the photoreceptor 
layer, demonstrating partial co-localization of RAB28 and RPGRIP1L at the base of the 
connecting cilium. (C) A higher magnification of the connecting cilium region. The retinal 
layers are retinal pigment epithelium (RPE), photoreceptor layer (Ph), outer nuclear layer 
(ONL), outer plexiform layer (OPL), inner plexiform layer (IPL), ganglion cell layer (GCL).
Figure 2
A B C
D FE
Figure 2 Clinical presentation of CRD associated with RAB28 mutations
A-C: Retinal imaging of the right eye of individual A-II:2 of family A at age 25. A) Fundus 
photography showed slight hyperpigmentation of the foveal region; B) Autofluorescence 
imaging revealed a slight hyperfluorescent leash at the fovea without striking pathology 
(central brightening is an artifact); C) Optical coherence tomography (OCT) displayed 
altered photoreceptors in the central fovea with an intact periphery.
D-F: Retinal imaging of the right eye of individual B-II:1 of family B at age 33. D) Fundus pho-
tographs showed foveal atrophy with no marked peripheral changes; E). Autofluorescence 
imaging revealed a hyperfluorescent ring surrounding the hypofluorescent fovea; F) OCT 
scans confirm the presence of foveal atrophy while the photoreceptor layer is largely intact 
further out. 
Wide expression is found for variant 1 in contrast to variant 2, which has been reported to 
be primarily expressed in testis.22 Expression analysis in RNA samples from various human 
tissues showed highest expression of variant 1 in lung, bone marrow, retinal pigment epithe-
lium (RPE) and kidney, wide and abundant expression of variant 2, and highest expression of 
variant 3 in heart, lung, bone marrow, retina, brain and RPE (Supplemental Figure 1). Staining 
of rat retina showed localization of RAB28 to the basal body and the ciliary rootlet of the 
photoreceptors(Figure 3 and Supplemental Figure 3). 
Both nonsense mutations identified in the CRD families in this report are found in the shared 
mRNA segment, and are therefore predicted to truncate all three RAB28 isoforms. To deter-
mine whether the RAB28 mRNA is subjected to nonsense-mediated decay (NMD), RT-PCR 
analysis was performed in RNA samples isolated from lymphocytes of affected individuals of 
families A and B using a primer set amplifying exons 2-3, a region that is shared by all three 
RAB28 isoforms, as well as three different primer sets to evaluate the expression of the three 
isoforms individually. RAB28 transcript was detected in affected members of both families, 
excluding complete loss of RAB28 transcript by NMD (Supplemental Figure 2). 
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Supplemental Figure 1 Expression profile of alternatively spliced mRNAs of RAB28 
in various tissues
Primers were designed to amplify the three mRNA variants (Table S3) to verify the expres-
sion of adult total RNA from heart (H), testis (Te), skeletal muscle (Sk), spleen (Sp), liver (Li), 
thymus (Th), bone marrow (Bo), retina (R), placenta (Pl), brain (Br), retinal pigment epithelium 
(RPE), duodenum (D), and kidney (K). The size of the products was compared to a 100 bp 
ladder (M); (A) expression of mRNA with primers in exon 1-3 showing a 238 bp product in an 
overlapping region for all isoforms. (B) expression of mRNA variant 1 with primers located in 
exons 5-9 represented by the smaller product at 195 base pairs (bp); (C) expression of mRNA 
variant 2 with primers located in exons 5-8 as shown by a 177-bp product; (D) expression of 
mRNA variant 3 with primers located in exons 5-7 displaying a 152-bp product; (E) expression 
of GUSB, a ubiquitously expressed gene, in all tissues showing a 245-bp product. 
The exact role of RAB28 in cone and rod photoreceptors remains to be determined. The 
localization of RAB28 to the basal body and ciliary rootlet suggests a role in ciliary transport. 
Interestingly, RAB8 and RAB11, which have so far not been shown to be associated with dis-
ease, coordinate primary ciliogenesis,28 and together with RAB3A and RAB6A are involved 
in rhodopsin transport from the photoreceptor inner to outer segments through the con-
necting cilium.29-32 RAB28 may have adopted a similar function with specific importance for 
the highly active vesicle-based transport of photoreceptor proteins through the connecting 
cilium. Identification of RAB28 mutations emphasizes the role of disrupted ciliary processes 
in the pathogenesis of CRD. In addition to RAB28, three proteins involved in CRD (C8orf37, 
RPGRIP1 and TULP1) have so far been shown to localize to the connecting cilia of photore-
ceptor cells, and approximately one third of the gene defects underlying retinal degeneration 
affect the connecting cilium structure and/or function in photoreceptors.33 The observation 
that nonsense mutations in RAB28 cause a phenotype only in the eye may point to functional 
redundancy in other tissues. 
In conclusion, a combined approach of homozygosity mapping and exome sequencing identified 
nonsense mutations in RAB28 as a rare cause of AR CRD. This study reveals a crucial role for 
RAB28 in photoreceptor function, and suggests that mutations in other Rab proteins may also 
be associated with retinal dystrophies. The functional implications of RAB28 mutations remain 
unclear and warrant further investigation.
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Supplemental Table 1 Shared homozygous regions identified in Families A and B 
Ranking Chr Start position (hg19) End position (hg19) Size (Mb) Homozygous SNPs
Family A
1 4 11,015,508 15,700,443 4.68 592
2 11 38,017,394 39,444,614 1.43 144
3 2 21,043,923 22,474,801 1.43 132
4 4 171,827,483 172,984,650 1.16 130
5 1 212,950,206 214,009,363 1.06 117
6 7 85,490,315 86,550,497 1.06 95
7 14 65,647,955 67,062,093 1.41 94
8 14 54,327,340 55,261,166 0.93 82
9 4 32,595,139 33,321,361 0.73 71
10 5 130,168,579 131,314,824 1.15 69
Family B
1 7 114,302,855 142,163,046 27.86 103
2 4 6,2222,138 21,764,761 15.54 75
3 13 31,518,595 44,239,557 12.72 58
4 19 16,051,902 28,492,600 12.44 21
5 1 5,774,674 14,304,168 8.53 17
Supplemental Table 2 Primer sequences for RAB28
Ranking Chr Start position (hg19) End position (hg19) Size (Mb) Homozygous SNPs
Family A
1 4 11,015,508 15,700,443 4.68 592
2 11 38,017,394 39,444,614 1.43 144
3 2 21,043,923 22,474,801 1.43 132
4 4 171,827,483 172,984,650 1.16 130
5 1 212,950,206 214,009,363 1.06 117
6 7 85,490,315 86,550,497 1.06 95
7 14 65,647,955 67,062,093 1.41 94
8 14 54,327,340 55,261,166 0.93 82
9 4 32,595,139 33,321,361 0.73 71
10 5 130,168,579 131,314,824 1.15 69
Family B
1 7 114,302,855 142,163,046 27.86 103
2 4 6,2222,138 21,764,761 15.54 75
3 13 31,518,595 44,239,557 12.72 58
4 19 16,051,902 28,492,600 12.44 21
5 1 5,774,674 14,304,168 8.53 17
Exon in RAB28 Forward Reverse Product size (bp)
Exon 1 gcaactacctcccttcctcc agggctcggggtaacgag 270
Exon 2 ctgcttaaatttgcttgttgg gcagccccaaaattttacac 314
Exon 3 taaaggcaaattgggctcag tgcatttgggagtagatttgc 292
Exon 4 tgctagtaagcaatttaaatggaag ccagacaccatcattttggg 411
Exon 5 tatagatgtggaaactgagtca cattacgggtggtttatattcatt 507
Exon 6 gctatttttggaatcacctgct tgggaaagaatttatgggtga 320
Exon 9 isoform 1 tccatcatcagaagttcagca tgtgtggtcccaaagttgaa 400
Exon 8 isoform 2 tgcgtgtgtgtgtgagacat ctggcagaggaccaattttt 397
Exon 7 isoform 3 ctgccacttccatttccagt aaggctctgcagattccaaa 426
Supplemental Table 3 Primer sequences for RAB28 expression study
RAB28 mRNA variants Forward Reverse Product size (bp)
Exon 1-3 atgtcggactctgaggagga tcccaaatttgaagggtaaca 238
Exon 2-3 ctcaagaaacttttgggaaaca tcccaaatttgaagggtaaca 106
Isoform 1 (exon 5-9) acttacggttttgccaggaa tccttgacataggttcctggtt 195
Isoform 2 (exon 5-8) acttacggttttgccaggaa ccgggtacttcactatttctgc 177
Isoform 3 (exon 5-7) acttacggttttgccaggaa gaaatggccctgtgactgtt 204
GUSB ctgtacacgacacccaccac tacagataggcagggcgttc 245
Supplemental Figure 2 Expression profile of alternatively spliced mRNAs of RAB28 
in family A and B 
The occurrence of NMD in the affected individuals of families A (II-1, II-2, II-3, all homozygous 
mutants) and B (II-1 homozygous mutant, I-2 heterozygous carrier) was explored in RNA iso-
lated from lymphocytes (primers are indicated in Table S3) and compared to controls. The size 
of the products was compared to a 100 bp ladder (M). (A) expression of mRNA with primers 
in exon 2-3 showing a 106 bp product in an overlapping region for all isoforms. (B) expression 
of mRNA variant 1 with primers located in exons 5-9 represented by the smaller product at 
195 base pairs (bp); (C) expression of mRNA 2 with primers located in exons 5-8 as shown 
by a 177-bp product; (D) expression of mRNA 3 with primers located in exons 5-7 displaying 
a 152-bp product; (E) expression of GUSB, a ubiquitously expressed gene, in all individuals 
showing a 245-bp product.
Supplemental Figure 3 Validation of the anti-RAB28 antibodies 
Western blot showing expression of RAB28 in non-transfected HEK293-cells (NT; negative con-
trol), HEK293-cells transfected with pEGFP-C2 (GFP; positive control for GFP), and with pEGFP-
RAB28 (RAB28). The left panel revealed a band at ~53 kDa for the GFP-RAB28 fusion protein, 
correlating with its predicted size, using mouse polyclonal α-RAB28 antibodies. The right panel 
shows the detection of GFP using mouse monoclonal α-GFP (Roche, 11 814 460 001).
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introduCtion
Inherited macular and cone diseases like achromatopsia (ACHM), cone dystrophy (COD) and 
cone-rod dystrophy (CRD) have an estimated worldwide prevalence of 1:30.000-1:40.000.1-3
Typically, individuals with ACHM present shortly after birth with significantly reduced visual 
acuity, severe photophobia, a congenital pendular nystagmus, and color vision defects in all 
color axes. Absent or residual cone responses with normal rod responses are measured with 
full-field electroretinography (ERG),4, 5 Optical coherence tomography (OCT) shows initial loss 
of inner- and outer cone segments with disruption of the ciliary layer, followed by the appear-
ance of a bubble with cell loss in the cone photoreceptor layer. The end stage of ACHM is 
characterized by atrophy of the RPE. This degradation takes place in the second decade of life 
and progresses with age.6 Individuals with COD present with a normal cone function at birth, 
but develop progressive loss of cones and central vision during the first or second decade of 
life. Most individuals develop severe visual acuity loss before the fourth decade.7 Clinical fea-
tures of COD are poor visual acuity, disturbances in color vision, a fundus appearance varying 
from normal, to a bull’s eye maculopathy, or total atrophy of the macular region, with a variable 
degree of temporal pallor of the optic nerve. The visual fields of these individuals show a cen-
tral scotoma and ERG demonstrates progressive deterioration of the cone-derived photopic 
amplitude responses. Both diseases are characterized by loss of cone photoreceptors and a 
progressive visual decline, but CRD can be distinguished from COD by early involvement of 
rod photoreceptors. Besides the symptoms seen in COD, patients with CRD may also experi-
ence nyctalopia due to rod dysfunction.8 Both disorders have a high genetic heterogeneity and 
display all Mendelian inheritance forms. The most prevalent mode of inheritance is autosomal 
recessive (ar). Eight genes have been implicated in ar COD (ABCA4,9 CACNA2D4,10 CNGA3,11 
CNGB3,12, 13 KCNV2,14 PDE6C,3 PDE6H,15 TULP116). Three of these genes have initially been associ-
ated with ACHM, a form of cone-dysfunction that can develop into cone dystrophy. Eighteen 
genes have been associated to ar CRD (ABCA4,17 ADAM9,18 C8orf37,19 CDHR1,20, 21 CERKL,22 
CNGB3,23 CRB1,24 CRX,24 EYS,25 FSCN2,26 GUCY2D,27 KCNV2,14 PDE6C,23 POC1B,28, 29 PROM1,30 
RAB28,31 RPE65,24 RPGRIP1,23 and TULP116). In both disorders mutations in these genes explain 
disease in an estimated 21% (COD) and 25% (CRD) of patients.1;2 14, 32, 33
In the past few years, exome sequencing has shown its power to elucidate genetic defects 
in inherited retinal diseases.19, 31, 34, 35 The aim of this study was to identify novel causes of ar 
maculopathies and cone disorders using linkage analysis and next generation sequencing (NGS).
methods
Subjects and clinical evaluation
A large non-consanguineous Dutch family (Family A) with five family members and an isolated 
Dutch case (Family B) affected by macular dystrophy with central cone involvement were 
included in this study. An additional cohort of individuals with inherited maculopathies and 
cone disorders (ACHM, n=22; COD, n= 110; CRD, n= 112), the majority of which represent 
isolated cases, were ascertained from various ophthalmic centers in the Netherlands, Belgium, 
the United Kingdom, and Canada. Individuals were diagnosed with central cone disease if they 
showed a progressive decline of visual acuity, color vision disturbances, and reduced multifocal 
ERG. Individuals are diagnosed with ACHM when they showed shortly after birth a significantly 
reduced visual acuity, severe photophobia, a congenital pendular nystagmus, and color vision 
defects in the protan, deutan and tritan color axes. Persons were diagnosed with COD if they 
showed a progressive decline of visual acuity, color vision disturbances, and reduced cone 
amplitude responses on ERG, with normal rod responses for ≥5 years. Inclusion criteria for 
CRD were a progressive decline of visual acuity, color vision disturbances, and a reduction of 
both cone and rod ERG responses, with cones equally or more severely reduced.36
abstraCt
Purpose: This study aimed to identify the genetic defects in two families with autosomal reces-
sive macular dystrophy with central cone involvement.
Design: Case series
Participants: Two families and a cohort of 244 individuals with various inherited maculopathies 
and cone disorders.
Methods: Genome-wide linkage analysis and exome sequencing was performed in one large 
family with five affected individuals. In addition, exome sequencing was performed in the pro-
band of a second family. Subsequent analysis of the identified mutations in 244 patients was 
performed by Sanger sequencing or restriction enzyme digestion. 
The medical history of individuals carrying the MFSD8 variants was reviewed and additional 
ophthalmic examinations were performed, including electroretinography (ERG), multifocal 
ERG (mfERG), perimetry, optical coherence tomography (OCT), fundus autofluorescence 
(FAF), and fundus photography.
Main Outcome Measures: MFSD8 variants, age at diagnosis, visual acuity, fundus appearance, 
color vision defects, visual field, ERG, mfERG, FAF and OCT findings. 
Results: Compound heterozygous variants in MFSD8, a gene encoding a lysosomal transmem-
brane protein, were identified in two families with macular dystrophy with a normal or subnor-
mal ERG, but reduced mfERG. In both families a heterozygous missense variant, p.Glu336Gln, 
was identified, which was predicted to have a mild effect on the protein. In the first family a 
protein-truncating variant (p.Glu381*) was identified on the other allele, and in the second 
family a variant (c.1102G>C) was identified which results in a splicing defect leading to skipping 
of exon 11 (p.Lys333Lysfs*3). The p.Glu336Gln allele was found to be significantly enriched 
in patients with maculopathies and cone disorders (6/488) compared to ethnically matched 
controls (35/18,682; p-value <0.0001), suggesting that it may act as a genetic modifier. 
Conclusions: In this study we identified variants in MFSD8 as a novel cause of non-syndromic 
autosomal recessive macular dystrophy with central cone involvement. Affected individuals 
showed no neurological features typical for variant late-infantile neuronal ceroid lipofuscinosis 
(vLINCL), a severe and devastating multisystem lysosomal storage disease previously associ-
ated with mutations in MFSD8. We propose a genotype-phenotype model in which a combina-
tion of a severe and a mild variant cause non-syndromic macular dystrophy with central cone 
involvement, while two severe mutations cause vLINCL. 
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(FAF) imaging (Heidelberg Spectralis HRA+OCT, Heidelberg Engineering, Germany) was per-
formed of the macula at 488 nm wavelength using a 30° lens: a mean image out of 16 single 
images was calculated. In addition we performed a volume scan (20x15°, 37 lines, 36 frames per 
line) for all affected individuals. Individual A:II-2 was examined by a neurologist at age 48 due to 
a suspected optic neuropathy. Examinations included a cerebral computed tomography (CT) 
scan, measurement of evoked potentials, and an electroencephalogram (EEG). This study was 
approved by the Institutional Review Board, and adhered to the tenets of the declaration of 
Helsinki. The probands of both families provided written informed consent to perform exome 
sequencing.
Molecular Genetic Analysis
Blood samples were obtained of all probands, and when possible, their parents, affected and unaf-
fected siblings. DNA was isolated from peripheral blood lymphocytes by standard procedures. 
Mutations in various genes previously implicated in inherited maculopathies and cone disorders, 
i.e. ABCA4, CNGA3, CNGB3, KCNV2, PDE6C and RAB28, were excluded by Sanger sequencing. 
Employing genomic DNA of four affected members of family A (II-1, II-2, II-3, II-4) genome-wide 
linkage analysis was carried out using 250K SNP arrays. Multipoint parametric linkage analysis 
was performed with Genehunter (Decode Genetics Reykjavik, Iceland) in the Easylinkage Plus 
software package (University of Würzburg, Germany) using the Marshfield genetic SNP map and 
the Caucasian allele frequencies. An autosomal recessive mode of inheritance was assumed since 
neither the parents nor the 10 children of the five affected siblings were affected. The disease-
allele frequency was estimated at 0.001.
For all five affected members of family A and their available unaffected family members, micro-
satellite analysis was performed for selected markers to analyze the established linkage peaks 
on chromosomes 1, 2 and 4. Microsatellites D1S2779, D1S2813, D2S103, D2S143, D4S406 and 
D4S2989 were amplified with primers containing a M13 forward and reverse sequence tail. 
An additional polymerase chain reaction (PCR) was performed with a fluorescently labeled 
M13-forward primer and an unlabelled M13-reverse primer. PCR products were mixed with 
a fluorescent size marker (Applied Biosystems, Bleiswijk, the Netherlands) and samples were 
analyzed on a 3100 or 3730 DNA Analyzer (Applied Biosystems, Bleiswijk, the Netherlands). 
Fragment lengths were analyzed with GeneMapper software (Applied Biosystems, Bleiswijk, the 
Netherlands). Haplotypes were constructed based on the size of the alleles of the microsatel-
lites. 
Subsequent exome sequencing was performed for probands of family A and of an unrelated fam-
ily (family B) on a SOLiD4 sequencing platform (Life Technologies, Carlsbad, CA, USA). Exomes 
were enriched according to the manufacturer’s protocol using the Agilent SureSelect Human All 
Exon v.2 Kit (50Mb), which targets the exonic sequences of approximately 21,000 genes (Agilent 
Technologies, Inc., Santa Clara, CA, USA). LifeScope software v2.1 (Life Technologies, Carlsbad, 
CA, USA) was used to map color space reads along the hg19 reference genome assembly. The 
high-stringency calling DiBayes algorithm was used for single-nucleotide variant calling, and small 
insertions and deletions were detected using the small Indel Tool.
Nonsense, frameshift, (canonical) splice site or missense variants with a nucleotide conservation 
score of PhyloP score >2.7 were selected for further analysis when presenting a frequency <0.5% 
in dbSNP and an in-house database containing exome sequencing variants of 2,095 individuals 
(4,190 alleles). Based on the assumption of autosomal recessive inheritance, potential compound 
heterozygous variants were selected when present on ≥20% variant reads, whereas homozygous 
variants were selected when present on ≥80% variant reads. Confirmation of identified variants 
and segregation analysis was performed using PCR and subsequent Sanger sequence analysis. 
All primers were designed with Primer3 software and are presented in Supplemental Table 1. 
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Figure 1 MFSD8 variants in two Dutch pedigrees with macular dystrophy with 
central cone involvement
A) Segregation analysis in family A with five affected and eight non-affected family members 
demonstrated autosomal recessive inheritance of variants M1 (c.1006G>C; p.Glu336Gln) and 
M2 (c.1141G>T; p.Glu381*). Microsatellite marker positions are based on the UCSC human 
genome reference sequence, version hg19. In family B biallelism of M1 (c.1006G>C; p.Glu336Gln) 
and M3 (c.1102G>C; p.Lys333Lysfs*3) was confirmed by restriction fragment length analysis. 
B) Alignment of MFSD8 protein orthologs. The glutamic acid residue at position 336 is highly 
conserved among mammalian MFSD8 orthologs, but is not conserved in zebrafish. Identical 
amino acids are indicated in black boxes, and conserved residues are indicated in gray boxes.
After identification of the genetic defect, the medical history of the affected individuals of 
families A and B was reviewed. Ophthalmologic examinations included best-corrected visual 
acuity (BCVA; Snellen chart), slit-lamp biomicroscopy, ophthalmoscopy, color vision testing 
(Hardy–Rand–Rittler color vision test and Lanthony Panel D-15 tests), and visual field test-
ing using Goldmann kinetic perimetry (targets V-4e, and I-4e to I-1e). Fundus photographs 
centered on the macular area as well as on the four peripheral quadrants was performed using 
standard procedures. Electroretinography (ERG) was performed according to the extended 
protocol for the full-field ERG and multifocal ERG (mfERG) using 61 hexagons (central 28°) 
of the International Society for Clinical Electrophysiology of Vision (ISCEV).37 For individual 
II-5 of family A and II-1 of family B spectral-domain optical coherence tomography (SD-OCT; 
Heidelberg Spectralis HRA+OCT, Heidelberg Engineering, Germany) was used to obtain 
cross-sectional images of the macular region through dilated pupils, one horizontally and one 
vertically (30° wide, 51 frames per line). For the same individuals fundus autofluorescence 
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Figure 2 Clinical evaluation of macular dystrophy with central cone involvement 
caused by MFSD8 variants
A–C, Clinical characteristics of patient II-3 of family A. A) The fundus photograph showed 
retinal pigment epithelium (RPE) changes in the macula with a normal periphery. B) Fundus 
autofluorescence (FAF) revealed a hypofluorescent central area surrounded by a hyperfluores-
cent ring. C) Optical coherence tomography (OCT) displayed foveal atrophy and a generally 
thinned retina. D-F, Clinical characteristics of patient II-5 of family A. D) Fundus photographs 
showed a mild peripapillary atrophy with a granular aspect of macula. The periphery is without 
abnormalities E) FAF showed symmetrical central alterations at the level of the outer retinal 
layers F) OCT displayed relatively symmetrical central alterations at the level of the outer 
retinal layers. G-I, Clinical characteristics of patient II-1 of family B. H) Fundus photographs 
revealed a pale optic disc, attenuated vessels. Also, atrophy of the RPE in the posterior pole 
was noted with a normal appearance of (mid)peripheral RPE. H) FAF showed a decreased auto-
fluorescence in the central macula and a perimacular mottled pattern of hypofluorescence) I) 
OCT displayed loss of retinal layers at the fovea, which are partially present, but show irregular 
outer retinal layers perifoveally and in posterior pole. Furthermore, an intact inner retina and 
thickened choroid were noted.
The p.Glu381* and p.Lys333Lysfs*3 variants in families A and B were not identified in an in-house 
exome (4,190 alleles) database, in 12,006 alleles of the online databases (Exome Variant Server, 
http://evs.gs.washington.edu/EVS/, 6 November 2013), nor in 2,184 alleles of the 1000genomes 
Additional screening of patients and controls for the observed mutations in MFSD8 was per-
formed by sequencing of exons 11 and 12 (892 basepairs (bp)). To prove the presence of the 
mutations on separate alleles in family B, digestion by HaeIII of the amplified product of exon 
11 (589 bp) was performed. Mutant alleles carrying the c.1006G>C; p.Glu336Gln variant were 
digested into 333, 236 and 20 bp fragments, whereas the wildtype allele was digested into frag-
ments of 569 and 20 bp. The undigested 569 bp product was subsequently Sanger sequenced to 
confirm the presence of c.1102G>C on the opposite allele. Using the same method 151 ethnically 
matched controls were evaluated for the presence of the missense variant p.Gly336Gln. EBV-
transformed lymphocytes of affected individual B:II-1 were grown with or without cycloheximide 
to visualize the effect of the c.1102G>C mutation on the transcript level, and to determine possi-
ble degradation of nonsense-containing mRNAs by nonsense mediated decay (NMD).38 Reverse 
transcription with iScript (Biorad, Veenendaal, The Netherlands) was performed on total RNA 
(1 µg) to obtain cDNA. RT-PCR experiments were performed using 2.5 µl cDNA with forward 
primers in exon 10 or 11 and a reverse primer in exon 12, followed by Sanger sequencing of the 
obtained PCR products.
Furthermore, the pathogenicity of the p.Gly336Gln mutation was evaluated using the Grantham- 
and PhyloP-scores,39 SIFT,40 and Polyphen-2 (version 2.2.2; http://genetics.bwh.harvard.edu/
pph2/).
results
Identification of MFSD8 variants in families A and B
Genome-wide linkage analysis using DNA of four affected members of family A revealed three 
linkage peaks that were located on chromosome 1 (25.2 Mb; SNP_A-1923543-SNP_A-1910059; 
containing 206 genes), 2 (53.7 Mb; SNP_A-2027807-SNP_A-2039109; containing 327 genes) and 
4 (29.7 Mb; SNP_A-1902084-SNP_A-2036896; containing 95 genes) with a LOD-score of 1.81. 
Using microsatellite marker analysis in all available individuals of family A, haplotypes at the link-
age region on chromosome 4 were found to fully segregate with the disease phenotype (Figure 
1A). Using Easylinkage a maximum LOD-score of 3.4 was determined, thereby reaching genome-
wide significance, whereas haplotypes at the regions on chromosome 1 and 2 did not segregate 
(not shown). To elucidate the gene defect in II-1 of family A, exome sequencing was performed.
Under the hypothesis of autosomal recessive inheritance, we identified three potential com-
pound heterozygous variants (>20% variation) and no homozygous (>80% variation) variants 
based on our sequence variant filtering criteria for II-1 of family A (Supplemental Table 2). Only 
one of these genes, Major Facilitator Superfamily Domain Containing 8 (MFSD8), which car-
ried the compound heterozygous variants p.Glu381* and p.Glu336Gln, resides within the linkage 
region on chromosome 4. Segregation analysis of the variants using Sanger sequencing confirmed 
segregation within the family (Figure 1A). Exome sequencing in the proband (B:II-1) of a second 
family (Family B, figure 1B) revealed two heterozygous variants in the same gene, and also three 
homozygous variants in other genes (Supplemental Table 3). This isolated case is a heterozy-
gous carrier of the same missense variant identified in family A, p.Glu336Gln, and of the variant 
c.1102G>C. The latter variant is predicted to alter a highly conserved amino acid (p.Asp368His) 
and in addition can affect splicing as it changes the last nucleotide of exon 11.41 Analysis of the 
effect of this variant at the transcript level revealed that it leads to skipping of exon 11, as the C 
residue could not be detected at position c.1102 (Figure 1C, Supplemental figure 1), indicating 
that only cDNA of the other mutant (p.Glu336Gln) allele could be amplified. The c.1102G>C 
variant thereby is predicted to result in a truncated protein (p.Lys333Lysfs*3). Since parental 
DNA was not available, segregation analysis could not be performed. However, due to the prox-
imity of both variants within one amplicon, restriction analysis with HaeIII showed that the 
p.Glu336Gln and c.1102G>C variants lie on different alleles.
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a decreased sensitivity for the red axis in color vision analysis and decreased central sensitivity 
on visual field testing. ERG responses lie within normal limits, although mfERG shows a sig-
nificantly reduced central response (Figure 3). For this case also FAF and OCT examinations 
were performed, both indicating alterations at the outer retinal layers. EOG performed in all 
individuals of family A yielded normal results. 
Figure 3
Figure 3 Multifocal electroretinogram of individual II-5
The mfERG of individual II-5 of family A visualized reduced responses.
Individual A:II-2 was examined by a neurologist at age 48. Walking and sensibility were undis-
turbed. A cerebral CT scan suggested slight cortical atrophy. However, brainstem auditory 
evoked potentials (BAEP), somatosensory evoked potentials (SSEP) and visual evoked poten-
tials (VEP) were normal, and normal variant EEG waves were observed. All affected individuals 
of family A at advanced age (range 54-71 years) have not experienced seizures throughout their 
lives, and have normal mental and psychomotor abilities.
Individual II-1 of family B was diagnosed with cone dystrophy at the age of 27. His visual acuity 
deteriorated to counting fingers at the age of 40. The most recent recorded visual acuities 
were 2/60 and 1/60, respectively, with eccentric fixation. Through the years an enlargement of 
the central scotoma on Goldmann perimetry was documented. ERG was performed on nine 
different occasions, and showed normal rod function with mildly abnormal cone function on 
eight of these. On the ninth occasion, at the age of 60, the responses generated after dark 
adaptation seemed more reduced than under light adaption suggesting a tendency towards a 
rod-cone pattern, which might be explained by the progression of retinal atrophy towards the 
midperiphery. Color vision tested with the saturated version of the Panel D15 was normal at 
the age of 29 and developed into a deutan deficiency at the age of 42. Individual B:II-1 at age 
62 has not experienced seizures throughout his life, and has normal mental and psychomotor 
abilities.
project, www.1000genomes.org, 6 November 2013). Both mutations were previously described 
and are presumed to be loss-of-function mutations, causing variant late-infantile neuronal 
ceroid lipofuscinosis (vLINCL).41, 42 However, the missense mutation p.Glu336Gln identified in 
both families was also identified in 1/302 (0.3%) alleles of healthy ethnically-matched control 
individuals. Furthermore, the mutation was found in 9/4,190 alleles (0.21%) in our in-house 
exome database, and in 25/12,006 alleles (0.19%) of European Americans in the Exome Variant 
Server, but it was not identified in 2,184 alleles in the 1000genomes project. Screening of 
our inherited maculopathy and cone disorder cohort for the missense mutation p.Glu336Gln 
yielded four additional individuals carrying this mutation in a heterozygous state. Subsequent 
sequence analysis of the MFSD8 gene in these individuals did not identify a second variant on 
the other allele. The frequency of the p.Glu336Gln allele in 6/488 (1.2%) affected individuals 
with inherited maculopathies and cone disorders is significantly higher than in controls with a 
frequency of 35/18,682 (0.18%) alleles (P-value < 0.0001, Chi-square test, two-tailed). 
At the nucleotide level, c.1006G>C (p.Glu336Gln) is highly conserved with a PhyloP score of 
5.53. The mutation is predicted to be possibly damaging with a score of 0.927 by Polyphen-2, 
but the glutamic acid to glutamine change at this position yields a low Grantham score of 29 and 
appears to be tolerated by SIFT. The wild-type glutamic acid residue is negatively charged, acid-
ic and large, while the mutant glutamine residue is neutrally charged, and smaller in size. The 
glutamic acid residue at this position is conserved from human to fruitfly with the exception of 
zebrafish (Figure 1B) and it is located in the cytoplasmic region, two amino acids N-terminal 
to the 9th transmembrane domain of the protein. The mutant residue might disturb the core 
structure of this domain. 
Clinical features of patients of families A and B
Table 1 summarizes the clinical findings of families A and B. The clinical images of the affected 
individuals are shown in Figure 2. Individual II-1 was diagnosed at the age of 65 with a visual 
acuity of 20/200 for both eyes. A macular bull’s eye was noted on fundoscopy with a relatively 
spared fovea and minor superior RPE defects. ERG responses were normal in photopic and 
scotopic testing, whereas mfERG indicated severely reduced responses. Individual II-2 (Figure 
2D, E, F) presented at 53 years of age with a visual acuity of 100/200 in the right eye and 16/200 
at the left eye. The fundus showed a subtle foveal change with an intact periphery. Color vision 
tests showed a red-green defect. Visual field testing revealed no abnormalities apart from a 
reduced central sensitivity in the macula. ERG was normal whereas mfERG showed severely 
reduced responses. Individual II-3 presented with a visual acuity of 1/60 in the right eye and 
50/200 in the left eye at the age of 59 years. Fundoscopy showed diffuse macular retinal pigment 
epithelium (RPE) changes with a normal periphery and color vision tests showed red-green 
defects. FAF imaging showed a hypofluorescent central area surrounded by a hyperfluorescent 
ring and foveal atrophy. OCT studies showed a strikingly thinned fovea (188 µm juxtafoveal; 41 
µm central fovea), with a complete loss of the inner segment/outer segment junction and loss 
of the outer nuclear layer. Both eyes show decreased central sensitivity on visual field analy-
sis. The ERG has normal scotopic and reduced but within normal limits photopic responses, 
while mfERG revealed severely reduced responses. Individual II-4 of family A (Figure 2A, B, 
C) presented at the age of 29 with a visual acuity of <20/200 in the right eye and 100/200 in 
the left eye. Fundoscopy detected a small bull’s eye maculopathy with attenuated vessels and a 
relatively pale papillary rim. Color vision defects were identified in the red-green axis and the 
visual field appeared with reduced central sensitivity and a normal periphery. ERG responses 
appeared normal, while mfERG responses were severely reduced. Patient II-5 presented at the 
age of 53 years with a visual acuity of 125/200 in the right eye and 50/200 in the left eye, respec-
tively. The fundus displayed mild peripapillary atrophy and a granular macula. Both eyes display 
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diag-
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Visual 
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tion) Fundus 
Auto- 
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Color 
vision
Visual 
field 
(Gold-
mann) ERG
A:II-5
(54 yrs)
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125/200
LE: 50/200
RE: SE 
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Mild peripapillary 
atrophy, granular 
aspect of macula, 
periphery no 
abnormalities
Symmetri-
cal central 
alterations 
at the level 
of the out-
er retinal 
layers
Relative-
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metrical 
central 
alter-
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the level 
of the 
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retinal 
layers
BE red-green 
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decreased 
red-sensi-
tivity  
(37 yrs)
Decrease 
of central 
sensitivity, 
no other 
abnormal-
ities
Phot-
opic and 
scotopic 
responses 
within nor-
mal limits.
mfERG: 
significantly 
reduced 
responses 
central 
B:II-1
(62 yrs)
27 RE: CF 
LE: CF 
RE: SE 
-4.0D
LE:-
SE-3.25D
Optic disc pallor, 
attenuated arteri-
oles, RPE atrophy 
in posterior pole, 
normal appear-
ance of (mid)
peripheral RPE
Decreased 
auto-fluo-
rescence 
in central 
macula, 
perimacu-
lar mottled 
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present, 
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or pole, 
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inner 
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thick-
ened 
choroid
BE deutan 
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central 
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tive intact 
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significantly 
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mixed re-
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significantly 
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single flash 
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normal 
limits LE 
(latencies 
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To date, no extraocular features present in vLINCL have been noticed in these persons. In 
view of the advanced age of the affected persons of families A and B at their last examination 
(range 54-71 years), these individuals are unlikely to develop other features of vLINCL. Clinical 
variation has been noted among other MFSD8-associated cases. In a single Dutch case with a 
homozygous p.Ala157Pro variant in MFSD8, a protracted course of the disease process was 
described.43 This substitution affects a highly conserved alanine residue located in the fourth 
cytosolic loop. This individual was diagnosed with visual failure at 11 years of age and only 
developed motor impairment, seizures and ataxia at the ages of 24, 25 and 28, respectively. 
Subsequently mental and speech regression was observed at 30 and 36 years, and this person 
became wheelchair bound at 39 years. Interestingly, the visual impairment clearly preceded 
the neurological defects. In almost all other younger vLINCL cases, the visual impairment was 
noted when the neurological defects were diagnosed, but it is very well possible that the initial 
retinal defects occurred earlier. 
The explanation for the phenotypic variability most likely resides in the genotype of these 
patients. Although several types of mutations have been found in MFSD8, the individuals with 
non-syndromic macular dystrophy with central cone involvement present a severe hetero-
zygous mutation in combination with a heterozygous missense variant (p.Glu336Gln), which 
we hypothesize to yield a mild effect. The aggregate carrier frequency of this variant in the 
Caucasian population is 1/267 individuals. If this variant, i.e., the most frequent MFSD8 variant 
in public databases, had a severe effect on the function of the mutant protein it should have 
been previously found in multiple vLINCL cases, either in compound heterozygous or homo-
zygous state. The fact that this has never been observed strongly suggests that it represents 
a hypomorphic variant that only causes cone dysfunction when it is present in combination 
with a severe variant. It seems logical to propose a threshold model in which the residual 
activity of MFSD8 suffices for its proper function in all organs except the eye. We therefore 
propose a mechanism in which the combination of a severe (truncating) mutation together with 
a mild variant is the cause of non-syndromic macular dystrophy with central cone involvement. 
Interestingly, the frequency of the p.Glu336Gln allele is significantly enriched in individuals with 
inherited maculopathies and cone disorders (6/488 alleles) compared to controls (35/18,682 
alleles; P-value <0.0001). This suggests that this allele might act as a potential risk factor or 
modifier allele for such disorders.
A similar disease mechanism involving mild and severe mutations has also been proposed for 
several other genes causing syndromic and non-syndromic retinal disease. Juvenile NCL or 
Batten disease, like vLINCL, belongs to the disease spectrum of the neuronal ceroid lipofusci-
noses, which can be caused by mutations in CLN3. The onset of disease is between 5-8 years 
and results in premature death in the third decade of life. Sarpong et al. (2009) described a 
protracted mild phenotype of juvenile NCL in a large Lebanese pedigree segregating CLN3 
mutations, which presents similarities to our cases of non-syndromic disease caused by MFSD8 
mutations.52 Analysis of the homozygous CLN3 p.Tyr199* variant in affected individuals indi-
cated a nearly equal distribution of transcripts compared to control individuals, implying that 
the mRNA transcript is not degraded by nonsense mediated decay, nor affected by corrective 
splicing. Although severely affecting the structure of CLN3, it is assumed that residual func-
tion is retained as the mutant mRNA potentially encodes a truncated protein containing part 
of the catalytic domain.52 In contrast, a common deletion of exons 7 and 8 in CLN3 shows a 
complete loss of function.53 More recently, several cases with retinitis pigmentosa (RP), a single 
case of non-syndromic Leber congenital amaurosis (LCA), and a single case of CRD have been 
described to carry mutations in CLN3.54, 55 Some of these mutations have been described to 
have a mild effect or result in a protracted phenotype. Most of these cases are far above the 
disCussion
In this study, we describe two families with ar macular dystrophy with central cone involvement 
due to variants in the MFSD8 gene. MFSD8 variants have previously been described to cause 
vLINCL, an early-onset severe lysosomal storage disorder with intralysosomal accumulation 
of autofluorescent lipopigments known as ceroid-lipofuscin which presents with seizures and 
mental regression.43, 44 Other common initial symptoms are ataxia and poorly described visual 
impairment.43 The progression of the disease is rapid with neurological regression (motor and 
mental), loss of vision and seizures developing early in disease.43 The majority of individuals lose 
their capability to walk two years after disease onset and the outcome is fatal within the sec-
ond decade.44 The diagnosis can be confirmed by electron microscopy of biopsied tissues such 
as skin, muscle and rectal biopsies, showing fingerprint profiles of the cytosomes, although 
ultrastructural abnormalities are not always seen in MFSD8-positive vLINCL patients.41, 45, 46 
Very recently, a mouse model was described in which a lacZ gene-trap cassette was inserted 
between exons 1 and 2.47 Protein analysis revealed that residual Mfsd8 was present, probably 
due to a low degree of normal exon 1 to exon 2 splicing. Mutant mice showed neurological 
defects similar to NCL due to MFSD8 variants in humans. At 8.5 months of age, the retinae of 
these mice showed a severe degeneration, both in central and peripheral regions.47 As younger 
mice were not analyzed, a distinction between initial cone or rod degeneration was not made. 
MFSD8 is a transmembrane lysosomal protein41, 48, 49 and belongs to the major facilitator super-
family of transporter proteins. Therefore, it is presumed to function as a lysosomal transport-
er protein41, but its substrates remain to be identified. MFSD8 contains two N-glycosylation 
consensus sites, 12 transmembrane domains, and its N- and C-termini are cytosolic. A main 
dileucine-based motif at the N-terminus is presumed to direct MFSD8 to the lysosomes.41, 48, 
49 Studies in gene-targeted mouse embryonic fibroblasts show that MFSD8 is asymmetrically 
double cleaved for proper function.50 Analysis of two missense mutations demonstrates that 
the cleavage occurs in the luminal L9 loop, and the proteolytic cleavage is altered by these 
mutations.50 The c.1102G>C mutation induces a splice defect and skipping of exon 11, resulting 
in a truncated protein (p.Lys333Lysfs*3). Nevertheless, a wildtype transcript lacking exon 11 
was also seen in a control sample, suggesting that this event also occurs naturally, although 
more normal transcript (containing exon 11) was observed in the control sample compared to 
affected individual B:II-1. The p.Glu381* and p.Lys333Lysfs*3 variants likely result in nonsense-
mediated decay of the mRNA, and thus in severely reduced levels of the predicted proteins 
which lack the 137 and 184 carboxyterminal amino acid residues, respectively, with no residual 
function.
Whereas MFSD8 mutations have previously been associated with vLINCL, the individuals 
described in this study have a non-syndromic macular dystrophy with central cone involvement 
due to MFSD8 variants. We describe two families, one with a macular dystrophy with central 
cone involvement (Family A) and one with a macular dystrophy with central cone involvement 
that developed into a cone-rod dystrophy (Family B). Affected individuals of family A initially 
experienced a drop in central vision, while photopic and scotopic responses were normal. 
Only slight pigmentary alterations and color vision abnormalities pointed towards a macular 
dystrophy. Due to their recent implementation as diagnostic tools, OCT and mfERG could 
not be performed during the early phases of the disease. At later stages OCT showed loss of 
central photoreceptors and mfERG was abnormal in affected individuals. In summary, the clini-
cal details of all affected individuals of family A were consistent with a diagnosis of central cone 
disease as described by Pinckers, a term used for normal to subnormal ERG, but a (severely) 
reduced mfERG.51
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Supplemental figure 1  Analysis of the c.1102G>C mutation in individual II-1 of 
family B
A
Exon 11 - Exon 12 Exon 10 - Exon 12
- + exon11
- Δ exon 11
AAATACAGTGGGAAG TTTGCACAATAATT
AAATACAGTGGGAA ATTTGCACAATAATT
BII-1 - CHX
Δ exon 11
exon 11 exon 12
exon 11 exon 12
G
exon 10 exon 12
C1 - CHX 
Δ exon 11
BII-1 - CHX
+ exon 11
C1 - CHX
+ exon 11 
GTTGCTTTCCAAAAAATTTGCACAATAATT
GTTGCTTTCCAAAAAATTTGCACAATAATT
exon 10 exon 12
A
BII-1
+CHX
200 -
300 -
400 -
- -
MQ
GUSB
100 -
+
C1
200 -
300 -
400 -
100 -
GUSB
BII-1
+CHX
C1
- - +
B
C D
The effect of mutation M3 (c.1102G>C) on the transcript level was determined using forward 
primers in exon 10 and 11 and a reverse primer in exon 12. A) Primers in exon 11 to exon 12 
determined the presence of the wildtype allele in individual B:II-1. B) Using primers in exon 
10 to exon 12 it was shown that the c.1102G>C mutation affecting the last nucleotide of exon 
11, induces a splice defect and skipping of exon 11, predicted to result in a truncated protein 
(p.Lys333Lysfs*3). A transcript lacking exon 11 was also seen in the control sample (C1), sug-
gesting that this event also occurs naturally, although more normal transcript (containing exon 
11) was observed in the control sample compared to affected individual B-II:1. The ratio of 
normal transcript containing exon 11 and the transcript lacking exon 11 in individual B-II:1 is 
quantified as 1:4, whereas in the control this ratio is 1:1. C) Sequence analysis of the abundant 
cDNA product in the CHX treated samples shows the exon transition from 11 to 12. The C 
residue was not detected at position c.1102 of individual B-II:1, indicating that only cDNA of 
the other mutant (p.Glu336Gln) allele could be amplified. D) The right panel shows sequences 
of the aberrant product from exon 10 to 12, skipping exon 11.
age-threshold to develop neurological NCL features, with the exception of two unrelated indi-
viduals (age 9 and 10), who are too young to exclude the development of non-ocular features.
Another hypomorphic genetic variant that is associated with inherited retinal disease is the 
most frequent intronic variant in CEP290 (c.2991+1655A>G), which has only been found (homo-
zygous or compound heterozygous) in persons with LCA, whereas combinations of other 
(severe) CEP290 mutations can cause a broad range of syndromic phenotypes ranging from 
Senior Løken syndrome to the lethal Meckel Gruber syndrome phenotype.56
The retinal phenotype in individuals with vLINCL has not been documented in detail, although 
post-mortem NCL studies revealed neuronal degradation starting in the photoreceptor outer 
segments, followed by the inner segments. Subsequently neuronal cell bodies of the retina 
degenerate, progressing towards the ganglion layer. The RPE cells containing lipopigments may 
proliferate and enter the depleted neuronal retinal layers.57 In the retina, lysosomes in the RPE 
play a role in the phagocytosis of photoreceptor outer segments. Kim et al (2013) reported that 
a noncanonical autophagy pathway, involving Atg5 and LC3 triggering phagosome fusion with the 
lysosome, is also involved in photoreceptor outer segment degradation.58 Elevated lysosomal 
pH is also noticed in cultured RPE cells of the Abca4-/- mouse and human ARPE-19 cells exposed 
to N-retinylidene-N-retinylethanolamine (A2E), tamoxifen or chloroquine. After restoring the 
lysosomal pH by directly elevating the intracellular cAMP, an enhanced photoreceptor outer 
segment clearance was observed. This showed that an elevated lysosomal pH interfered with 
degradation of outer segments and the contribution to the A2E associated pathologies.59 
Recently, two general strategies were investigated towards treatment of individuals with NCL. 
The identification of a master regulator of lysosomal biogenesis and autophagy, transcription 
factor EB, has uncovered the adaptive behavior of lysosomes in response to environmental cues 
as starvation. A novel therapeutic strategy may be developed to modulate lysosomal function 
in human disease by targeting transcription factor EB.60 A second strategy to treat NCL is 
directed to suppress the reactive Müller glia cells, which, due to photoreceptor degeneration 
induce rapid loss of vision and retinal function by releasing toxins. Dietary supplementation 
with immuno-regulating compounds, curcumin and docosahexaenoic acid, resulted in a reduced 
number of reactive Müller glia and improved retinal function. Moreover, intake of docosahexae-
noic acid also improved the retinal morphology by preservation of the photoreceptor layer 
thickness.61 Our hypothesis that non-syndromic retinal degeneration is caused by relatively mild 
MFSD8 deficiencies could imply that only a minor increase of protein function, or suppression 
of Müller cell activation, could result in a significant therapeutic effect. 
In conclusion, employing linkage analysis and exome sequencing, mutations in MFSD8 were 
identified as a novel cause of non-syndromic macular dystrophy with central cone involve-
ment. This finding highlights the genetic overlap between lysosomal storage disorders and non-
syndromic inherited retinal dystrophies, which opens new avenues for treatment by targeting 
lysosomal dysfunction.
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Supplemental Table 3 Variants after stringent filtering for family B
Gene 
name Genomic Protein Coverage
% 
varia-
tion
SNP 
frequency
Frequency
In house- 
database PhyloP
Gran-
tham
SNP 
identity
Homozygous
CREB3L2 300GGTG>A p.Thr100del 2 100 -1 0 1.812 1000 rs66593747,
rs111266186,
ITIH6 2261G>A p.Thr754Met 75 96 0.4898 0.23 -0.001 81 rs41306886
SHCBP1 14G>A p.Ser5Leu 5 80 -1 0 -0.339 145
Compound heterozygous
CENPT 1333G>A p.Arg445Trp 9 44.4 -1 0 0.369 101
CENPT 782G>A p.Thr261Met 45 44.4 -1 0.08 0.261 81
MFSD8 1102C>G p.Asp368His/p.? 34 50 -1 0 5.543 81
MFSD8 1006C>G p.Glu336Gln 88 43.9 0.1776 0.46 5.543 29 rs150418024
Supplemental Table 1 MFSD8 gene primers
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Exon Forward Reverse Product size (bp)
exon 1 tcaactcccacgtttcagc aggtagaggtggcttccagc 213
exon 2 gatgggagaaagcaggtgtc ggaaaggaaccagtcccaac 184
exon 3 tctgtgcatgtcaatggtagc caaagtttgctagggcttgg 652
exon 4 taaaatccatgccacggttc gcacaataaagcatatggtcac 308
exon 5 gcgctaatggctgtttaacg ggaggtctccctatgttaccc 985
exon 6 ggtccattaattgatgcatttg tttcctccctttcccttcag 410
exon 7 ccccatcaagaaccaattcc cttcaaagaccttccttttctg 511
exon 8 gtaggggaaaggcatggaag aagatcttccccaatcaccc 639
exon 9 tgggcgtggtagtacatctg tgcacaaggcagagattttg 851
exon 10 aaaaggcatgcacattcttg ttttcctggtatatccatttgc 337
exon 11-12 tttgctgtgaaagatctgagc ccacaatgccactcctacaac 892
exon 11 (alternative) tttgctgtgaaagatctgagc agctgatgtaaggaactggg 589
exon 12 (alternative) caatttcccaaaatacagtg ccacaatgccactcctacaac 583
exon 13 agggcttcagcagacagtaag tcaccgcaattgtctagcag 512
mRNA variants
exon 10-12 acaatggatatgtatgcctgg cagctgatgtaaggaactgg 391
exon 11-12 tgctattctactgggaggac cagctgatgtaaggaactgg 260
GUSB ctgtacacgacacccaccac tacagataggcagggcgttc 245
Supplemental Table 2 Variants after stringent filtering for family A
Gene Genomic Protein Coverage
% 
varia-
tion
SNP  
frequency
Frequency 
In house- 
database PhyloP
Gran- 
tham
SNP  
identity
Compound heterozygous
MFSD8 c.1141C>A p.Glu381* 52 57.7 -1 0 2.544 1000
MFSD8 c.1006C>G p.Glu336Gln 71 38 0.1776 0.46 5.543 29 rs150418024
MUC6 c.4232G>A p.Thr1411Met 9 55.5 -1 0 1.282 81
MUC6 c.1532A>G p.Leu511Pro 37 37.8 -1 0 2.342 98
XDH c.1274G>C p.Ser425Cys 47 17 0.0879 0.23 3.245 112 rs138649664
XDH c.364T>A p.Met122Leu 32 25 -1 0.15 5.075 15
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funCtion of novel disease genes
The genetic studies described in this thesis have lead to the discovery of several new genes 
involved in CD: PDE6C (Chapter 4A), RAB28 (Chapter 4B) and MFSD8 (Chapter 4C). In addi-
tion, several genes previously implicated in other retinal dystrophies were found to be involved 
in CD: TULP1 (Chapter 3A) and CEP290 (Chapter 3B). New gene findings contributed to an 
increased knowledge on the disease mechanisms in CD and can potentially result in the eluci-
dation of novel pathways involved in the development of CD. Thus far, genes causing CD were 
found in major pathways of the visual system like the phototransduction cascade, retinoid cycle, 
transport processes, disk membrane morphogenesis, and synaptic transduction (Chapter 1.2; 
review). Mutations in PDE6C were identified in ACHM cases by a combination of homozygosity 
mapping and a positional candidate gene approach. PDE6C was considered a strong candidate 
gene due to its crucial role in cone phototransduction, and due to functional evidence of rapid 
cone degeneration in zebrafish with a Pde6c defect.1 
PDE6C defects lead to CD due to the absence or reduced activity of the α’ subunit caus-
ing reduced hydrolysis of cGMPresulting in the reduction of loss of the catalytic activity.2; 3 
As a consequence the phototransduction cascade is interrupted and the cone photoreceptor 
remains in the dark state.2 
The identification of mutations in three proteins localizing to the connecting cilium in this 
thesis (CEP290, RAB28 and TULP1) stresses the role of disrupted ciliary processes in the 
pathogenesis of IRDs, and may indicate that many other ciliary proteins can be defective in 
persons with CDs. This process is highly important for the transport of proteins from the 
inner segment towards the outer segment and vice versa; which is crucial for the develop-
ment and homeostasis of cone photoreceptors. The exact function of some newly identified 
CD-associated proteins, such as RAB28, is currently unknown and requires further studies, 
such as protein localization and interaction studies, as well as in vivo analyses in animal models. 
Interestingly, the identification of MFSD8 mutations in this thesis pinpoints lysosomal dysfunc-
tion as a novel disease mechanism in non-syndromic CD. Syndromic CD has previously been 
found to be due to lysosomal dysfunction through LAMP2 defects observed in Danon disease.4 
More recently more cases of nonsyndromic retinal dystrophy (RP, LCA and CRD) have been 
described to be caused by a defect in the lysosomal protein CLN3.5; 6 Further studies are war-
ranted to determine the exact role of the transmembrane protein MFSD8 in the lysosomes, 
and how variants in this gene result in non-syndromic photoreceptor dysfunction.
uniParental isodisomy
The association of CD with TULP1 mutations was facilitated by the discovery of an individual 
with uniparental disomy (UPD), which is a rare phenomenon that occurs approximately in 
1:5000 or even less individuals.7 This event can lead to the inheritance of two copies of a 
chromosome carrying a recessive mutation from the same parent, resulting in disease. Similar 
to our case, the majority of the cases seem to be associated with an advanced maternal age.8 
Only seven other cases of maternal UPD of chromosome 6 have been described previously.9-15 
Of these, several cases were diagnosed with intrauterine growth retardation, which was also 
suggested for our case. Other retinal dystrophies in which UPD was involved were caused 
by mutations in MERTK, RPE65 and USH2A on chromosome 1, 1 and 2, respectively.16-18 UPD 
could play a role in more cases of CD, which can be identified through dedicated homozygosity 
mapping or homozygous calls in WES.
hyPomorPhiC mutations in syndromiC disease genes in Cd
Strikingly, two novel CD-associated genes identified in this thesis, CEP290 and MFSD8, have 
previously been implicated in multi-systemic syndromes. Based on the mutations identified in 
these genes, we hypothesize that combinations of severe and mild variants, or the combination 
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of two moderately severe variants, can result in CD because of residual protein activity, while 
loss-of-function mutations lead to more severe, multi-system syndromes. The phenotypic 
spectrum of CEP290 mutations was previously established to be broad, ranging from early-
onset non-syndromic retinal dystrophies (Leber congenital amaurosis or early-onset retinitis 
pigmentosa) to syndromes involving neurological and renal disorders (Senior-Løken, Joubert 
syndrome, Bardet-Biedl syndrome), to Meckel-Gruber syndrome leading to prenatal lethal-
ity.19 Although it remains difficult to establish an exact genotype-phenotype correlation for 
CEP290 mutations in these different diseases,20 we were able to add another phenotype to the 
CEP290 disease spectrum. In this thesis we describe two compound heterozygous truncat-
ing mutations in CEP290 that cause CD. Usually, truncating mutations result in a shortened 
protein or the absence of protein, since the aberrant transcripts may be degraded by the 
process of nonsense mediated decay (NMD). NMD serves as a protective mechanism against 
translation of mRNAs containing a premature termination codon likely resulting in a truncated 
protein with dominant-negative or deleterious gain-of-function properties.21 However, studies 
on mutational mechanisms have unraveled cases of truncating mutations undergoing nonsense-
associated altered splicing (NAS). This mechanism is presumed to correct the translated pro-
tein by excluding one or more exons from the mature mRNA when a premature termination 
codon is recognized, leading to a restoration of the open-reading frame.22 Using RNA studies 
it was demonstrated that both RNAs carrying truncating CEP290 mutations identified in CD 
(p.(Arg151*) and p.(Lys1575*)) undergo NAS, in both cases leading to a restoration of the open 
reading frame. The p.(Arg151*) mutation was previously described in non-syndromic early-
onset retinal dystrophy,23 whereas p.(Lys1575*), with one exception, was described to cause 
LCA when found in a homozygous state.20; 24  In a compound heterozygous state this variant 
was described to cause LCA, Senior Løken or cerebello-oculo-renal syndrome, depending on 
the severity of the second allele.20; 24-27 Although the hypomorphic character of p.(Arg151*) and 
p.(Lys1575*), p.Leu148_Glu165del/wildtype and p.Glu1569Glyfs/wildtype respectively, provide 
new insights into the genotype-phenotype correlation of CEP290 mutations, it remains unclear 
how these two mutations cause oligocone trichromacy rather than a pan-retinal, early-onset 
retinal dystrophy previously associated with these mutations. The second unexplained event 
is the occurrence of initial cone defects in these individuals, with progressive rod defects 
later in life. Though, a distinct function for CEP290 in cones and rods has been suggested. 
Potentially the skipped exons harbor essential functional domains for proper function in the 
cones, whereas rod function is longer retained. As the clinical examinations in these individuals 
uncovered a progressive peripheral degeneration one could argue that the cones are more 
vulnerable compared to rods due their higher metabolism.
In this thesis, I also established a novel genotype-phenotype correlation for MFSD8 by the dis-
covery of mutations in this gene in families with CD. Defects in the lysosomal transmembrane 
protein MFSD8 were previously associated with variant-late infantile neuronal ceroid lipofusci-
nosis (vLINCL), an early-onset severe syndromic lysosomal disorder with fatal outcome within 
in the second decade of life.28; 29 Although visual impairment is the first feature in most persons 
with vLINCL, whole exome sequencing (WES) unexpectedly enabled us to associate MFSD8 
mutations to a non-syndromic CD phenotype. Although we cannot completely exclude that 
these individuals may develop extra-ocular features in the future, their advanced age (current 
ages 55-73) demonstrates a tremendous phenotypic difference compared to vLINCL. Persons 
diagnosed with vLINCL usually present two rare severe (truncating) mutations, while in the 
non-syndromic CD individuals presented in this thesis were found to carry a rare severe muta-
tion in combination with a predicted mild mutation. The truncating mutations in this study 
were previously described to cause vLINCL in combination with other severe mutations.30; 31 
The second allele, classified by us as mild, was not described previously in vLINCL cases and 
was present in 0.19% of the alleles in the Caucasian population.
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The studies described in this thesis have important implications for future studies directed 
towards disease gene identification in CD. Future studies, in most cases, will be based on WES 
as it is most time- and cost-effective. Often, it is not easy to pinpoint the genetic defect(s) 
among the large number of variants that are identified by WES. However, several lessons can 
be learned from the gene identification studies we present in this thesis. 
First of all, the identification of mutations in three genes encoding proteins localized in or 
near the connecting cilium (CEP290, RAB28 and TULP1) demonstrates that genes encoding 
ciliary proteins are excellent candidate genes for CD. Upcoming gene identification approaches 
should thus take such genes into consideration. These studies could include experiments to 
unravel protein-protein interactions of the known ciliary CD-associated proteins, which may 
not only give clues about its functional network in the connecting cilium but also enable the 
identification of novel candidate genes. Alternatively, candidate gene directed searches can 
be performed in online ciliary databases based upon functional relevance or interactions with 
known CD proteins.
Second, our results show that it is critical when analyzing WES data to consider genes associ-
ated with various retinal phenotypes as candidate genes for CD. Different functional effects 
of variants in known CD genes can lead to unexpected phenotypes. For example, an effect 
on splicing, as demonstrated in this thesis for CEP290 mutations, which lead to the skipping 
of exons carrying a truncating mutation, can also be induced by missense or silent mutations 
disrupting an exonic splice enhancer and thereby affecting the process of splicing. The mecha-
nism behind this oligocone trichromacy seems to be caused by NAS, preserving an intact 
protein lacking the in-frame exon 36. Although the exact mechanism of NAS has not yet been 
revealed,22; 32 it potentially enables us to explain multiple milder or unexpected phenotypes 
of disease in the future. The potential effect of all types of variants on splicing should thus be 
taken into account when analyzing WES data. 
Third, a group of genes previously described to be involved in various syndromes unexpectedly 
are associated with with non-syndromic CD. In this thesis, we detected mutations in MFSD8 as 
a cause of non-syndromic CD due to the combination of a severe and a mild mutation. Several 
other genes associated with syndromes have been involved in retinal dystrophies, like CEP290 
for which in this thesis another phenotype has been added to the disease spectrum. In addition, 
mutations in the CLRN1 gene cause Usher syndrome as well as non-syndromic RP,33 defec-
tive IQCB1 underlying Senior-Løken disease can also lead to non-syndromic LCA,34 and muta-
tions in BBS1 provoke Bardet-Biedl syndrome or non-syndromic RP.35 The mild p.Met380Arg 
allele found in BBS1 is described in 21/4,014 (0.52%) alleles in RP probands versus 8/3,648 
(0.22%) control alleles. Interestingly, the occurrence of this hypomorphic BBS1 mutation as 
a low-frequency variant in the population is in line with our finding in MFSD8. In our cases, 
the p.Glu336Gln variant in MFSD8 is found 1/302 (0.3%) in ethnically matched control alleles, 
in 6/2,604 alleles (0.23%) of the in-house exome database, 25/12,006 alleles (0.19%) in the 
Exome Variant Server and 1/1000 (0.1%) in the 1000genomes project. The high prevalence 
in control individuals argues to increase the filter to <2% in dbSNP and in-house database 
to allow the identification of mild variants which can occur relatively frequent in the general 
population as long as they are not associated with a retinal phenotype in a homozygous state. 
The highest frequency of a mild genetic variant associated with an IRD is the c.2588G>C 
(p.Gly863Ala/DelGly863) variant in ABCA4, which was found heterozygously in ~3% of Dutch 
controls and (in a compound heterozygous state) in 1/3 of persons with Stargardt disease.36; 
37 The involvement of MFSD8 in non-syndromic CD reveals an unexpected group of lyso-
somal genes with possible involvement in CD. vLINCL belongs to a family of neuronal ceroid 
lipofuscinosis (CLN) which can be due to variants in 14 members of CLN proteins of which 
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at least eight are associated with visual impairment.38 Visual impairment is the first symptom 
in the majority of these, but as the disease progresses over time and other features occur, 
therefore minor attention is assigned the retinal phenotype. For instance, it is unknown if the 
degeneration occurs in a cone-rod or rod-cone pattern. As mutations in CLN3 were recently 
described to cause non-syndromic RP and LCA,5; 6 we hypothesize that the other CLNs are 
potential candidate genes to cause non-syndromic CD, but also rod-dominated retinal disease. 
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WES facilitates disease gene discovery
Throughout the years, with the development of improved technological approaches, the rate 
of gene discoveries has grown linearly (Figure 1). Whereas the majority of genes has been 
discovered using traditional positional cloning approaches which made use of genetic linkage 
studies and candidate genes, already six genes have been discovered in the last two years with 
the implementation of WES.
Figure 1 Gene discovery for CD throughout the years
The large number of genes underlying IRD is illustrative of the high heterogeneity, and the num-
ber of disease genes is anticipated to increase when taking into account all currently unsolved 
cases (Figure 2). In 2014, the majority of all CD cases remain unsolved and the expectations 
are that these will largely be explained by rare gene findings, as the latest gene discoveries are 
represented by small numbers of families (Chapter 1.2).39 
imPlementation of wes in diagnostiCs 
Since a few years, WES has been integrated in the diagnostic screening methods for individuals 
with inherited disease. This was initiated with a targeted approach with probe arrays targeting 
including all coding exons, noncoding exons, and untranslated regions of 111 known blindness 
genes.41 This method resulted in the detection of causal variants in 36 RP probands in a reces-
sive, dominant or X-linked inheritance pattern. As these patients were derived from a larger 
group of families pre-screened for variants in several RP genes, the corrected yield was ~54%. 
Surprisingly, three out of 28 (10.7%) isolated cases showed a de novo causative mutation, hav-
ing a large effect on the subsequent genetic counseling.41 The targeted approach was quickly 
replaced by the current WES in diagnostics. Although this routine implies a filtering step show-
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exonic mutations due to a lack of family members for segregation analysis or discrepancies of 
in silico prediction programs.42 Besides the identification of exonic and intronic variants in an 
individual genome, WGS can robustly identify heterozygous deletions, duplications, inversions, 
and intronic variants.48 The issues regarding confirmation of pathogenicity may be partially 
diminished by testing large patient cohorts through collaborative efforts. In addition, the cau-
sality of novel variants can be tested through cellular and animal models. 
Figure 2 Genetic heterogeneity in inherited retinal disease 
Clinical diagnoses are indicated by colored circles. Genes in the overlapping areas represent 
genes in which mutations can lead to multiple phenotypes. COD/CRD: cone and cone-rod 
dystrophy; CVD: color vision defects (ACHM, blue cone monochromatism, oligocone trichro-
macy, tritanopia); MD: macular degeneration; ERVR/EVR: erosive and exudative vitreoreti-
nopathies. Adapted from updated figure from Berger et al. 2013.40
Future research in the identification of novel genes as a cause of CD could be facilitated by the 
expansion of public databases currently containing data of thousands of human genomes. Using 
the exome variant server (12,006 alleles), 1000genomes project (2,184 alleles), an in-house 
database (5,812 alleles) together with panels with DNA of ethnically matched control samples 
(384 alleles), we are able to generate a fair estimate of the allele frequency of specific variants. 
The ongoing growth of these public and local databases will allow more reliable assessments of 
allele frequencies of candidate variants. Potentially, this can be done in a more origin-specific 
fashion by detailed registration of the individuals’ background such as place of birth from the 
individuals and their parents, and thereby determine the origin of a specific variant.
In a similar way, with the expansion of human genome data, the knowledge on the effect of 
variants is likely to grow. This knowledge can be used as training sets for in silico programs and 
ing only variants within the boundaries of previously assigned genes, in this case genes causing 
IRD. Especially in heterogeneous diseases like IRD, WES can be time-saving and cost-effective 
as all kinds of genetic variation at base-pair resolution can be identified throughout the human 
genome in a single experiment compared to traditional Sanger sequencing which would cost 
many years and millions of Euros. WES provides an unbiased analysis when a clinical diagno-
sis may be incomplete as non-ocular features such as late onset of kidney dysfunction, may 
appear later in life. In addition, the age of the investigated individual can influence the final 
diagnosis, the end stage of some diseases tend to overlap significantly, like CRD and rod-cone 
dystrophies.42 Finally, identification of the genetic defect can help to determine the pattern of 
inheritance, in particular in isolated cases which can be due to mutations in genes implicated in 
autosomal dominant, recessive or X-linked genes, some of which can be de novo.41
WES may also identify multigenic causes of IRDs. In the era of Sanger sequencing but also in 
WES, it may occur that cases with additional features are incorrectly addressed to defects in a 
single gene as other genes will not be analyzed after the gene defect has been elucidated. One 
would continue the investigation for the involvement of multiple genes in exceptions to these, 
i.e. families which include differences in phenotypes or features. The involvement of a second 
gene may be unmasked faster by analysis if the entire genome, however, in most cases addition-
al functional analysis are required to proof the additive or protective effect of a second gene. 
Moreover, the direct analysis of an entire exome would prevent reporting mutations of uncer-
tain pathogenicity to the patient, while mutations outside the filter could immediately result in 
convincing mutations as the cause of the IRD in the individual. Furthermore, the analysis of the 
entire exome of an affected individual makes it possible to investigate in a single experiment all 
possible combinations of genetic modifiers which result in phenotypic variability.
unCovering non-Coding mutations by transCriPtomiCs and whole-
genome sequenCing
Although WES facilitates the discovery of rare variants, elucidation of complex and unexpected 
modes of inheritance, still a subset of pathogenic mutations is still missing. Excellent examples 
are the deep intronic mutations in CEP29043 and USH2A,44 which result in the ‘exonification’ 
of intronic sequences containing stop mutations. To identify mutations explaining genetically 
unsolved cases, transcriptomics offers a powerful approach in studying the transcriptional 
landscape of a specific cell or tissue. Recently, transcriptome analysis on RNA from human 
donor eyes was used to perform deep mRNA sequencing of the ABCA4 mRNA, uncovering 
19 alternative splice products of ABCA4, the most frequently mutated IRD gene.45 Sequencing 
these alternative exons in individuals with STGD1 revealed five deep-intronic variants with an 
effect on splicing by creating novel splice sites. Furthermore, human retinal tissue was shown 
to carry 79,915 novel alternative splice events and over a hundred novel genes were elucidated. 
It was presumed that 15-36% of these will be transcribed into coding transcripts, as they con-
tain an open reading frame.46 Transcriptomics may not be applicable in all cases as the affected 
tissue must be analyzed and compared to tissue in the healthy situation. One option could be 
performing transcriptomics on blood cells, however gene expression profiles may differ in each 
tissue or potentially completely absent. In these cases other cell systems have to be used to 
study IRD defects. An example is the differentiation of induced pluripotent stem cells (iPSC) 
into photoreceptor precursor cells and/or retinal pigment epithelium. This is possible by repro-
gramming patient’s fibroblasts or keratinocytes (derived from a skin biopsies) into iPSCs, which 
can be subsequently differentiated to the preferred cell type for further studies.47
Transcriptomics will be performed in parallel to whole genome sequencing (WGS) which 
reveals almost all (~ 3 million) genomic variants . The huge challenge resides in the confirma-
tion of the pathogenic effect of intronic variants, which occasionally is still troublesome with 
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are likely to determine the effect of other/similar candidate variants with higher levels of con-
fidence. Better than in silico analyses would be to perform functional approaches to determine 
the effect of each variant or assess the gene function to draw a conclusion on the pathogenicity 
of this particular variant.
Clinicians can facilitate the process of gene identification by performing detailed clinical exami-
nations of ocular and non-ocular features. Detailed clinical examination of a patient prior to 
genetic studies allows geneticists to anticipate on possible novel candidate genes. Analysis of 
DNA of the patients’ parents and affected and unaffected siblings allows to determine the 
pathogenicity of a variant, a possible unexpected inheritance pattern and the recurrence risk in 
siblings or offspring. Exome sequencing for all affected individuals for a family quickly excludes 
the majority of variants as the assumption is that all affected members from a family carry the 
same gene defect(s). Therefore only variants present in both individuals have to be investigated. 
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introduCtion
Many proteins require posttranslational modification to function in several cellular processes. 
Protein prenylation is a posttranslational lipid modification which allows protein-protein inter-
actions and ensures correct cellular localisation of the protein via covalent attachment of one 
or two prenyl groups (farnesyl or geranylgeranyl).49-52 Prenyl residues belong to a large family 
of chemicals consisting of terpenoids. In animals, these compounds may contain from one to 
six isoprene units, each containing a 5-carbon backbone; higher polyterpenoids are present in 
bacteria and plants (e.g. rubber, consisting of long chains of isoprene subunits). Farnesyl and 
geranylgeranyl residues consist of three and four C5 isoprene units, respectively. Protein farne-
sylation and geranylgeranylation may provide lipid residues necessary to anchor the respective 
proteins to cell membranes or intracellular membranous structures. The covalent attachment 
of prenyl groups occurs through a thioether bond to one or two cysteines at, or in close 
proximity of, the carboxy-terminus of the protein. More than 100 proteins, collectively called 
the prenylome, are involved in the molecular pathways producing these lipid moieties, or serve 
as potential substrates for prenylation,53 PRENbase (http://mendel.imp.ac.at/PrePS/PRENbase/, 
date accessed 22 October 2013 54). 
In vision-related phenotypes, the first prenylation defects were identified in persons with 
choroideremia (CHM). Mutations in the choroideremia CHM gene that encodes Rab escort 
protein-1 (REP-1), a subunit of the geranylgeranyltransferase II (GGTase II; also called Rab gera-
nylgeranyltransferase) protein complex, were found to cause progressive atrophy of the cho-
roid, retinal pigment epithelium (RPE) and photoreceptors, resulting in visual impairment that 
eventually leads to blindness.55; 56 Since then, variants in genes encoding prenylated proteins, 
chaperones of prenylated protein, or other proteins involved in prenylation, were discovered 
to underlie inherited retinal diseases (IRDs). Herewith, we will summarise the knowledge on 
these proteins and hypothesise on the underlying molecular mechanisms that may be common 
in these diseases.
Prenylation
Prenoid synthesis pathway
Farnesyl and geranylgeranyl residues are synthesized from acetyl coenzyme A via the mevalon-
ate pathway, which was discovered in the early 1950s.57 This process, also called the terpenoid 
or isoprenoid backbone pathway, is a crucial mechanism of creating sterols, including choles-
terol, ubiquinone, squalene and dolichol, which play key roles in various metabolic pathways. 
Noteworthy, unlike in plants, protozoa and bacteria, where the so-called MEP/DOXP pathway 
represents an alternative to obtain these compounds, in higher organisms these molecules 
must exclusively be synthesized through the mevalonate pathway (Supplemental Figure 1).
Starting with two molecules of acetyl-coenzyme A, the terpenoid synthesis continues to meva-
lonic acid via 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA reductase is a rate-
limiting enzyme of the pathway. Hence, it has been targeted as a crucial phase to reduce the 
endogenous cholesterol synthesis in patients with hypercholesterolaemia.58 Ever since then, 
HMG-CoA inhibitors (statins) have been successfully used for diminishing cholesterol levels. 
The product of the next step, mevalonic acid, is converted into phosphomevalonate by meva-
lonate kinase (MVK). At the end of this pathway, the farnesyl and geranylgeranyl residues are 
synthesized directly from isoprenyl diphosphate and subsequently attached to various proteins 
by prenyltransferases in the process called prenylation, which provides posttranslational modi-
fication essential for membrane attachment and protein-protein interactions.
Prenylation process
The prenyltransferases represented by farnesyltransferase (FTase) and geranylgeranyltransfer-
ase (GGTase-I), consist of two subunits, an α and β subunit; in FTase and GGTase-I the α sub-
summary
Many proteins depend on posttranslational prenylation for a correct subcellular localisation 
and membrane anchoring. This involves the covalent attachment of farnesyl or geranylgeranyl 
residues to cysteines residing in consensus motifs at the C-terminal parts of proteins. Retinal 
photoreceptor cells are highly compartmentalised and membranous structures, and therefore 
it can be expected that the proper function of many retinal proteins depends on prenylation, 
which has been proven for several proteins that are absent or defective in different inherited 
retinal diseases (IRDs). These include proteins involved in the phototransduction cascade, such 
as GRK1, the phosphodiesterase 6 subunits and the transducin γ subunit, or proteins involved 
in transport processes, such as RAB28 and retinitis pigmentosa GTPase regulator (RPGR). In 
addition, there is another class of general prenylation defects due to mutations in proteins 
such as AIPL1, PDE6D and rab escort protein-1 (REP-1),which can act as chaperones for sub-
sets of prenylated retinal proteins that are associated with IRDs. REP-1 also is a key acces-
sory protein of geranylgeranyltransferase II, an enzyme involved in the geranylgeranylation 
of almost all members of a large family of Rab GTPases. Finally, mutations in the mevalonate 
kinase (MVK) gene, which were known to be principally associated with mevalonic aciduria, 
were recently associated with nonsyndromic retinitis pigmentosa. We hypothesise that MVK 
deficiency results in a depletion of prenyl moieties that affects the prenylation of many proteins 
synthesized specifically in the retina, including Rabs. In this review, we discuss the entire spec-
trum of prenylation defects underlying progressive degeneration of photoreceptors, the retinal 
pigment epithelium and the choroid.
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the CaaX-prenyltransferases, the heterodimer GGTase-II is unable to prenylate any peptide 
without the use of an accessory REP as a substrate.62; 63 The gene encoding the α subunit of 
GGTase-II (RABGGTA, Rab geranylgeranyltransferase, α subunit) was found to be mutated in 
the gunmetal mouse, a model of Hermansky-Pudlak syndrome;64 however, thus far no mutation 
in this gene was identified in humans with this syndrome.
In the retina, the cyclic GMP phosphodiesterase 6α subunit, transducin γ subunit, rhodop-
sin kinase and ceroid lipofuscinosis neuronal 3 protein are substrates for FTase, whereas the 
cGMP phophodiesterase 6β subunit and X-linked retinitis pigmentosa (RP) GTPase regulator 
(RPGR) are substrates for GGTase-I. These proteins will be discussed below.
genes imPliCated in general Prenylation-assoCiated retinal diseases
Rab escort protein-1
The first retinal prenylation defect was identified when protein-truncating mutations in, or 
deletions of CHM , the gene encoding REP-1, a chaperone for Rabs and a crucial accessory pro-
tein of GGTase-II, were found to be the cause of X-linked choroideremia.55; 65 In this disease, 
there is a progressive mid-peripheral atrophy of the retina, RPE and the choroid, which results 
in night blindness, tunnel vision and eventually blindness. REP-1 is known to bind unprenylated 
Rabs and presents them to the GGTase-II heterodimer for geranylgeranylation (Figures 1 and 
2).56; 66 Despite the ubiquitous expression of CHM, only the retina and choroid are affected in 
male patients with mutations in this gene. This is explained by the compensation of geranyl-
geranylation of most Rab GTPases by REP-2 in all tissues except the eye. Indeed, REP-2 shows 
functional overlap with REP-1.67 Possibly, REP-1 preferentially prenylates a subset of retinal 
Rabs through a higher substrate affinity compared with REP-2. Larijani et al.68 proved that in 
cells of choroideremia patients, Rab27a accumulated in an unprenylated state due to differ-
ences in its ability to bind REP1 and REP2. The REP2-Rab27a complex was shown to have a 
lower affinity for GGTase II compared with REP1-Rab27a. Defects in intracellular membrane 
traffic pathways, including melanosome transport and phagosome processing, were described 
for the defective REP-1 protein.69 REP-1 was also shown to be essential for geranylgeranylation 
of RAB27A in lymphoblasts isolated from choroideremia patients, meaning that defective REP-
1 results in an accumulation of unprenylated RAB27A, specifically in the RPE.70 Missense muta-
tions in RAB27A result in a dysfunction in melanosome transport and regulation, as RAB27A 
cannot recruit the effector MyRip (Myosin VIIA and Rab-interacting protein) that regulates 
melanosome transport in the RPE in complex with RAB27A and MYO7A.71; 72 These mutations 
cause Griscelli syndrome, which is characterised by cutaneous albinism and immunodeficien-
cy.73 Both of these features are not described in choroideremia patients, and thereby provide 
no clue as to the crucial cellular defect(s) underlying this disease.
Several preclinical studies have been carried out to develop a therapy for choroideremia. 
Contrary to males with choroideremia that only show a chorioretinal defect, male Chm knock-
out mice are not viable due to trophoblast defects at embryogenesis.74 To overcome this early 
lethality, Tolmachova and colleagues developed conditional knockout models in which Rep-1 
was exclusively depleted either in the neural retina or in the RPE. In both models, defects were 
seen in the neural retina or RPE, respectively, suggesting cell-autonomous pathologies.75 This 
disease therefore requires a therapeutic approach preferably targeting both cell types.
HIV-based lentiviral vectors have been used for in vivo CHM gene transfer studies.76 Rep-1-
deficient mice received a subretinal injection with a vector that expresses CHM under the con-
trol of the elongation factor-1 α promoter and showed a specific transduction of the RPE for 
6 months. Functional restoration was confirmed by a reduced number of unprenylated Rabs.
A second therapeutic strategy involves the use of adeno-associated virus (AAV) serotype 
2-based vectors to transduce both photoreceptor cells and the RPE. In conditional knockout 
mice, it showed efficient RPE transduction and compared to the lentiviral approach allowed 
unit is encoded by the same gene, FNTA (farnesyltransferase, CAAX box, α; Figure 1). All genes 
encoding the α subunits of the prenyltransferases are members of the tetratricopeptide repeat 
family, which includes proteins that are functionally relevant in the process of transcription, 
transport, co-chaperoning, control of the cell cycle and phosphorylation.59 The β subunits, 
although less thoroughly investigated, are hypothesized to function in lipid anchor attachment 
or catalytic activity involving polyisoprenes. In general, the obtained products are processed to 
essential substances like cholesterol, steroid hormones or vitamin D and equivalents to these.
The CaaX prenyltransferases, FTase and GGTase-I, can catalyse the modification of peptides 
and substrate proteins containing the Ca1a2X-motif (where C = cysteine, a1a2 = two aliphatic 
amino acids, being more flexible in a1, X = C, S, Q, A, M, T, H, V, N, F, G or I for FTase and 
L, F, I, V, M for GGTase-I).60; 61 Subsequently, CaaX endoprotease causes removal of the ‘aaX’ 
residue and methyl esterification of the carboxyl-group at the terminal cysteine. 
Figure 1 Overview of proteins taking part in or being dependent on prenylation
Schematic representation of the proteins which are prenylated and proteins taking part in pre-
nylation process in the retina. Mutations in some of their corresponding genes were discovered 
to cause choroideremia (CHM), cone-rod dystrophy (CRD), congenital stationary night blind-
ness (CSNB), Joubert syndrome (JS), Leber congenital amaurosis (LCA), mevalonate kinase 
deficiency (MKD), retinal disease (RD) and retinitis pigmentosa (RP). Proteins for which knock-
out mice displayed retinal disease are marked with a hash (#). Alpha (α) and beta (β) subunits 
of the prenylation enzymes encoded by different genes are depicted in different shades of grey.
The third prenyltransferase, called non-CaaX-prenyltransferase, Rab geranylgeranyltrans-
ferase or geranylgeranyltransferase-II (GGTase-II; used hereafter), recognises Rab (member 
RAS oncogene family) proteins with a CC, CXC, CCX, CCXX, CCXXX or CXXX termina-
tion sequence, where methyl esterification only occurs in the CXC residues. In contrast to 
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were diagnosed with retinal degeneration.100-102 Recently, we reported that mutations in MVK 
cause late-onset nonsyndromic RP, which may be accompanied by mild MKD features.103
It was previously hypothesized that neuronal degeneration observed in MEVA could be a result 
of toxic mevalonic acid levels in the brain. The same process may also underlie photoreceptor 
degeneration.101 However, the spectrum of disorders associated with MVK mutations is wide 
and it is difficult to assess the role of external factors in this process. Recently, in an attempt to 
lower the toxic levels of mevalonate, lovastatin and simvastatin were applied in MKD. However, 
the results were ambiguous. The administration of lovastatin in patients with classic MEVA 
caused severe crisis (high fever, acute myopathic changes, diarrhoea) and the trial had to be ter-
minated.104 Conversely, in HIDS, the administration of simvastatin resulted in reduced excre-
tion of mevalonic acid and a decreased number of febrile days.105 In patients displaying retinal 
dystrophy these medications have not yet been tested. It has also been hypothesized that the 
unique isoprenoid metabolism in photoreceptors is responsible for MVK-associated retinal 
degeneration.100 Intriguingly, the same mutations that have previously been described to cause 
MEVA were shown to result in MKD displaying predominantly the RP phenotype. Clearly, 
we still lack fundamental knowledge on the action of other proteins, often referred to as the 
‘genetic background’. It may be hypothesized that mutations in other proteins may rescue the 
severe neurological phenotype, perhaps by alleviating the toxicity of mevalonic acid in these 
tissues, while the retina would remain affected. The contribution of epigenetic and/or environ-
mental factors should also be taken into consideration. For example, an enhanced expression 
of a downstream enzyme may set the prenylated residues to a level acceptable in neurons. 
However, it may be still insufficient for the correct function of photoreceptors, which possess 
many membranous structures and therefore are more dependent on prenylated proteins.
Prenylated Proteins mutated in nonsyndromiC retinal diseases
Guanine nucleotide-binding protein subunit gamma, Tγ 
The γ chain of transducin is encoded by GNGT1 (guanine nucleotide binding protein gamma 
transducing activity polypeptide 1). Transducin is a membrane-bound heterotrimer contain-
ing α, β and γ subunits, and in its inactive state it is bound to a guanosine diphosphate (GDP) 
molecule. Activation by metarhodopsin II results in binding of guanosine triphosphate (GTP) 
and detachment of the α subunit from the membrane, which results in the activation of PDE6. 
The remaining subunits (called Tβγ) then diffuse to the inner photoreceptor segment. A CaaX 
motif is present on the α and γ subunits of rod transducin, but only the γ subunit has been 
found to be farnesylated.106 This modification is neither necessary for rhodopsin binding nor 
for the interaction with the α subunit. During dark adaptation dislocated transducin subunits 
must return to the outer segment for rod sensitivity restoration.107 It was established that this 
process may be mediated by the farnesyl residue;108 the potential Tγ partners include PrBP/δ 
and phosducin.
In the study by Lebanova et al.109, knockout of the gene encoding the transducin γ subunit in mice 
resulted in severe down regulation of α and β subunits of PDE6, despite normal mRNA levels. 
The mice also underwent fairly rapid photoreceptor degeneration. In contrast, Kolesnikov 
et al.110 described no retinal degeneration during the early stages of postnatal life. GNGT1 
has previously been suggested to play a role in human retinal degeneration disorders,111 but 
thus far no mutations have been found in this gene in human IRDs,112 which may be due to its 
relatively small size (225 bp open- reading frame) and the associated low mutation frequency. 
Mutations in the gene encoding the transducin α subunit, GNAT1, were identified in Nougaret-
type congenital stationary night blindness. These findings, along with the lack of photoreceptor 
degeneration in one of the mouse models, suggest that mutations in GNGT1 may be involved 
in a similar disease.
more potent transduction of neuroretinal cells.76; 77 The AAV2 vector, expressing REP-1 under 
the control of CMV-enhanced chicken β-actin promoter with a Woodchuck hepatitis virus 
post-translational regulatory element to enhance transgene expression vector, was able to 
provide efficient, functional and non-toxic transgene expression in diseased and healthy RPE 
and photoreceptor cells.78; 79 Currently, the first gene augmentation clinical trials using this vec-
tor are ongoing (clinicalTrials.gov Identifier: NCT01461213). No adverse effects of subretinal 
injections have been noticed in two groups consisting of three patients each.80
Aryl-hydrocarbon-interacting protein-like 1
Aryl-hydrocarbon-interacting protein-like 1 (AIPL1) functions as a chaperone for farnesylated 
proteins (Figures 1 and 2).81 AIPL1 has been found to be mutated in persons with autosomal-
recessive Leber congenital amaurosis (LCA) or autosomal-dominant cone-rod dystrophy.82 
AIPL1 is expressed in rods and cones in the early stages of retinal development,83 whereas in 
later stages expression is restricted to the rod photoreceptor cells.84 In Aipl1-/- mice, an LCA 
model, rapid rod degeneration is described, followed by cone degeneration.85; 86 Kirschman et 
al described a slower development of cone-rod degeneration in the absence of Aipl1, which was 
restricted to cone photoreceptor cells,87 This protein interacts with DnaJ (Hsp40) homologue, 
subfamily A, member 2 (DNAJA2), γ-transducin 81 and the α and β subunits of rod phosphodi-
esterase 88 in the presence of FTase. In the light of newly published research, it may be hypoth-
esized that, similarly to chaperoning PDE6 subunits,86 AIPL1 may function as a chaperone of 
other retinal Rab GTPases or proteins crucial in cone photoreceptors. 
Prenyl binding protein δ
PrBP/δ, encoded by the phosphodiesterase 6D, cGMP-specific, rod, delta (PDE6D) gene, facili-
tates intracellular trafficking.89 PrBP/δ was shown to interact in vitro with RPGR,90 the prenyl 
side chains of GRK1 and the PDE6α and PDE6β subunits.91 Due to its ability to solubilise 
prenylated proteins, a role in transport was suspected.92 Interestingly, through its binding to 
carboxy-terminal prenyl groups of the phototransduction proteins PDE6α and PDE6β, PrBP/δ 
dissociates the PDE6αβγγ complex from the rod segment membrane discs. Likewise, it is 
thought that PrBP/δ can dissociate RAB13 from the membrane.93 As RAB13 is also predicted 
to be farnesylated, PrBP/δ may also interact with other prenylated proteins, such as RAB28.94 
Pde6d-/- mice present with a slowly progressive rod-cone dystrophy,83 thereby making it an 
excellent candidate gene to be mutated in human retinal degeneration. Very recently, muta-
tions in this gene were discovered to result in Joubert syndrome.95 It was also shown that 
PrBP/δ function is required for ciliary targeting of INPP5E. INPP5E is also a farnesylated pro-
tein, and the loss of its CaaX box was earlier proven to cause MORM (mental retardation, 
truncal obesity, retinal dystrophy, and micropenis syndrome), with features similar to Bardet 
Biedl syndrome.96; 97
Mevalonate kinase
As mentioned above, MVK is an enzyme catalysing the transformation of mevalonic acid into 
phosphomevalonate. In a group of disorders called mevalonate kinase deficiency (MKD), this 
reaction is significantly hindered due to mutations in the MVK gene that encodes this enzyme. 
The metabolic block results in two distinct phenotypes of MKD: mevalonic aciduria (MEVA) 
or hyper-immunoglobulin D and periodic fever syndrome (HIDS). Both diseases may result 
from the same mutations within MVK; however, the clinical outcome is different.98; 99 MEVA is a 
severe condition characterised by progressive cerebellar ataxia, psychomotor retardation, and 
recurrent febrile crises, the latter usually being the only symptom occurring in HIDS. Several 
additional symptoms of MKD include abdominal complications and retinal dystrophy. Being a 
rare disorder, MKD has only been described in approximately 300 cases worldwide, 7 of which 
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Figure 2 General overview of visual phototransduction and ciliary transport 
Depicted is a scheme of rod phototransduction and transport process crucial for vision. 
Prenylated proteins, as well as proteins involved in the prenylation process discussed in this 
review are marked in colours: prenylated proteins are in orange, while chaperones are in green. 
Farnesyl and geranylgeranyl residues are depicted as a red and blue tags, respectively. PrBP/δ 
is depicted by delta (Pδ) in a green balloon. PDE6 subunits are marked as alpha (Pα), beta (Pβ), 
gamma (Pγ); transducin subunits are marked as (Tα), beta (Tβ), gamma (Tγ); and GGTase-II 
subunits are marked as GGTα and GGTβ; activated rhodopsin (a), phosphorylation (P), gua-
Phoshodiesterase 6α and 6β subunits
Several proteins essential for the process of vision require farnesyl and geranylgeranyl resi-
dues for proper functionality. Among them, rod cyclic guanosine monophosphate (cGMP)-
specific phosphodiesterase 6 (PDE6) consists of catalytic α and β subunits, two inhibitory γ 
subunits, and a δ subunit. This enzyme is crucial for the phototransduction pathway. Briefly, in 
response to a photon, rhodopsin is activated and stimulates GTP synthesis (Figure 2). In turn, a 
G-protein, transducin, is activated and displaces the inhibitory γ subunits thus activating PDE6. 
This phosphodiesterase is involved in the reduction of cGMP concentration, which leads to 
closure of cGMP-gated channels. As a direct result of ensuing transient hyperpolarisation, at 
the synapse glutamate release is then reduced and the signal travels via the optic nerve to the 
brain.
PDE6 is anchored to the membrane through isoprenyl residues attached to the C-termini of 
PDE6α and PDE6β. Mammalian PDE6A was proven to contain one farnesyl residue; in compari-
son, PDE6B is geranylgeranylated.113 These modifications are thought to facilitate membrane 
attachment.114 The prenyl moieties of PDE6 subunits were recently shown to bind AIPL1, the 
aforementioned chaperone protein involved in LCA.115 PDE6 subunits form a complex con-
taining prenyl-binding protein delta (PrBP/δ), which is highly expressed in photoreceptors. 
Mutations in both PDE6A and PDE6B (phosphodiesterase 6A, cGMP-specific, rod, α and β, 
respectively), encoding the α and β subunits, are responsible for a small subset of autosomal-
recessive RP cases.116; 117
RAB28, member RAS oncogene family
Rab GTPases are key regulators in trafficking of proteins and function as molecular switches to 
regulate fusion steps in vesicle transport, vesicle budding, motility, tethering,118 and membrane 
fission.119 The human genome contains more than 60 Rab genes,120; 121 and for at least 16 dif-
ferent Rab proteins the structure in either the active (GTP-bound) or inactive (GDP-bound) 
state has been elucidated.122-124 The first prenylated small Rab GTPase demonstrated to be 
involved in retinal disease is RAB28, as protein-truncating mutations in RAB28 cause cone-rod 
dystrophy.125 Although the exact role of RAB28 in cone and rod photoreceptors remains to be 
determined, a unique feature is that isoforms 1 and 2 of RAB28 are predicted to be farnesyl-
ated at their CaaX-motifs,54; 126-128 in contrast to the large majority of other RAB GTPases that 
are geranylgeranylated by GGTase-II. The farnesylation was experimentally proven for isoform 
1 of RAB28.
Other Rabs, like Rab8 and Rab11, are found to coordinate primary ciliogenesis.84 Together with 
Rab3a and Rab6, they are involved in rhodopsin transport through the connecting cilium to 
the outer segments of photoreceptor cells.129-132 Interestingly, a single mutation in the RAB3A-
interacting molecule, RIMS1, was associated with dominant cone-rod dystrophy (Figure 1).133 
RAB28 is also localised to the basal body and ciliary rootlet, which suggests a role in ciliary 
transport (Figure 2).125 In addition, Rab17 and Rab23 were found to be essential for ciliogenesis, 
but are not present in the cilium.134
The disease mechanism underlying photoreceptor degeneration due to protein-truncating 
mutations in RAB28 remains to be elucidated. The retina-specific phenotype is surprising in 
view of the wide expression of this gene in the human body. Either there is functional redun-
dancy outside the eye through the action of other Rabs or RAB28 may be involved in the 
transport of crucial retina-specific proteins.
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defects, mutations affecting AIPL1 and PrBP/δ exert a more general effect as both are chaper-
ones for a subset of prenylated retinal proteins. Defects in the corresponding genes thereby 
may affect the function of the respective proteins with which they normally interact.
REP-1 does not only act as a chaperone for RABs but it also is a key accessory protein of 
GGTase-II, which is involved in the geranylgeranylation of almost all RABs. It is thus far not 
understood how REP-1 deficiency, despite the presence of a functional homologue REP-2 
(encoded by choroideremia-like gene, CHML) that is also widely expressed, results in a specific 
chorioretinal disease. The same is true for the surprising recent finding that mutations in 
mevalonic kinase, which were known to be principally associated with MEVA, were associated 
with nonsyndromic RP. We hypothesise that MVK deficiency results in a depletion of prenyl 
moieties, which affects the prenylation of many proteins synthesized specifically in the retina. 
It stands to reason that the prenylated proteins illustrated in Figures 1 and 2 would most 
prominently be affected, though some of the associated retinal phenotypes differ from the RP 
phenotype observed in persons with MVK deficiencies.
Assuming that the depletion of isoprenyl moieties underlies RP in MKD, there may be an over-
lap with another ‘general’ prenylation defect, that is the underprenylation of one or several 
RABs due to mutations in the CHM gene. Clearly, future studies are needed to shed light on 
these issues.
ConCluding remarks
The mechanisms underlying retinal dystrophies due to variants in prenylated proteins in the 
retina are straightforward as each of these proteins, maybe except for RAB28, plays a unique 
function in the retina. Similar to other geranylgeranylated RABs, the farnesylated RAB28 is 
synthesized widely in human tissues. Nevertheless, it apparently fulfils a crucial function in 
the transport of as yet unknown molecules. Possibly, it also is involved in the shuttling of key 
molecules towards the connecting cilium, such as rhodopsin. The chaperone proteins AIPL1 
and PrBP/δ play diverse roles in the assembly and transport of several key protein complexes, 
but the full spectra of their function are not yet known. Mutations in CHM result in X-linked 
choroideremia and MVK variants are associated with a late-onset form of autosomal-recessive 
RP in a small subset of MKD cases. There is a conspicuous phenotypic overlap between these 
two diseases. Although choroideremia is characterised by the degeneration of all posterior 
cell layers (neural retina, RPE, choroid), and RP is characterised by the dystrophy of the neural 
retina and RPE, their similarity is striking. Both display a midperipheral-to-centre degenera-
tion, primarily affecting rods, preserving the macular region for a long time. Both result from 
general prenylation defects, although at different levels. MKD potentially leads to a widespread 
shortage of prenoids, which include farnesyl and geranylgeranyl moieties. CHM mutations, on 
the other hand, cause an insufficiency of GGTase-II to geranylgeranylate the large majority of 
RABs. We hypothesise that the comparable phenotypes result from depletion of prenylated 
RABs.
Many studies suggest that the retina displays specific requirements for proteins possessing lipid 
moieties, most probably due to the membranous structure of the photoreceptors. The retina 
therefore may be particularly susceptible to underprenylation of proteins, which would give 
rise to retinal symptoms before (if at all) affecting other tissues. Several genes implicated in 
IRDs encode proteins that either require prenylation or are crucial in the prenylation process. 
Mutations in these genes may result in diminished or abolished protein synthesis, but can also 
cause loss of function and accumulation of inactive prenylated proteins, which may be toxic to 
photoreceptor cells. The recent finding of LCA-specific features in a patient with CLN3 variants 
may also point to a disease mechanism involving the accumulation of toxic molecules in retinal 
lysosomes.
Many IRD genes are being explored as targets for gene augmentation therapy, and it may be 
nosine monophosphate (GMP) and its cyclic counterpart (cGMP), guanosine-5’-triphosphate 
(GTP), guanosine diphosphate (GDP). Activation of rhodopsin with a photon is indicated by a 
lightning symbol. PC – photoreceptor.
Retinitis pigmentosa GTPase regulator
Another prenylated protein involved in retinal dystrophy is RPGR, a ubiquitously expressed 
protein. RPGR can act as a GTP-GDP exchange factor for RAB8,135 a protein involved in cili-
ary transport and rhodopsin trafficking to the photoreceptor outer segment.136 Since some 
disease-causing RPGR mutations do not affect this GTP-GDP exchange function, RPGR may 
have additional roles in the photoreceptors. The geranylgeranylation of RPGR is required for 
its correct localisation in the Golgi apparatus,137 but the lack of this isoprenylation does not 
seem to disrupt the retinal function.138 Several splice variants are found in different tissues, 
and the RPGR ORF15 isoform is crucial for normal functioning of the retina. Mutations in this 
part of RPGR were shown to be involved in the majority of X-linked retinal dystrophy cases.139; 
140 However, the RPGR ORF15 transcript lacks the CaaX prenylation signal at its C-terminus. 
Therefore, although both transcripts are expressed in photoreceptors, it remains unclear 
whether this modification is necessary for retinal function.
G protein-coupled receptor kinase 1
G protein-coupled receptor kinases specifically recognise and phosphorylate the numerous G 
protein-coupled receptors after the release of bound G proteins. Rhodopsin kinase (GRK1), 
which belongs to this group and regulates cellular responses. It is activated allosterically by its 
own substrate, the light-activated form of rhodopsin. Membrane association of GRK1 occurs 
after its farnesylation. Since in PDE6D knockout mice GRK1 is absent in the photoreceptor 
outer segments, it is suggested that PrBP/δ is required for its correct trafficking.83 GRK1 muta-
tions are a cause of Oguchi disease, a form of stationary night blindness with prolonged dark 
adaptation. Since GRK1 is crucial for visual processes, it is hypothesized that in cones GRK7 
compensates for the loss of GRK1 activity, and hence patients with mutations in GRK1 only 
display a relatively mild phenotype.141; 142
Ceroid lipofuscinosis neuronal 3
Mutations in ceroid lipofuscinosis, neuronal 3 (CLN3), encoding a lysosomal transmembrane 
protein, are a cause of Batten disease. Vision loss often is the first clinical feature in Batten 
disease, preceding severe and progressive neurodegeneration leading to death in the second 
decade of life.143 Recently, a mutation has been described in a patient with nonsyndromic LCA.5 
This previously described mutation (p.Y199*) was found to result in a milder, protracted phe-
notype due to the escape of nonsense-mediated decay, hypothetically leaving a partially func-
tional protein.144 The CLN3 protein is described to be farnesylated,145 and it has been shown 
that mutations in the CLN3-binding motif of FTase display normal trafficking, but result in a 
functionally impaired protein.146
are there overlaPPing meChanisms of disease due to defeCts in the 
retinal Prenylome?
The photoreceptors are highly compartmentalised and membranous structures, and therefore 
it can be expected that many retinal proteins depend on prenylation for a proper subcellular 
localisation and trafficking. This is true for several proteins found to be mutated in different 
IRDs. The mechanisms underlying retinal degeneration due to defects in the prenylated pro-
teins described above are not fully understood, but can be inferred from their known roles in 
the phototransduction cascade (GNGT1, PDE6A, PDE6B), transport processes close to or at 
the connecting cilium (RAB28, RPGR), or lysosomes (CLN3). Apart from these ‘gene-specific’ 
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Supplementary Figure 1 Mevalonate pathway
The mevalonate pathway (HMG-CoA reductase pathway/isoprenoid pathway), is a crucial cel-
lular metabolic route for the production of dimethylallyl diphosphate and isopentenyl diphos-
phate. These compound are the basis for the biosynthesis of molecules used in diverse pro-
cesses, e.g. protein prenylation, hormone synthesis, protein anchoring, and N-glycosylation. It 
is also a part of steroid biosynthesis.
hypothesized that targeting the prenylation process could provide a more generic treatment. 
However, in view of the diversity of the proteins and cellular processes in question, the devel-
opment of a more generalised therapy does not seem plausible at the moment. 
Although a general prenylation therapy seems incredibly challenging, steps are currently being 
made to devise a therapy directed to specific geranylgeranyl or farnesylation defects. One 
of the deficiencies that may be addressed is retinal degeneration caused by the loss of MVK 
functionality. Although it was proven that patients with RP and mild MKD symptoms display the 
same, severe decrease in MVK activity compared with MEVA patients, it may be hypothesized 
that boosting the concentration of substrates for prenyl synthesis either by direct supplemen-
tation or by targeting one of the downstream enzymes in mevalonate pathway would increase 
the overall supply of prenyl residues and rescue the phenotype. However, it is very difficult 
to predict how this would affect the target cells. FTase inhibitors have been previously used 
as a target for decreasing prenylation in treatment of some cancer types.147-150 Nevertheless, 
the K-RAS protein that is involved in some neoplasms appears to be geranylgeranylated in the 
absence of FTase.151 Therefore, a similar method involving both farnesyltransferase and geranyl-
geranyltransferase inhibitors was investigated, but the dual prenylation of proteins caused the 
agent to exhibit dose-limited toxicities in the clinic and were withdrawn for further investiga-
tion.152; 153
Considering all of the above issues, stimulating the synthesis of prenyl residues in the retina may 
cause undesirable side effects, such as neoplastic growth. It is also possible that manipulating 
these levels will have no effect at all since there are multiple feedback loops in the isoprenoid 
pathway, and increased concentration of one of the compounds may result in inhibition rather 
than stimulation of prenyl synthesis.
Targeting the inhibitors of prenyltransferases was already tested in other genetic disorders. In 
progeria, a disease of rapid aging, farnesyltransferase inhibitors have shown their potential in 
vitro by blocking the expression of the defective farnesylated protein laminin A (or progerin), as 
well as in vivo with respect to longevity, body weight and bone integrity phenotypes.154
In retinal diseases, for example in case of a malfunctioning chaperone, it is conceivable that a 
prenylated protein might accumulate at an improper location and result in retinal degenera-
tion. However, general inhibition of either farnesylation or geranylgeranylation would probably 
result in underprenylation of other targets. Therefore, it is not certain whether such therapies 
should be considered. At this point, gene augmentation therapy still presents the best option 
for treatment of such diseases. Although the eye has excellent properties for the development 
of treatment, the bottleneck will remain that each prenylation defect requires a different thera-
peutic approach, posing significant challenges for the future.
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describes compound heterozygous mutations in MFSD8 in a large Dutch family with central 
cone disease, identified by linkage analysis and exome sequencing. Mutations in this gene are 
known to cause variant late infantile neuronal ceroid lipofuscinosis, a severe neurodegenerative 
disorder. We hypothesize that neuronal ceroid lipofuscinosis is caused by two severe muta-
tions, while central cone disease in this family is caused by a severe mutation on one allele and 
a mild variant on the other allele. In line with this hypothesis, the same mild variant was found 
in combination with another severe mutation in a second Dutch family with a CRD.
In Chapter 5 the main findings and implications of this thesis are discussed. First, in Chapter 
5.1 the efficiencies of the genomic technologies are described and the advantages of imple-
menting exome sequencing as well as the disadvantages of the current approach in routine 
diagnostics. Chapter 5.2 highlights the observations that hypomorphic mutations, in com-
bination with more severe variants, can be associated with phenotypes limited to the eye, 
whereas combinations of truncating mutations cause a range of more severe, often syndromic, 
phenotypes. Chapter 5.3 provides a review on prenylated proteins that are associated with 
retinal dystrophies, such as RAB28. In addition, chaperones guiding prenylated proteins to 
their proper subcellular location are discussed (i.e. AIPL1, PrBP/δ), which can be defective in 
persons with a retinal dystrophy. Finally, a possible overlap is hypothesized for the underlying 
retina dystrophy-associated disease mechanisms due to MVK defects (retinitis pigmentosa) or 
CHM defects (chorioderemia). In both diseases it is possible that a crucial set of RAB GTPases 
shows geranylgeranyl deficiencies which result in intracellulair transport function abnormalities 
and subsequently retinal degeneration. 
The leading causes of hereditary blindness worldwide are retinal disorders, which primarily 
affect the photoreceptors. An affected person with cone dysfunction (CD) has difficulties per-
ceiving colors and seeing details. In this thesis I mainly focused on early-onset cone-dominated 
phenotypes leading to severe visual impairment, such as achromatopsia (ACHM), cone dys-
trophy (COD) and cone-rod dystrophy (CRD). CDs can be inherited in all Mendelian forms 
of inheritance, however, in this thesis I focused on those inherited in an autosomal recessive 
fashion. Although important steps are being made, there are currently limited therapeutic 
options to inhibit, stop, or reverse the degenerative disease process. In order to develop effec-
tive therapeutic approaches the genetic etiology of CD needs to be elucidated. Throughout 
the years, dozens of genes have been found to cause CD, but still significant percentages of CD 
cases are unexplained. Mutations in the 5 genes implicated in ACHM explain approximately 
93% of the cases. On the contrary, only 21% of autosomal recessive CRD cases (17 genes) 
and 25% of autosomal recessive COD (8 genes) have been elucidated. In this thesis I aim to 
elucidate novel genetic causes for CD using homozygosity mapping and exome sequencing, 
to increase the molecular genetic knowledge of CDs and open new avenues for generating 
therapeutic approaches. 
Chapter 1 provides a comprehensive background on CD, the topic of this thesis. In Chapter 
1.1 a general introduction is given on the human eye and its properties which enable color 
vision. Subsequently, in Chapter 1.2 insight is provided in homozygosity mapping and exome 
sequencing which are currently used to identify novel gene defects. Finally, Chapter 1.3 
reviews the current knowledge about the clinical phenotypes representing CD, the molecular 
processes in which the 42 CD-associated genes are involved, an update on animal models with 
cone defects and current therapeutic approaches.
Chapter 2 describes the identification of pathogenic CNGA3 and CNGB3 mutations in COD, 
while previous studies only showed involvement of these genes in stationary ACHM. The 
underlying mechanism how different phenotypes can be caused by similar mutations remains 
unexplained. 
Chapter 3 describes novel genotype-phenotype correlations for two genes, TULP1 and 
CEP290. Mutations in these genes were known to cause inherited retinal disease, but have not 
previously been associated with CD. Chapter 3.1 describes the identification of an uncom-
mon phenomenon of maternal uniparental isodisomy of chromosome 6 in a patient with CD. 
Subsequent sequencing of all retinal disease associated genes on chromosome 6 led to the 
identification of a homozygous TULP1 mutation, which was also identified in another unrelated 
case with CD. In Chapter 3.2 exome sequencing in two siblings with oligocone trichromacy 
enabled the identification of compound heterozygous nonsense mutations in CEP290, which 
were demonstrated to have a hypomorphic effect. These mutations caused a relatively mild 
phenotype in these siblings, while CEP290 mutations are known to cause a spectrum of diseases 
ranging from early-onset retinal dystrophy to Meckel-Gruber syndrome.
Chapter 4 describes the identification of three novel genes associated with CD. Chapter 
4.1 reports the identification of PDE6C as a new disease associated gene for ACHM and early-
onset COD. Several ACHM families and one COD family carried mutations in PDE6C, a gene 
expressed specifically in the cone photoreceptor cells. These mutations were discovered using 
homozygosity mapping and provided evidence for a genetic overlap between ACHM and COD. 
In Chapter 4.2 we used exome sequencing to unravel the genetic defect in two CRD families. 
Both families showed truncating mutations in the farnesylated small GTPase RAB28, local-
ized at the base of the connecting cilium, as the cause of their retinal disease. Chapter 4.3 
262 263
Samenvatting
264 265
Samenvatting
en COD. In Hoofdstuk 4.2 werd exoom sequencing gebruikt om het genetisch defect in 
twee CRD families te ontrafelen. Beide families droegen stopmutaties in het RAB28 gen, welke 
codeert voor een gefarnesyleerd GTPase dat in het netvlies gelocaliseerd is nabij het con-
necting cilium. Hoofdstuk 4.3 beschrijft de ontdekking van samengestelde heterozygote 
mutaties in het MFSD8 gen in een grote familie met CD door middel van koppelingsonderzoek 
en exoom sequencing. Het was al bekend dat mutaties in dit gen infantiele neuronale ceroid 
lipofuscinose, een ernstige neurodegeneratieve aandoening, veroorzaken. Onze hypothese is 
dat neuronale ceroid lipofuscinose in MFSD8 wordt veroorzaakt door twee ernstige mutaties, 
terwijl CD wordt veroorzaakt door een ernstige mutatie op het ene allel en een milde variant 
op het andere allel. Deze hypothese werd bevestigd doordat in een tweede familie met CD 
dezelfde milde variant gevonden werd in combinatie met een andere ernstige mutatie.
In Hoofdstuk 5 worden de belangrijkste bevindingen en implicaties van dit proefschrift bedis-
cussieerd. In Hoofdstuk 5.1 worden de efficiëntie van de genomische technologieën beschre-
ven, de voordelen van implementatie van exoom sequencing, en de nadelen van de huidige aan-
pak in de routine diagnostiek. Hoofdstuk 5.2 belicht de observatie dat hypomorfe mutaties 
in combinatie met een ernstigere variant geassocieerd kunnen worden met een ziekte die zich 
beperkt tot het oog, terwijl combinaties van stopmutaties een spectrum van ernstigere, syn-
dromale ziekten kunnen veroorzaken. Hoofdstuk 5.3 biedt een overzicht over geprenyleerde 
eiwitten die geassocieerd zijn met retinale dystrofie, zoals RAB28. Daarnaast worden chape-
ronnes van geprenyleerde eiwitten bediscussieerd (o.a. AIPL1, PrBP/δ) die defect kunnen zijn 
in personen met dystrofie van de retina. Tenslotte wordt een mogelijke overlap voorgesteld 
van de ziektemechanismen die ten grondslag liggen aan retina dystrofie-geassocieerde ziekten 
als gevolg van MVK defecten (retinitis pigmentosa) of CHM defecten (choroideremie). Bij beide 
ziekten is het mogelijk dat een cruciale set van RAB GTPases geranylgeranyl deficiënties verto-
nen, waardoor intracellulaire transportfuncties uitvallen hetgeen leidt tot retinale dystrophie.
De belangrijkste oorzaken van erfelijke blindheid zijn retinale aandoeningen, die voorname-
lijk de fotoreceptoren aantasten. Een persoon met kegel dysfunctie (CD) heeft problemen 
met het waarnemen van kleuren en details. In dit proefschrift heb ik onderzoek verricht naar 
CDs die op jonge leeftijd ontstaan en tot ernstige visuele beperkingen leiden, zoals achroma-
topsie (ACHM), kegel dystrofie (COD) en kegel-staaf dystrofie (CRD). CDs kunnen via alle 
Mendeliaanse vormen overerven, echter, dit proefschrift concentreert zich op de vormen die 
op de autosomaal recessieve wijze worden overgeërfd. Alhoewel er belangrijke stappen zijn 
gezet in het onderzoek naar behandelingen, zijn er momenteel weinig therapeutische moge-
lijkheden.. Om effectieve therapieën te kunnen ontwikkelen is het belangrijk om de genetische 
etiologie van CD te ontrafelen. De afgelopen jaren zijn er tientallen genen gevonden die CD 
kunnen veroorzaken, maar nog steeds blijft een groot deel van alle CD gevallen onverklaard. 
Ongeveer 93% van ACHM wordt verklaard door mutaties in 5 genen. Bij autosomaal recessieve 
CRD en COD werden echter 21% (17 genen) en 25% (8 genen) van de families genetisch opge-
lost. Het doel van mijn proefschrift is om nieuwe genetische oorzaken voor CD te vinden door 
middel van homozygotie mapping en exoom sequencing, om hiermee de moleculair genetische 
kennis over CDs te vergroten waardoor nieuwe therapeutische mogelijkheden ontwikkeld 
kunnen worden.
Hoofdstuk 1 omvat een uitgebreide achtergrond over CD, het onderzoeksthema van dit 
proefschrift. In Hoofdstuk 1.1 wordt een algemene introductie gegeven over het menselijk 
oog en de eigenschappen die kleurzien mogelijk maken. Vervolgens wordt in Hoofdstuk 1.2 
inzicht gegeven in homozygotie mapping en exoom sequencing, geavanceerde genetische tech-
nieken die gebruikt kunnen worden om nieuwe gendefecten te identificeren. Tenslotte volgt in 
Hoofdstuk 1.3 een overzicht van de huidige kennis van het klinisch beeld van CD, de molecu-
laire processen waarbij de 42 CD-geassocieerde genen zijn betrokken, diermodellen met kegel 
defecten en de huidige therapeutische mogelijkheden voor CD.
Hoofdstuk 2 beschrijft de identificatie van mutaties in CNGA3 en CNGB3 bij CD, terwijl 
eerdere studies alleen betrokkenheid van deze genen lieten zien bij stationaire ACHM. Het is 
nog onduidelijk hoe deze verschillende ziekten veroorzaakt kunnen worden door vergelijkbare 
mutaties.
Hoofdstuk 3 toont nieuwe genotype-fenotype correlaties aan voor twee genen, TULP1 en 
CEP290. Het was reeds bekend dat mutaties in deze genen erfelijke retinale aandoeningen 
veroorzaken, echter, ze waren niet eerder geassocieerd met CD. Hoofdstuk 3.1 beschrijft 
een zeldzaam fenomeen van maternale uniparentale isodisomie van chromosoom 6 in een 
persoon met CD. Sequentie analyse van alle retinale dystrofie geassocieerde genen gelegen op 
chromosoom 6, leidde tot de identificatie van een homozygote TULP1 mutatie, die vervolgens 
ook bij een niet-verwante persoon met CD werd gevonden. In Hoofdstuk 3.2 heeft exoom 
sequencing bij een broer en zus met een bijzondere vorm van ACHM geleid tot de identificatie 
van samengestelde heterozygote stopmutaties in CEP290, waarvan gedemonstreerd werd dat 
deze een hypomorf effect hebben. Deze mutaties veroorzaakten een relatief milde ziekte bij 
deze broer en zus, terwijl het bekend is dat CEP290 mutaties een spectrum van aandoeningen 
variërend van een ernstige retinale dystrofie tot afwijkingen niet verenigbaar met het leven.
Hoofdstuk 4 beschrijft de vondst van mutaties in drie nieuwe genen die CD veroorzaken. 
Hoofdstuk 4.1 rapporteert de bevinding van PDE6C als een nieuw ziekte-geassocieerd gen 
voor ACHM en COD. Drie ACHM families en één COD familie dragen mutaties in PDE6C, 
een gen dat specifiek in de kegel fotoreceptoren tot expressie komt. Deze mutaties werden 
gevonden middels homozygotie mapping en tonen een genetische overlap aan tussen ACHM 
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wordt een mogelijke overlap voorgesteld van de ziektemechanismen die ten grondslag liggen 
aan een aantal retinale aandoeningen.
Retinale aandoeningen zijn de belangrijkste oorzaken van erfelijke blindheid, die met name 
de fotoreceptoren aantasten. De mens kent twee typen fotoreceptoren: de kegeltjes en de 
staafjes. Het beeld dat op het netvlies valt wordt door de kegeltjes en staafjes omgezet in een 
elektrisch signaal naar de hersenen. Bij een persoon met kegel dysfunctie werken de kegel 
fotoreceptoren niet goed, waardoor er problemen ontstaan in het waarnemen van kleuren en 
details. In de studies beschreven in dit proefschrift heb ik onderzoek verricht naar kegel dys-
functies die op jonge leeftijd ontstaan en tot ernstige visuele beperkingen leiden, zoals achro-
matopsie, kegel dystrofie en kegel-staaf dystrofie. Dit proefschrift concentreert zich op kegel 
dysfuncties die op een recessieve wijze overerven. Bij recessieve overerving zijn beide gezonde 
ouders drager van het gendefect. Als de gendefecten van beide ouders doorgegeven worden 
aan hun kind, dan zal hij/zij kegel dysfunctie ontwikkelen. De afgelopen jaren zijn er afwijkingen 
in tientallen genen gevonden die kegel dysfunctie kunnen veroorzaken, maar nog steeds zijn 
de genetische oorzaken van een groot aantal personen met kegel dysfunctie onbekend. Het 
doel van mijn promotieonderzoek was om nieuwe genetische oorzaken van kegel dysfunctie 
te vinden door middel van de nieuwste genetische methoden. Door de moleculair genetische 
kennis over kegel dysfuncties te vergroten kan de diagnose verbeterd worden, en kunnen in de 
toekomst nieuwe behandelingen ontwikkeld worden.
Hoofdstuk 1 omvat een uitgebreide achtergrond over kegel dysfunctie, het onderwerp van dit 
proefschrift. Er wordt een algemene introductie gegeven over het menselijk oog en de eigen-
schappen die kleuren zien mogelijk maken. Vervolgens wordt inzicht gegeven in geavanceerde 
genetische technieken die gebruikt kunnen worden om nieuwe gendefecten op te sporen. 
Tenslotte volgt in het laatste deel een overzicht van de huidige kennis van het klinisch beeld 
van kegel dysfunctie, de moleculaire processen waarbij de 42 kegel dysfunctie genen betrokken 
zijn, diermodellen met kegel defecten, en de huidige therapeutische mogelijkheden voor kegel 
dysfunctie.
Hoofdstuk 2 beschrijft de identificatie van afwijkingen in de CNGA3 en CNGB3 genen bij kegel 
dystrofie, een progressieve ziekte waarbij de kegel functie steeds verder afneemt. Eerdere 
studies toonden alleen betrokkenheid van deze genen aan bij achromatopsie, een ernstige 
oogziekte die vanaf de geboorte aanwezig is maar niet of nauwelijks steeds erger wordt. Het 
is nog onduidelijk hoe deze verschillende ziekten veroorzaakt kunnen worden door genetische 
afwijkingen die niet veel van elkaar verschillen.
Hoofdstuk 3 bestaat uit twee artikelen waarin gendefecten in twee genen, TULP1 en CEP290, 
worden beschreven in personen met kegel dysfunctie. Het was reeds bekend dat afwijkingen 
in deze genen erfelijke retinale aandoeningen veroorzaken, echter, ze waren niet eerder geas-
socieerd met kegel dysfunctie. 
Hoofdstuk 4 beschrijft in drie artikelen de vondst van afwijkingen in drie nieuwe genen die 
kegel dysfunctie veroorzaken. In deze artikelen toonden we aan dat gendefecten in PDE6C, 
RAB28 en MFSD8 achromatopsie, kegel dystrofie en kegel-staaf dystrofie kunnen veroorzaken. 
Het vinden van afwijkingen in deze genen biedt nieuwe perspectieven voor de ontwikkeling van 
behandelingen voor patiënten met kegel dysfunctie.
In Hoofdstuk 5 worden de belangrijkste bevindingen en implicaties van dit proefschrift bedis-
cussieerd. Deze omvatten onder andere de doeltreffendheid van de gebruikte genomische 
technieken, de voordelen van het aflezen van alle humane genen (ook wel ‘exome sequen-
cing’ genoemd), de nadelen van de huidige aanpak in de routine diagnostiek, en de observatie 
dat verschillende genafwijkingen kunnen leiden tot verscheidene oogaandoeningen. Tenslotte 
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